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INTRODUCTION 
“Medicine is a science of uncertainty and an art of probability” 
                   -Sir William Osler 
 Siddha Medicine, a native Medicine of Tamilnadu, is the first system to 
emphasize health as the perfect state of physical, psychological, social and spiritual 
components of human being. Siddha System of Medicine, well known for its simplicity 
and credibility has been evolved by spiritual scientists called Siddhars.The advantage 
and unique feature is the removal of the root causes of the disease and perfect remedy for 
body and mind. 
“The aim of Medicine is to prevent disease and prolong life, 
  The ideal of Medicine is to eliminate the need of a Physician” 
 The human body is made up of Imboothangal ie, Akayam, Vayu, Theyu, Appu, 
Pirthivi in different combinations. The physiological function in the body is mediated by 
three uyirthathus(humours), which are also made up of these Impoothenkal. They are 
Vatham, Pitham and Kabam. In each and every cell of the body, these three thathus co-
exist and function harmoniously. 
 Thiruvalluvar in Thirukkural, has mentioned that the derangement of the three 
humours i.e. Vatham, Pitham and Kabam is the main cause for the onset of diseases in 
our body. It is, 
   “kpfpDk; FiwapDk; Neha;nra;Ak; EhNyhh; 
   tspKjyh naz;zpa %d;W” 
                    -jpUf;Fws; 
 The five elements constitute the three uyirthathus and their imbalance causes 
disease. The three thathus are made up of 5 elements. The five elements are Pirthivi, 
Appu, Theyu, Vayu and Akayam. 
   thjk; - thA + Mfhak; 
   gpj;jk; - NjA 
   fgk;  - gpUj;tp + mg;G 
 Skin is one of the components of five elements ie Prithvi (earth) and this is 
indicated in Sathaka naadi, 
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   “Nrug;gh rlkhr;R kz;zpd; $W 
   nrwpkaph; Njhy; vYk; gpiwr;rp euk;ige;jhFk;” 
         -rjfehb 
   Njhy; = gpUj;tp + NjA 
 So any dearrangement in Theyu and its component may affect the skin by 
disturbing the functions of saaram, senneer, oon and kozhuppu. Skin acts as a linking 
media between our body and the outer world. The skin is the first organ affected by any 
change in the universe. Food habits and life style modifications of an individual and 
seasonal variation also plays an important role in causing disease by altering the three 
humours. It is also mentioned in Thirukkural as below, 
   “khWgh by;yhj cz;b kWj;Jz;zp 
   DhWgh by;iy Aaph;f;F” 
          -jpUf;Fws; 
 In Siddha System of Medicine, the diseases are classified into four thousand four 
hundred and forty eight (4448). The disease  Karappan is one among them. Siddha 
Medicines are very effective in treating chronic diseases and particularly skin 
diseases.The incidence of Karappan is considerably increasing now-a-days. A great 
number of patients are reporting daily in our Ayothidoss Pandithar Hospital for this 
disease. 
  “When the „I‟ is replaced by „WE‟ even ILLNESS becomes 
WELLNESS” 
 There is no cure for eczema, but eczema can be controlled with regular medical 
care and a good treatment plan. Effective eczema management requires a combination of 
prevention and treatment. In addition to prevent eczema flare-ups by minimizing any 
known triggers, treatment is also an important part of eczema management. It is not a 
contagious disease. It is generally not a serious condition, but there is a potential for 
complications, such as a secondary bacterial or fungal infection of the eczema rash, 
thickening of skin, hyper or hypopigmentation. Early diagnosis and treatment can reduce 
the risk for complication. 
     “DECLARE the PAST 
     DIAGNOSE the PRESENT 
     FORETELL the FUTURE” 
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 The drugs given for treatment are also made up on the basis of this theory. So by 
prescribing a drug of the same constituents (gunam) the equilibrium is restored. The 
correction of the imbalance is made by administering the drug which is predominately of 
the opposite nature. Siddha Medicine revitalizes and rejuvenates the organs, the 
dysfunction of which causes the disease. This brings back normal functioning of the 
organs. It also maintains the ratio of Vatham, Pitham and Kabam, thus maintaining the 
healthy state of the body.   
   “The Good Physician treats the disease;  
   The Great Physician treats the patient who has the disease” 
        -Sir William Osler 
   That‟s why I have selected one of the skin diseases “Karappan” as my 
dissertation topic. In the stream of Siddha Medicine we exclusively treat Karappan by 
Leech Therapy which is one of the bloodletting technique. It not only cure the disease 
but also helps for rejuvenation. 
    “Nature cures everything” 
           -Hippocrates 
 Siddha medicines are very effective in the treatment of dermatological ailments. 
Many herbal and herbo-mineral formulations have been indicated for skin diseases. Most 
of them have been proved effective clinically. As it is one of the chronic diseases which 
is difficult to cure through pure herbal formulations, so the author selects the herbo-
mineral formulations for this dissertation work.  
 “The Doctor of the future will give no medicine, but will interest her or his 
patients in  the care of the human frame, in a proper diet, and in the cause and 
prevention of  disease” 
      -Thomas Edison   
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AIM AND OBJECTIVES 
The aim of this dissertation is: 
 A Comparative Clinical trial of Siddha formulation of NILAVAAGAI  
CHOORANAM internally and THENGAAI THYLAM externally in the treatment of 
KARAPPAN (ECZEMA) with and without LEECH THERAPY. 
The objectives of this dissertation are: 
 To study the incidence of the disease with respect to age, gender, socio-economic 
status, habit and family history. 
 To ascertain that according to the mukkutram theory, Karappan‟s effect varies 
with respect to body constitution (prakriti), taste (suvai) and seasonal variation 
(paruvakalam). 
 Relevant evidence from various Siddha literatures and other system of Medicine 
to be attached 
 To know the correlation of aetiology, signs and symptoms of Karappan in Siddha 
aspect with eczema in modern aspect. 
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SIDDHA ASPECTS 
fug;ghd; - KARAPPAN 
Neha; ,ay; (DEFINITION) 
 Njhypy; jpkph;> FU> Gz;> jbg;G Mfpa FwpFzq;fis cila gilfis 
cz;lhf;fp mt;tplq;fsp;y; tPf;fk;> nfhg;Gsq;fs; fz;L my;yJ nrjpy; Nghd;W 
Njhy; RuRug;ghfp Njhypd; ,aw;if epwj;ij NtWgLj;jp rpyNtis ntbg;G 
cz;lhf;fp ePh;frpjy; Mfpa FwpFzq;fis fhl;Lk; Njhw;gpzpfis fug;ghd; 
my;yJ fug;gd; vd;W $Wth;. ,jpy; jpdTk; nrhhpTk; ,Uj;jYk;> 
,y;yhjpUj;jYk; cz;L.  
 It is characterized by itching, papules, vesicles formation, scaling, hardening of 
skin with change in colour, sometimes manifesting with cracking of lesion and exudating 
watery fluid. 
Neha;f;fhuzk; (AETIOLOGY )  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AETIOLOGICAL FACTORS ACCORDING TO SAINT YUGI 
MUNIVAR 
     FOOD      HABIT 
Consumption of non-vegetarian 
foods, Intake of maize, pearl millet, 
foxtail millet, kodo millet, little 
millet and certain tuberous roots 
Excessive physical 
activities, Excessive 
sexual indulgence, Stress 
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According To Yugi Vaidhya Chinthamani - Karappan Roga  
Nithanam: 
 “Vohd fug;ghdpd; cw;gj;jpf; Nfsha; 
  Vw;w khkprq;fs; Grpf;ifahYk; 
 $ohd fk;Gjpid tuF rhikf; 
  nfhbjhd fpoq;F tifaUe;jyhYk; 
 ghohd ngz;khia jd;dPw; rpf;Fk; 
  ghq;fhd tpufj;jhd; Kaw;rpahYk;” 
Vaithya chinthamani Karappan Roga Nidhanam: 
  Karappan is produced due to  
 Consumption of offending food substances 
 Sexual indulgence with elderly women 
 Cutting of fruit bearing trees 
 Psychosomatic factors 
According To Guru Naadi Nool: 
 “tay;jdpNy G+ehf kz;izj; jhNd 
  tUe;jpaJ Gj;Jg;Nghy tj;ij ahFk; 
 gay; nkhopaPh; Njfj;jpy; fpUkpjhNd 
  gue;JUfp Fl;lk; Nghy; Gs;spfhZk; 
 kayJTq; fpUkpAe;jhd; ele;JGf;fpy; 
  NkdpaJ rurnud ntbj;Jg; Gz;zhk; 
 fay;ngUFk; Foy;kltPh; nrhy;yf; Nfsph; 
  fufuj;Jr; nrhwpngUFq; fughd; jhNd” 
 “rq;ifapy; tp\fug;ghd; tUkhNwJ 
  rhuKld; fpUkptpOe; jd;ikNaJ 
 cl;bzNk mjpfk;tU kpe;jphpa Nghfj;jh 
  YDUfp aj;jpNy NtT nfhz;L 
 el;lzkha; nte;jnjhU kr;ir jd;dpy; 
  ehl;lkpl;Nl fpUkpaJ aZFk; NghJ 
 kl;LlNd fpUkpnay;yhk; gwe;jq;Nfwp 
  tifAlNd khq;fp\j;ijj; Jisj;J NkTk; 
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 jpl;lKld; tplfug;ghd; gwe;JNkNy 
  jpdTlNd guguj;Jr; nrhwp Az;lhNk”  
        -FUehb Ehy;   
Relevance of Guru Naadi Nool: 
 Karappan occurs due to infestation with parasites and worms it is 
symptomised by itching, cracking and ulceration of skin. 
 Vida Karappan is a type of karappan and is produced due to destruction of 
vital organs of the body by the infection, excessive sexual indulgence 
which is symptomised by intensive itching. 
 Pararaasa Sekara Kirandhi Nidhanam: 
  “thj gpj;jq; fgkpit %d;Wte; 
   NjJtha; ntapyhd;kb ahypfw; 
  Nfhij ahh;kayhh; ntah;thw;Fsph; 
   NgjePupit khYs NgRNfspd; 
  Ntjf; fhw;wpdh; gidnty;yj;jhy; 
   ghfkpf;fyhd; Nkjpg; ghntapyhy; 
  jhfkhypd; tLf;fdp rhh;jyhy; 
   Nkhf thio tOjiy Ks;spf;fhd; 
  fhAk; gy;yplj; jhw;Ruj; jhw;fdy; 
   VAk; tz;nlyp ahy; tUNkJntd; 
  UA ey;ywp thd uUspdhw; 
   khakhd fug;ghd; tiffNs” 
       -guuhrNrfuk; fpue;jp epjhdk; 
 Living in torrid climate 
 Excessive sexual indulgence 
 Living in cold weather 
 Drinking contaminated water 
 Airborne infection 
 Excessive intake of palm jaggery, banana, fish, mangoes, wheat 
 Excessive exposure to sunlight 
  Poisonous bite may cause the disease 
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According to Pararaasa Sekara Kirandhi Nidhanam: 
 Drinking of contaminated water 
 Eating of banana, cucumber, brinjal, fish 
 Poisons of rat bite 
 Food items inducing Karappan as mentioned in the text, Siddha Maruthuvam 
Sirappu, 
  “ngUFQ; Nrhs kpWq;Fk; ngUq;fk;G 
  tuF fhUld; thioapd; fhnahL 
  ciunfhs; ghfw; nfspw;WkPd; cz;bby; 
  tphptjha;f; fug;ghD kpFe;jNj” 
        -rpj;j kUj;Jtk; rpwg;G 
 Nrhsk; - Maize 
  “Nrhsnkdg; Ngh;gilj;j NrhWfsp dhYlypy; 
  kPsr; nrhwp rpuq;F tph;j;jpahk; - ehSq; 
  fug;ghDk; cz;lhk; fdkUe;Jk; ghohk; 
  gug;guida fzkhdNj! awp” 
        -mfj;jpah; Fzthflk; 
 fk;G - Pearl millet 
  “fk;G Fsph;r;rpnadf; fhrpdpapw; nrhy;Yth;fhz; 
  gk;G nrhwprpuq;ifg; ghypf;Fk; - ntk;Gk; 
  clypd; nfhjpg;gfw;Wk; cl;gy Kz;lhFk; 
  mlyapw;fz; khNj! awp” 
        -mfj;jpah; Fzthflk; 
 tuF - Kodo millet 
  “vwpfgj;Njh NlgyNeh naa;Jk; twl;rp 
  nrhwprpuq;F gpj;je; njhlUk; - epiwAq; 
  fufnkdg; G+hpj;j fr;R Kiy khNj! 
  tufhprpr; Nrhw;why; tOj;J” 
        -mfj;jpah; Fzthflk; 
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 fhh; mhprp 
  ”fhuhprp ke;jq; fdg;Glypy; Jhypg;Gk; 
  ghuwpa thAitAk; gz;Zq;fhz; - NeNu 
  fug;ghndd; ghh;nghUe;jpw; fhakJ nkj;j 
  cug;ghFk; vd;Nw Aiu” 
        -mfj;jpah; Fzthflk; 
 ghfw;fha; - Bitter gourd 
  ”kUe;Jfspd; ew;Fzj;ij khw;Wk; m/njhd;Nwh 
  jpUe;jtyp thjj;ijr; Nrh;f;Fk; - nghUe;Jgpj;jq; 
  $l;Lkj gj;jpaijf; nfhz;bUf;Fk; td;fug;ghd; 
  fhl;Lf;nfhk;Gg; ghfw; fha; ” 
        -mfj;jpah; Fzthflk; 
 thiof;fha; - Unripened Banana 
  ”thioapd; fdpaiu thjkha;f; fha;KO 
  jhOkk; kUe;jt uf;fpdp%yk; ”  
        -mfj;jpah; Fzthflk; 
  Consumption of maize, pearl millet, kodo millet, unripened banana, bitter 
gourd  will lead to Karappan disease. 
 Other factors which are inducing Karappan are: 
 RizAs;s rpy nghUl;fs; (Poison ivy) 
  fk;gsp Nghd;wit Njhypy; cuha;tjhYk; (Contact Irritants) 
 me;jf; fuz NtWghLfs; (Psychosomatic Disorder) 
                  -rpj;j kUj;Jtk; rpwg;G 
 According to the text, Siddha Maruthuvam Sirappu, Karappan in children may be 
 induced by ingestion of following food items 
 nfha;ah (Psidium guava) 
 Kl;il (Egg) 
 kPd; (Fish) 
 fUthL (Dry fish) 
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CLASSIFICATION: 
 As per ‘Yugi Vaidhya Chindamani - 800‟ the types of Karappan are seven.
  “Mnkd;w fug;ghd; jhd; VOtpjkhFk; 
  mlq;fhj thjj;jpd; fug;ghNdhL 
  fhnkd;w fz;lhkhq; fug;ghdhFk; 
  fUjpa Njhh; twl;rpahq; fug;ghNdhL 
  Njnkd;w jpkph;thjf; fug;ghd; whDk; 
  rpurpdpNy ngUf ghyf; fug;ghd; 
  Nghnkd;w gpj;jkhq; fug;ghNdhL 
  nghpa Nrl;Lkf; fug;ghd; ngah;jhNdNo“ 
       -A+fp itj;jpa rpe;jhkzp 
1. Vatha Karappan 
2. Kanda Karappan 
3. Varatchi Karappan 
4. Thimirvatha Karappan 
5. Kabala Karappan 
6. Azhal Karappan 
7. Iya Karappan. 
In “Agasthiyar 2000 Part III” 
  Karappan has been classified into six varieties. They are, 
1. Vaatha Karappan 
2. Sori Karappan 
3. Varal Karappan 
4. Silethuma Karappan 
5. Mandai Karappan 
6. Varatchi Karappan 
 In “Pathinen Siddhar Balavagada Thirattu”, Karappan is classified into18 
types: 
  “nrq;fug;ghd; mdy;fug;ghd; jhDk; kz;ilr; 
   rpuq;F Gz;Zk; mhpfug;ghd; nghhpfug;ghd; 
  mq;fkjp nyOfug;ghd; jhDkpf;f 
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   msuhk; cjpuf;fug;ghd; fl;bNahL 
  nghq;fkha; tPq;fpa fug;ghDe;jhd; 
   Gfyhpa rl;iljb ntb fug;ghd; 
  rpq;fKf Vhpfug;ghd; thj tpj;jr; 
   Nrj;k Njhl fug;ghd; gjpndl;lhNk” 
      -ghythflk; - fug;ghd; tFg;G 
1. Vali Karappan,  
2. Azhal Karappan,  
3. Iyya Karappan,  
4. Ari  Karappan,  
5. Oothu Karappan,  
6. Soolai Karappan,  
7. Vedi Karappan,  
8. Mandai Karappan,  
9. Pori  Karappan,  
10. Sattaik Karappan,  
11. Odu Karappan,  
12. Karun Karappan,  
13. Sen Karappan,  
14. Kolli Karappan,  
15. Thoda Karappan,  
16. Vaalai Karappan,  
17. Varal Karappan,  
18. Veengku Karappan. 
In Siddhar Aruvai Maruthuvam : 
 Diseases of the head are 46. Among this, karappan has been classified into 
6 types. 
1. Vaatha Karappan 
2. Piththa Karappan 
3. Kaba Karappan 
4. Ven Karappan 
5. Seng Karappan 
6. Karun Karappan 
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 In the text „Athma Rakshamirtham‟ the Karappan is classified into 20 types. 
These are 
1. Vali Karappan, 
2. Azhal Karappan, 
3. Iyya Karappan, 
4. Karun Karappan, 
5. Sen Karappan, 
6. Mandai Karappan, 
7. Ari Karappan, 
8. Pori Karappan, 
9. Kiranthisoolai Karappan, 
10. Vaalai Karappan, 
11. Othu Karappan, 
12. Sevvappu Karappan, 
13. Kolli Karappan, 
14. Kadi Karappan, 
15. Vengu Karappan, 
16. Uthir Karappan, 
17. Sattai Karappan, 
18. Vedi Karappan, 
19. Singamuga Karappan, 
20. Eri Karappan 
 
 In the text “Agathiyar Rathina Churukka Naadi” the types of Karappan are 
mentioned as 90  
 In “Gurunaadi Sasthiram” Karappan has been classified into 85 types. 
 CLINICAL FEATURES OF KARAPPAN: 
  “vz;gJ fug;ghd; jd;ik apak;gpLkhW Nfsph; 
  ed;gpLk; thjk; gpj;jk; eyq;nfl;Lj; jhsk;tPq;Fk; 
  gz;gLq; fuq;fs; re;J Giye;jply; fUj;J NehFk; 
  tdikAld; ntbj;Jr; #iy tUtJ uzkPnjd;Nd” 
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  “cisQ;R NkyapWj vd; rPjq; fhZk; 
   c\;zkha; %j;jpuj;jhYUq;fp tpOk; 
  misQ;RNk aq;fnky;yhQ; nrhhpAz;lhFk; 
   moyhf ntJk;gyhf; iffhNyhAk; 
  GisQ;RNk ypq;fj;jpw; Ad;NghypUj;jpg; 
   nghb nghbaha; Rz;zhk;Gf;fw; Nghy;tpOk; 
  fisQ;RNk ePNuhL kyKQ;rpf;Fk; 
   frpANk fug;ghdhk;” 
        -mfj;jpah; ,uzEhy; 
 According to Agasthiyar Rana Nool, clinical features about Karappan: 
 Classified into 80 types 
 Produced due to derangement of Uyirthathukal(Vital humors), 
Vaatham, Pitham and Kabam 
 Symptoms are  
 Itching 
 Cracking 
 Oozing 
 Pus exudation 
 Sloughing 
 Oliguria 
 Fatigue 
ehbeil: 
1. jhdKs;s Nrj;Jke;jhdpsfpy; 
..…… fug;ghd; tpuzNjhlk; 
2. rpwg;ghd thjj;jpy; cl;ze;jhNd Nrh;e;jpLfpy; 
……………………… kjfhpePh; fug;ghd; 
       -FUehb 
NAADI PATTERNS IN KARAPPAN: 
  Vaatha kabam 
  Kaba vatham 
  Vatha Pitham 
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DIAGNOSIS OF KARAPPAN 
 Diagnosis of Karappan in Siddha system is mainly based on Envagai Thervu 
(Eight types of examination), Poriyal arithal and vinathal. 
PATHOPHYSIOLOGY 
   Changes in lifestyle, occupation, food and habits 
  
 
  Derangement of macro elements in the body (Panchaboothangal) 
 
 
         Derangement of Uyir Thaathukkal  
 
 
    Derangement of seven Udal Thaathukkal 
 
      Karappan 
 
UYIR THATHUKKAL 
Vaatham 
 In Karappan commonly affected types of Vaatham are Abanan, Viyaanan, 
Samaanan and Devathathan. 
 Derangment ofAbaanan (Vaayu + Theyu) leads to constipation. 
 Derangement of Viyanan (Vaayu + Earth) leads to itching, dryness of skin, 
thickness. 
 Involvement of Samanan (Vaayu + Aahayam) leads to imbalance of functions of 
other Vaayukkal. 
 Derangement of Devathathan (Vaayu + Vaayu) leads to sleep disturbances. 
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Pitham 
 In Karappan commonly affected type of Pitham is Ullollithee (Prasakapitham). 
 Normally Prasakapitham gives complexion to the skin. In Karappan the skin 
becomes hyperpigmented and lose its normal colour. 
Kabam 
 In Karappan commonly affected type of Kabam are Avelambagam and 
Kilethagam. They may have indigestion and any lung disorders. 
 UDAL THAATHUKKAL 
Imboothangal are important in the formation of  body constituents mainly by 
Pancha bootha panchikaranam theory. Derangement of body constituents especially 
Saaram and Senneer causes karappan. 
Derangement of Saaram leads to depression and tiredness of mind and body. 
Deranged Senneer causes itching, affects colour of the skin. 
GNANENTHIRIYAM 
Imboothangal forming the basic constituents of Gnanenthiriyam get deranged. 
Commonly affected Gnanenthiriyam is Mei producing itching, papule, vesicle formation, 
oozing, crusting, scaling, and hyperpigmentation. 
KANMENTHIRIYAM 
Imboothams forming the basic constituents of Kanmenthiriyam were not 
commonly affected in karappan. 
PINIYARI MURAIMAI (DIAGNOSTIC METHODS) 
 Piniyarimuraimai is the method of diagnosing disease. It is based on the 
following principles: 
 1. Poriyalarithal (Examination by the sense organs) 
 2. Pulanalarithal (Examination of  the sensory function) 
 3. Vinaathal (Interrogation) 
 Poriyalarithal and pulanalarithal goes hand in hand with the concept of examining 
the patient‟s „Pori‟ and „Pulan‟ with that of physician‟s „Pori‟ and „Pulan‟. 
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„Vinaathal‟ is a method of enquiring about the details of the patient‟s problem 
from his own words or from the person who take care of the patient, when the patient is 
not able to speak (or) if the patient is a child.’ 
Envagai  Thervu (Eight Types of Examination) 
“ehbg; ghprk; eh epwk; nkhoptpop 
kyk; %j;jpukpit kUj;JtuhAjk;” 
     -Njud; 
The Eight Types of Examination 
1. Naadi (Pulse reading)  
2. Sparisam (Tactile sensation)  
3. Naa (Tongue)  
4. Niram (Color)  
5. Mozhi (Speech or Voice)  
6. Vizhi (Eyes)  
7. Malam (Stools)  
8. Moothiram (Urine)  
1. Naadi 
In Karappan the following types of naadi could be felt. They were, 
 Vathapitham 
Pithavatham 
Kabam 
2. Sparisam 
In Karappan patient’s general body temperature  - slight warmth, dryness, 
roughness and elevation of skin was noted. 
3. Naa 
In some patients, coated tongue was noted. 
4. Niram 
            Skin colour becomes hyper or hypopigmented in the affected area. 
5. Mozhi 
No change or disturbance in voice was noted. 
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6. Vizhi 
There are no changes in the vision. 
7. Malam 
           In Karappan some patients have constipation. 
8. Moothiram 
Neerkuri (Physical examination of urine) 
Urine is collected after taking a well-balanced diet, which do not alter the three 
vital humors. It should be examined within 3-3/4 Nazhigai. (90 minutes). 
 “te;j ePh;f;fhp vil kzk; Eiu vQ;rnyd; 
 iwe;jpaYstit aiwFJ KiwNa” 
       -Njud; ePh;f;Fwp nea;f;Fwp 
In Neerkuri the Niram (Colour), Manam (Odour), Nurai (froth), Eadai (specific 
gravity) and Enjal (deposits) are noted. 
Apart from these the frequency of urination, abnormal constituents such as sugar, 
protein, presence of blood, pus, and crystals must also be found out. In Karappan patients 
straw coloured urine was noticed. 
Neikkuri (oil in urine sign) 
The collected specimen as said above is to be analyzed by following method. The 
specimen is kept open in a glass dish or china clay container. It is to be examined under 
direct sunlight, without any shaking of the vessel. 
Then add one drop of gingelly oil on the surface of the urinary specimen and the 
Neikkuri was noted in direct sunlight, and conclude the diagnosis as follows:  
Character of Vatha neer 
 ”muntd ePz;bd/Nj thjk;”  
 When the oil drop lengthens like a snake, it is called “Vaathaneer”. 
Character of Pitha neer  
     “Msp Nghw;gutpd; m/Nj gpj;jk;” 
When the oil drop spreads like a ring, it is called “Pithaneer”. 
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Character of Kaba neer 
 “Kj;njhj;J epw;fpd; nkhoptnjd; fgNk” 
 When the oil drop appears like a pearl, it is called “Kabaneer”. 
Character of Thontha neer 
Snake in the ring, ring in the snake, snake in the pearl and ring in the pearl are the 
characters of Thonthaneer. 
NOIKANIPPU VIVAADHAM (DIFFERENTIAL DIAGNOSIS): 
 glh;jhkiu ngUNeha; (Gz;lhPff; Fl;lk;): 
  “$LNkjhkiuapd; G+tpjo;g; Nghy; 
   Ftpe;JNkfWg;NghL ntSg;GkhFk; 
  NjLNk rptg;Ggyth;zkhFk; 
   jpdTkpfthuhJnrhidapw; gd;dPh; 
  thl;Lnkma;apDk; gj;jpahfp 
   tUj;jkpfTz;lhfp NehTkhFk; 
  NghLNkrhPuq;fs; Kfq;fs; fhJ 
   Gz;lhPff; Fl;lj;jpd; GJikjhNd“ 
        -A+fp itj;jpa rpe;jhkzp 
 PADARTHAMARAI PERUNOI - YUGI VAITHYA CHINTHAMANI 
   Symptomised by  
 Erythematousness 
 Hypo and Hyperpigmentation 
 Excessive fatigue 
LINE OF TREATMENT 
 In Siddha system of medicine, the main aim of the treatment is to cure the disease 
by removing the root cause. Treatment is not only for perfect healing but also for 
prevention and rejuvenation. 
  “Neha;ehb Neha;Kj dhb aJjzpf;Fk; 
  tha;ehb tha;g;gr;nray;“; 
 Thiruvalluvar says in “Thirukkural“ about physician‟s duty to study the disease, 
study the cause, seek subsiding facts and do what is proper and effective. 
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 In Siddha system, the line of treatment consists of  
 Neekkam (Treatment) 
 Niraivu (Rejuvenation of wellbeing) 
 Kaappu (Prevention) 
 Rules for healthy living has been quoted in Patharthaguna chinthamani as 
follows, 
  “jpz;z kpuz;Ls;Ns rpf;f tlf;fhkw 
  ngz;zpd;gh nyhd;iwg; ngUf;fhky; - cz;Zq;fhy; 
  ePh;Ruf;fp Nkhh;ngUf;fp nea;Auf;fp Az;gth;jk; 
  NgUiuf;fpw; NghNk gpzp“ 
        -Njiuah; 
Treatment 
 tpNurdk; 
 cs;kUe;J 
 ntspkUe;J 
 gj;jpak; 
Viresanam(Purgation): 
  “tpNurdj;jhy; thje; jhOk; 
  tkdj;jhy; gpj;jk; jhOk; 
  erpa mQ;rdj;jhy; fgk; jhOk; 
  Jfpd;w kyf;fl;il nahopa itj;jhy;  
  clypYs;s thijnayh nkhLq;fpg; NghFk; 
  mwpe;jpLk; thjk; mlq;Fk; kyj;jpdpy;“ 
 For purgation, Agasthiyar Kuzhambu 130 mg with Sangan kuppi juice was 
administered at early morning empty stomach before starting the treatment to bring the 
vitiated  Uyirthathukkal to normal. 
Internal Medicine: 
 Nilavaagai chooranam - 1 gm, two times a day with ghee 
Anubanam: 
 “ mDghdj;jhNy atpo;jk; gypf;Fk; 
 ,dpjhd Rf;F,Q;rp - gpDKJfhy; 
 Nfhkak;ghy;Kiyg;ghy; Nfhnea;Njd; ntw;wpiyePh; 
 Mkpijah uha;e;J nra;ayhk; “ 
        -Njiuah; ntz;gh 
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External Medicine: 
 Thengaai Thylam 
Pathiyam (Dietary Regimen): 
 “ ngUFQ; Nrhs kpWq;Fk; ngUq;fk;G 
 tuF fhUld; thioapd; - fhnahL 
 ciunfhs; ghfw; nfspw;WkPd; cz;bby; 
 tphptjha;f; fug;ghD kpFe;jNj“ 
        -gjhh;j;j Fz rpe;jhkzp 
 “GspJth; tpQ;R fwpahh; G+hpf;Fk; thjk; “ 
        -gjhh;j;j Fz rpe;jhkzp 
 In Siddha system of medicine the importance of dietary habits also emphasised 
for the diseases management and prevention. This line is well understood in the verse, 
given above. In diseased conditions diet restrictions or pathiyam are strictly followed to 
increase the effectiveness of medicine for curing diseases.  
 Diet  restrictions or pathiyam should be strictly followed in Karappan patients. 
These are prescribed to normalize the deranged thodam and to increase the potency of 
the drugs. 
 Patients are strictly advised to follow the dietary and other restrictions: 
 Avoid the maize, pearl millet, kodomillet, fox tail millet, sesban, brinjal, 
kaararisi, bitter gourd, pickles, tamarind 
 Avoid all non-vegetarian foods such as fish, prawns, crab, chicken etc. 
 Avoid substances allergic to the particular individual 
 To take Thiridhoda samapporulkal (elam, manjal, seeragam, kaayam, 
chukku, venthayam, poondu, milagu) 
 To take vegetables and green leafy vegetables 
 To take more germinated grams, dates, figs and powder of fenugreek 
regularly 
 To avoid hard soaps or Sikakkai to clean the site of lesions 
 To use green gram powder or any other Siddha herbal preparation for 
bath 
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SPECIAL TREATMENT: 
BLOOD LETTING: 
 A person gets disease either because of his food habits or actions. His physical 
constituents are deranged. This is rectified initially by purgative, emetic, diaphrotic or 
nasal application methods. But in the later stages the impured blood is removed by 
blood letting. 
 Blood letting is done by 
1. Leech application 
2. Sucking using hollow horns (drains) and 
3. Venesection (incisions of the blood vessel) 
 Blood letting is done in psychiatric illness, diseases of the head, ear eye and 
tongue, colic pain, elephantiasis, swelling in the neck, infective mono-arthritis, 
lumbago, diseases of the blood caused by deranged Vatham, Pitham and dermatological 
conditions. Blood letting should not be done in respiratory diseases, inclusive of 
tuberculosis, paralysis of the whole body (quadriplegia), convulsion, jaundice and 
anaemia. 
 This should not be done to a person who is frightened, drunkard, dancer, involved 
in sexual activity, do not posses the manly qualities, children, elders and persons not 
afflicted with any disease. But if any person is suffering from a poisonous bite and if 
there is a danger for his life (ie acute condition) blood letting may be done. 
 Blood letting should not be done in a cloudy or a windy day for the bleeding will 
not be proper.       
(A Compendium of Siddha Doctrine)   
ml;il tply; - Leech Therapy 
 Leech application to locally affected areas, blocks or swelling is known as Attai-
vidal. A treatise compiled by Dhanwantri on the art of healing by the use of leeches; a 
science on leech-craft. Attai vidal is defined as application of leech in part of the body 
for sucking the blood for the purpose of curing the disease. 
   “ml;ilapd; tpjpjid awpa ahtUe; 
  jpl;lk jhfNt nrg;g Td;dpNdd; 
  kl;lkh; Foypdhs; tud spj;jpLk; 
  ,l;ltp ehafd; ,izab Nghw;wpNa“ 
      -mfj;jpah; ead tpjp Ie;Ehw;W 
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,Ug;gplk;: 
 Mokpy;yhjJk; MoKilaJkhd njspe;j ey;y ePhpy; my;yp> nea;jy;> 
nfhl;b Nghd;w kzKs;s nrbfs; ,Uf;Fkplq;fspy; fpilf;Fk;. kw;Wk; ,J> 
kzypd; fPo;> kiwthf xJq;fpf; fpilg;gJk; cz;L. ,t;tl;iliag; gpbj;J 
Kf;fhy; ghfk; ePUs;s thafd;w fz;zhbg; Gl;bapy; tpl;L me;ePhpy; czTf;fhfr; 
nrt;ty;yp> nfhl;b> gRkQ;rs; ,tw;wpd; fpoq;Ffspnyhd;iw miuj;Jr; Nrh;j;J> 
,t;tl;il gw;wpf;nfhz;L cwq;f ,iyfs; ,l;L> Gl;bapd; thia xU nky;ypa 
Jzpahy; %b> mbf;fb ePiu khw;wpf; nfhz;L te;jhy; gy jpq;fs; capUld; 
thOk;. 
  “MjpNah jpaNt jj;jpy; ml;ilf;F Nkdp Ae;jhd; 
  Vnjdpy; gy;Y %d;W kpad;wmQ; rLf;Fj; NjhYk; 
  Xjpa KfKk; gr;ir cjpuKQ; rptg;gha; gpd;id 
  jPjyhg; gf;f kpuz;Lk; gUj;jpLk; euk;G NrUk; 
  mutpd; tha;j; Njiug; Nghd;Wk; mzpkOj; jiyNa Nghd;Wk; 
  gUjpapd; igq;fz; Nghd;Wk; gykzp rpjwp dhw;Nghy; 
  tputpNa gy;ne fpo;e;J nkj;jnjdf; fbf;Fk; ml;il 
  fUjpNa fhyd; jd;idf; fl;bLq; fhae; jhNd. 
  nts;is epwj;jhd; Ntjpadhh; kpFnrq;fOePh; rj;jphpad; 
  nrhy;Yk; gtsk; itrpadhQ; #j;jpu ndYkpr; rk;gokhq; 
  fy;iyg; Nghyf; fjpj; njOe;j fUJ Gwj;jpy; tpLtPNuy; 
  nks;sf; fiuj;jpl; NlhLnkd tpsk;gpr; nrhd;Ndhk; Nkjpdpf;Nf“  
       -mfj;jpah; ead tpjp Ie;Ehw;W
   
tiffs;: 
 ml;il %d;W tifg;gLk;. mit ey;y ml;il> jPa ml;il> rhjhuz 
ml;il vdg;gLk;. ,tw;Ws; 1) ey;y ml;il ehd;F tifg;gLk;. 
 Kjy; tFg;G - ntz;ikAk; rpwpJ nghd;epwKk; nghUe;jpapUf;Fk;. 
 ,uz;lhk; tFg;G - nrq;fOePh; epwkhapUf;Fk;. 
 %d;whk; tFg;G - gto epwj;ijAk; mhprpapd; cUtj;ijAk; ngw;wpUf;Fk;. 
 ehd;fhk; tFg;G - gr;ir my;yJ vYkpr;irk;go epwkhFk;. 
2) jPa ml;il 
 fUepwk;> fUQ;nrk;ik epwk; my;yJ thdtpy; Nghd;w epwk; Mfpa gy 
epwq;fisg; ngw;wpUf;Fk;. 
3) rhjhuz ml;il 
 nghd;epwj;jpy; fUepwk; nghUe;jpapUf;Fk;. 
Mas;Ntj Ehypd; gb ,J 12 tifj;jhapDk; itj;jpaj;jpw;F 6 tif khj;jpuk; 
Njh;e;njLf;fg;gl;lJ. kw;w 6k; tp\ jd;ikAilaJ. gad;gLk; MW tifg;gLk;. 
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 fgpyk; (tawny leech) 
 gpq;fiy (one of pale red tinge) 
 rq;FKfp (one with a yellow long sharp head) 
 %\pfk; 
 Gz;lhPfKfp (that which is brown in colour and with mouth like the flower 
nelumbu) 
 rghpfk; (that which resembles the leaf of the lotus flower in colour) 
The other species of leeches common in South India are: 
1. The English or speckled leech. It has 6 stripes spotted with black and a belly 
greenish yellow and spotted. 
2. The Peculiar Madras leech is a bdellium found in stagnant ponds and ditches. It is 
larger than the European leech and very voracious. These are used by Vaidynas 
and Ilekeems in the same way as is done by Europeans. 
3. The large Horse leech has depressed body and a dusky coloured back with the 
belly yellowish green. 
4. The Ceylon leech about an inch long with point so sharp as to make its way 
through small openings is dangerous to pedestrians in certain seasons. It attacks 
the feet, the legs and the thighs. 
 In Surgery, it is used experimentally for intravenous and intraperitoneal 
injections. It has an extract prepared from the head which is employed to prevent the 
formation of blood clots. 
ml;ilapd; clyikg;G: 
 rhjhuz ml;il 2 (5 nr.kP) Kjy; 4 mq;Fy (10 nr.kP) ePsKs;sjha; 
rpwpJ $h;ikahd KidfSld; Gwj;Njhypy; 6 ePsf; NfhLfSilajha; FWf;Fr; 
RUf;fq;fisAk; ngw;wpUf;Fk;. ml;ilf;Fg; gy; %d;W> NjhyLf;F Ie;J> Kfk; 
gr;ir my;yJ rptg;G gf;fkpuz;bYk; gUj;j euk;G ,Uf;Fk;. Xh; ml;il Rkhh; 
120 Jsp ,uj;jk; tiu ,Of;Fk; td;ik cilaJ. ml;il cwpQ;Rtjdhy; 12 
mq;Fyk; tiu cs;s ,uj;jk; ntspg;gLk; vd;gij> 
 “ml;iltpb Yjpuk; Mwpuz;lq;Fyk; Nghk; “ vd;w njhluhy; mwpayhk;. 
gad;gLk; ml;ilapd; vz;zpf;if: 
 MWkhjj;jpw;Ff; fPo;g;gl;l Foe;ij - xU ml;il 
 xU tU\j;jpw;Ff;; fPo;g;gl;l Foe;ij  - ,uz;L ml;il 
 ,uz;L  tU\j;jpw;Ff;  fPo;g;gl;l Foe;ij - %d;W ml;il 
 %d;W  tU\j;jpw;Ff;; fPo;g;gl;l Foe;ij  - ehd;F ml;il 
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 jiyNehTld; tUk; Ruq;fSf;F gpzpahsp thypgdhAk; ngythdhAk; 
,Ug;ghdhfpy; - new;wpnahd;wpy; 4 my;yJ 6 ml;il(gplhpapd; Nkw; 
gf;fj;jpy; fbf;ftpl;lhy; mjpfFzq;nfhLf;Fk;) 
 Ruj;Jld; khh;gpYk; tapw;wpYk; fbdkhd typfSf;F - 8 my;yJ 10 
ml;il typapd; Nky;tpl Ntz;Lk; 
 tpg;GUj;jpfs;> gUf;fs;> miuahg;Gfs;> erpTfs;> RSf;Ffs;> fbfs; kw;Wk; 
Njhypd; Nky; tUk; ,uj;jr;Rug;Gfs; - 6 my;yJ 8 ml;il tpl;L 
RLjz;zPuhy; xw;wlkplTk; 
 ff;fpUky;  njhlq;fpdnghOJ Foe;ijapd; taJ xd;Wf;F xt;nthU 
ml;il tPjk; Kiwaha;f; $l;b MWtaJ tiutplyhk; mg;Gwk; vj;jid 
tajhapUg;gpDk; 6 ml;ilNa NghJkhdJ 
 fz;Nzha;fSf;F - 4 my;yJ 6 ml;il filf;fspd; mUNfapUf;Fk; 
nghl;Lfspy; tplTk; 
        -,uz itj;jpa rpe;jhkzp 
kUj;Jtj;jpw;F Mfhj ml;il: 
  “Mfh tl;il aJNfsha; 
   mytd; jtis ePh;g;ghk;G 
  Nkfh ryj;jpy; gpwe;jdTk; 
   Ntz;lh rUfpw; gpwe;jdTk; 
  Nghfhr; Ridapy; gpwe;jdTk; 
   nghy;yh tl;il apitnad;Nw 
  ghfhh; nkhopnfhs; ige;njhbNa 
   ghuh al;il tFg;gpidNa“ 
 ez;L> jtis> ePh;g;ghk;GfisAila ePh; Xl;lkpy;yh ePh;epiy> rU$wpa ePh; 
,itfspw; gpwe;j ml;il kUj;Jtj;jpw;fhfhthk;. 
nra;ifAk; Ml;rpAk;: 
  “Kd;Nd Nfsh al;ilajd; 
   Fzj;ijr; nrhy;td; nkha;FoNy 
  me;ehsd;dk; ghy;gUFk; 
   mJNghy; thq;Fk; tp\ePiu 
  ed;dhs; ghh;j;J Nehawpe;J 
   eade; jd;dpy; tpLthahy; 
  nrhd;NdhQ; nrhd;Ndhk; ehw;wpirAe; 
   Jyq;fr; nrhd;NdhQ; nrhd;NdhNk “ 
      -mfj;jpah; ead tpjp Ie;Ehw;W 
 md;dk; ePiug; gphpj;Jg; ghiyg; gUFtJ Nghy> ml;ilahdJ tplePiug; 
gUfp ,uj;jj;ijr; Rj;jp nra;Ak;. 
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 tPf;fk; ePf;FQ; nra;iff;fhf fhh; ,uj;jf; Foiyf;fPwp ,uj;jj;ij 
ntspg;gLj;jy; Nghy ,ijr; rpwg;ghf ,uj;jj;ij ntspg;gLj;j Kjpath;f;Fk;> 
ngz;fSf;Fk;> rpWtUf;Fk;> nkd;ik cliyg; ngw;Nwhh;f;Fk;> MAj rpfpr;irf;Fg; 
gae;jth;f;Fk;> gpj;j clk;gpdh;f;Fk; rpwg;gha; cgNahfpf;fyhk;. 
  Rit - ,dpg;G 
  jd;ik - Fsph;r;rp 
  gad; - gpj;j Neha;fs; ePq;Fk; 
ml;ilapd; Rj;jpKiw: 
  xU thafd;w gPq;fhd; ghj;jpuj;jpy; kQ;rs; fiuj;j ePhpl;L ml;ilia 
mjpy; tpl mjd; clk;gpdpd;W Nfhionahj;j fopg;nghUs; ntspahFk;. gpd;Ng 
me;j ml;ilia cgNahfpj;jy; Ntz;Lk;. ,f;fopg;nghUs; mjpfkhapUg;gpDk; mJ 
ePhpy; RWRWg;gha; XlhtpbDk; mt;tl;il gw;whJ. 
 
Nehahspiaj; jahhpf;Fk; tpjk;: 
    “rj;jpapy; khe;j Uf;Fe; 
   ijay;gps; isah;j kf;Fk; 
  xj;Jepd; Whl;L tpj;J 
   cwf;fKe; jtph;e;jp lhky; 
  kj;jpah dj;J Nkyha; 
   kz;nfhz;L Rj;jp gz;zpg; 
  gw;wpa Neha;fs; jd;idg; 
   ghh;j;JeP ml;il fl;Nl"  
 NehapdDf;F Kd;dhs; Ngjpf;F my;yJ tpah;it ngUFtjw;F my;yJ 
the;jpf;Ff; nfhLj;J kWehs; ml;ilia tplNtz;Lk;. ml;il tpLk;NghJ 
Nehahspf;Fg; gl;bdpNah Jhf;fkpd;ikNah $lhJ. mJ tpl Ntz;ba ,lj;ij 
cth; kz;Zk; kzYk; nfhz;L fOtpr; nrk;kz;zhy; G+r Ntz;Lk;. 
ml;il tpLjw;F Vw;w Neuq;fs;: 
 ml;il tpl eLg;gj;J ehopif rpwe;jjhapDk;> Foe;ijfSf;Ff; fhiyapy; 
tplNy ed;W. Vnddpy; khiyapy; tpl;lhy;> xUfhy; ,utpy; fbthapdpd;Wk; 
,uj;jk; ngUfpd; ftdpf;f ,ayhJ. mjdhy;> Mgj;J NeUk;. rpWth;fSf;F 
,uj;jk; tpiutpy; ntspg;gLkhifahy;> fz;fhzpg;ghf vd;gpUf;Fkplq;fspy; tplNy 
ed;W. 
fbf;Fk;gb nra;Ak; tpjk;: 
 tha; FWfyhd ePh; epiwe;j ghj;jpuj;jpy; ml;ilia tpl;L mg;ghj;jpuj;jpd; 
thiaf; fbf;ftpl Ntz;ba ,lj;jpy; ftpo;j;J ePh; ntspg;glh tz;zk; gpbj;jhy; 
gw;Wk;> gw;whtpbd; ,lj;ijj; Jilj;J xU Jsp ghiyj; jltp ePhpy; eidj;Jg; 
gpope;j gQ;rhy; ml;ilia nky;nydg; gpbj;Jtplg; gw;Wk;. ,jw;Fk; gpbf;fhtpbd; 
,lj;ijr; Rj;jkhd Fz;^rp nfhz;L ,uj;jk; rw;Nw frpAk; tz;zk; fPwp> 
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mjd;kPJ ml;ilia tpl m/J clNd gw;wpf; nfhs;Sk;. ml;ilapd; Kfk; 
nghpjhd Kid Fjpiuf; Fsk;G Nghd;w cUtj;Jld; kpf Ez;zpa tpah;itj; 
JspAld; Njhd;wpdhy;> ed;wha;f; nfstpf; nfhz;lnjd;W czh;e;J> mjd;kPJ < 
nkha;j;J ,uj;jk; ,Og;gijj; jLf;fhkypUf;f <uj;Jzpapl;L kiwf;fTk;. 
fbj;j ml;il fPNo tpo: 
 ml;il miukzpapypUe;J ehd;F kzp Neuj;jpw;Fs; ,uj;jj;ijf; Fbj;Jj; 
jhNd fPNo tpOe;J tpLk;. fPNo tpor; nra;a Ntz;Lkhapd; cg;G ePh; my;yJ 
fhbePiuf; fbthapy; njspf;fTk;. ml;il %f;fpd; njhis> Fjk;> Fa;ak; 
,tptplq;fspy; Gfe;Jtpbd; mjid ntspg;gLj;j Nkw;gb rpfpr;irNa nghUe;Jk;. 
fbthapy; ,uj;jj;ij epWj;jTk; ngUf;fTk;: 
 ml;il tpOe;jgpd; fbthapdpd;Wk; ,uj;jk; mjpfkhf ntspg;gbd;> nghhpj;j 
gbfj;Jhs;> JUrpd; Jhs;> kQ;rl; Jhs;> gQ;R Rl;l fhp> rPiyf;fhp> rpye;jpf;$L> 
khrpf;fha;j;Jhs; ,itfSs; Vjhtnjhd;iwf; fbthapypl ,uj;jk; epw;Fk;. 
epw;fhtpbd;> fbthia tpuyhy; rpwpJ Neuk; mOj;jpdhYk;> fhbf;fhuKidahy; 
njhl;lhYk; Jz;Lr; rPiy itj;J mOj;jkhff; fl;bdhYk; epd;WtpLk;. ,jw;Fk; 
gyd; ,y;iyNay;> gOf;ff; fha;r;rpa Crpahy; fbthiar; Rl epw;Fk;. 
 fbthapdpd;Wk; ,uj;jk; ntspg;gLk;gb nra;a> nte;ePh;> jtpL> nehr;rpapiy> 
Ntg;gpiy ,itfSs; xd;iwf; nfhz;L xw;wlkplTk;. ml;il tpLjy; ed;F 
epiwNtwpw;nwd;gjw;fwpFwp> nfl;l ,uj;jk; ePq;fpaTld; Nehapdhy; cz;lhd 
NrhfKk; NtjidAk; ePq;Fk;. ,jid> 
  “Jl;luj;jk; Nghdf;fhy; Nrhf Kld;$ba 
  jpl;lKld; NtjidAk; jPUNk - tl;ljd 
  khNd> cUtpDf;F kw;nwhd;Wk; thuhJ 
  jhNd jdf;Fepfh; jhd; “  
Fw;wj;jpd; msthff; FUjpapy; Vw;gLk; khWjy;fs;: 
 tspNflile;jpUgpd; FUjpapy; ntz;zpwKk;> moy; nfl;bUg;gpd; kq;fyhd 
ePy tz;zKk;> Iak; Nflilapd; ,Us; epwKk; fhzg;gLk;. 
,uj;jj;ij mjpfkhf cwpQ;RtjdhYz;lhFk; nfLjpfs;: 
 ml;il kpQ;rpdhYk;> ,uj;jk; mjpfkha; ntspg;gl;lhYk; fbthapy; jpdT 
cz;lha;f; fLj;J tPq;Fk;. 
  “mQ;Rtpuy; ePsj;jpy; ml;il tplyhFk; 
  kpQ;rNt ml;iltpl Ntz;lhk; - k-Q;rpd; 
  fbtha; jpdtha; fLj;Jtyp tPq;Fe; 
  JbahU ey;ypilaha; nrhy; “ 
 mjdhy; ePhpy;yhg; gaph; Nghy Nehahsp thl;lkile;J caph; Jwg;gjw;F 
topAz;L. 
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ml;ilf; fbapdhy; cz;lhd Gz;Zf;Fr; rpfpr;ir: 
 fhb> fhnus;> fw;whio ,k;%d;iwAk; miuj;J Nky; G+rpte;jhYk;> 
fw;whiokliyr; Rl;L ,uz;lha;g; gpse;J kQ;rs; Jhisj; Jhtpg; Gz;zpd; kPJ 
itj;Jf; fl;bdhYk; ePq;Fk;. 
xU Kiw cgNahfpj;j ml;ilia kWKiw ghtpf;f: 
 fbj;J tpOe;j ml;iliaj; jtpl;by; tpl;Lg; Gul;bNah Gul;lhkNyh> mjd; 
thapy; vs;spd; nghb my;yJ kQ;rs; nghbiaj; Jhtpd; ,uj;jj;ijf; ff;Fk;. 
mJ rhpahf ntspg;glhtpbd;> ,U tpuy;fshYk; nkJtha;;g; gpd;dpypUe;J Kd; 
ml;iliag; gpbj;Jtpl> ,uj;jk; ed;wha; ntspg;gLk;. gpwF> Gw;Wkz; fiuj;j 
njspePhpy; tpl;L itj;jpUe;J> mjd;gpd; Kw;$wpa ePhpy; gj;jpug;gLj;j Ntz;Lk;. 
,jid> 
  “Fbj;JtP ol;ilia nfhz;Ljtpl; by;tpl;Nl 
  gpbj;jjpd;tha; vs;sjidg; nga;J - gpbj;Jtpl 
  tpl;luj;jk; Nghdhy; JiyePhpy; ePe;jtpl;Lf; 
  fl;LtJ kz;Flitf; fz; “ 
 ghtpj;j ml;ilfisAk; ghtpahj ml;ilfisAk; ntt;Ntwhf itj;jy; 
Ntz;Lk;. xUKiw cgNahfpj;j ml;ilia VO ehl;fs; nrd;w gpd;Ng kWKiw 
ghtpf;fyhk;. ,t;thW ml;ilf;F Xa;tspf;fhky; jpUk;gj; jpUk;g tpbd;> mJ 
er;Rj;jd;ikia milAk;. mjdhy; fbthapy; tPf;fk;> Ntjid> Ruk;> jpdT> Gz;> 
fyf;fk; Kjypad cz;lhk;. ,jid> 
  “tpl;lTU NtNw tplhjTU jhd; NtNw 
  fl;Lk; FLitjdpy; “ vd;Wk; 
  “gl;l cUitg; gyfhYk; - tpl;LtpL 
  kj;jh YUtila khd tp\khFk; “ vd;Wk; 
  “tpl;lTUj; jhDk; tp\TUNt ahdf;fhy; 
  ntl;LUtha; tPq;FkJ Ntjidahe; - jpl;lQ; 
  Rukhq; fyf;fkhQ; #o;jpdTq; fhZk; 
  cukhFk; Gz;Z Kjph;e;J“ 
       -mfj;jpah; eadtpjp 
cgNahfk;: 
 mbgl;l tPf;fq;fs;> fl;bfs;> fpue;jp> tPf;fq;fs;> RSf;F> Njhy;> vd;G 
Nghd;w cWg;Gfisg; gw;wpa tPf;fq;fs; MfpaitfSf;F 
mt;tt;tplq;fspy; ml;ilia tpl;L ,uj;jj;ij ntspg;gLj;j me;Neha;fs; 
jPUk;. 
 kUj;Jtj;jpw;flq;fhj the;jpapy; neQ;Rf;Fopapy; tpl ePq;Fk;. 
 jhq;fhj; jiyNeha;f;Fg; nghl;by; tpl mJ jzpAk;. jzpahtpbd; gplhpapy; 
tplTk;. 
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 Ruj;jpYz;lhk; khh;GNeha;> tapw;WNeha; Mfpatw;wpw;F Neha; fz;l 
,lj;jpy; tplNtz;Lk;. 
 ,uj;j %yj;jpy; ,uj;jk; jilg;gLtjdhy; cz;lhk; jiyNeha;f;F> 
ml;iliaf; Fjj;ijr; Rw;wp tpl ePq;Fk;. Mdhy;> ,J Fjj;jpw;Fs; 
Gfhtz;zk; fhj;Jf; nfhs;sTk;. 
 #jfj; jilapdhy; cz;lhk; jiyNeha; ePa;fj; njhilfspd; cl;gf;fk; 
fbf;f tplTk;. 
 ,uj;j rPjNgjpapy; cz;lhk; tapw;Wf; fLg;Gj; jPu Fjj;ijr; Rw;wp tplTk;. 
 fy;yPuy; tPf;fj;jpw;F mt;tplj;jpy; tplg; gyd; jUk;. 
 rpwhUf;Fz;lhk; ff;Fthd; Neha; jPu eLKJfpd;Nky; tplTk;. 
 ehl;gl;lJk; gytifg;gl;lJkhd fPy;tPf;fq;fSf;F ml;il tpl;L ew;Fzk; 
fz;bUf;fpd;Nwhk;. 
 kw;Wk; fz;zpy; fdk; Njhd;wp typj;J> ePnuhOfpf; nfhz;L GUtj;jpy; 
typAz;lhdhy; ml;iltpbd; mJ ed;whFk;. ,jid> 
  “fz;zJ fdj;J nehe;J 
   fz;zpy; eP nuhOF khapd; 
  tpz;Zld; GUtj; NjhL 
   NkYw typj;j NghJ 
  epz;zpa ml;il tpl;L 
   epikngW ePse; jd;dpy; 
  jpz;zpa fpukj; jhNy 
   nra;tNjhh; fUkk; ed;whk; “ 
 NkNy Fwpg;gplg;gl;l FwpFzq;fs; vy;yhf; fz;Nzha;fSf;Fk; 
nghJthapDk;> rpwg;gha; Nej;jpur; #iy> thj fhrk;> fUtpopapy; cz;lhk; 
glh;tpuzk;> fhrNehapy; rhptur; r];jpu rpfpr;ir nra;ag;glhjjpdhy; cz;lhk; 
mow;rp ,itfSf;F ml;il tpl;Lg; gyd; fz;ldh;. kw;Wk; epikapy; ml;ilia 
tplNtz;Lnkd;W $wg;gl;bUf;fpwJ. mjw;F> filf; fz;zpypUe;J ½ mq;Fy (1.25 
nr.kP) Jhuj;jpy; GUt Kidf;Ff; fPo; tpLtJ eyk;. 
 Mz; jd;ikaw;wth;fSf;F ml;ilia ,ypq;fj;jpd; Nkw;Gwj;jpy; 
tpLtjdhy; nfl;l ,uj;jk; ePq;fpr; Rj;j ,uj;jj;jpdhy; Mz;Fwp 
tYtilAk;. 
ml;il tplf;$lhj ,lq;fs;> jpjpfs;: 
 ml;ilfisf; fhh; ,uj;jf; Foy;fs; Njhd;Wkplq;fspYk;> ehb 
ghprpf;fg;gLk; tPf;fq;fspYk;> fz;zpikfspYk;> Mz;Fwp> mz;lk;> Fa;ak;> 
];jdk; ,itfspd; kPJk; tplyhfhJ> tpbd; tPf;fj;ij cz;Lgz;Zk;. 
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  “rPUs gpujik NrUk; ngUtpuy; 
   Neh;ngWk; cs;sq; fhyJ Jjpia 
  jphpjpia Koq;fhy; Nrh;e;jpL nkd;f 
   rJh;j;jp ngUe;Jil jhtpa gQ;rkp 
  Fa;aj; jplj;Nj FbapUe;jpLkhk; 
   ma;aNd r\;b mah;e;jpLk; ehgp 
  rj;jkp Kiyapy; jhdpUe; jpLNk 
   xj;jpLk; m\;lkp NahjpNdhk; fuj;jpy; 
  nkj;jpL etkp Nktpa fOj;jpy; 
   mjue; jrkpap yhFkt; tplj;Nj 
  Vfh jrpapypUe;jpLk; ehtpy; 
   Jth jrpapy; Japd;wpLk; new;wp 
  jphpNah jrpapy; Nrh;e;jpLk; GUtk; 
   rJh;j;jp gplhp jhdpUe; jpLNk 
  cjpj;jpLk; G+uzk; cr;rpap YiwAk; 
   nrg;gpa tKjk; epiyepd; wjdhy; 
  rj;jpuk; gz;zpby; jhndOk; Neha;fs; 
   nfhg;gspj; jpbDk; Fj;jg; gbDk; 
  jg;gpyh mutk; jhd;fbj; jpbDk; 
   ml;il fbf;fpDk; mbjb rpye;jpAk; 
  tapw;wpy; gpzpnaDk; kuzk; jhFNk 
   fhrpdp jdpNy iftp\ jhhp 
  jpjpfis awpe;J nra;jplg; gypf;Fk; 
   kfpo;ngW Kdpth; kfpo;e;Jiuj; jdNu“ 
       -mf];jpah; ,uzitj;jpak;   
Description of Leeches 
 Leech taxonomy  
 Leeches are related to the phylum annelid, class clitellata, it is classified in to 4 
sub classes, 3 orders, 10families, 16 subfamilies, 131genera and 696 species. Leeches are 
hermaphrodite in nature and are distributed all over the world. In India, about 45 species 
belonging to 22 genera occur. The common Indian species are Hirudinaria granulosa, H. 
viridis, H.javanica, H. ventralis and H. manillensis. Hirudo medicinalis (Medicinal leech) 
is a European species which has been found in ponds and stream of the eastern portion of 
the United States. It is comparatively large in size and often growing up to 10 or more 
centimeters in length. 
 
30 
 
 Leech locality and ecology  
 The leeches are lived in different environment, including aquatic and moist area. 
Some leeches are live in fresh water, river, ponds, lake and sea. The leeches have high 
physiological flexibility, which make them able to withstand numerous environmental 
changes. According to Siddha system of medicine the medicinal leeches are live in pure 
water which contain Salli (Nymphaea stellata), Neithal (Nymphaea pubescens) and Kotti 
(Aponogeton monostachyon) plants. Small size leeches are only used for treatment 
purpose.   
Medicinal leech  
 There are about 600-650 species were found around the world, out of this only 
15-20 are used for treatment purpose. Hirudo medicinalis is the commonly used leeches 
for treatment purpose in western countries. In India, the leech Hirudo ventralis (Indian 
cattle leech) is used for medicinal purpose. Poisonous leeches are found in muddy water, 
gutters, or in water which is contaminated by urine.  Type of leeches The leeches are 
classified in to non-poisonous and poisonous. The poisonous leeches are lives along 
within frog and other water animals. They are comparatively bigger in size and darker in 
colour. After the application they produces severe pain, itching or allergic reaction  
 In Siddha system of medicine, the leeches are classified into three types (non- 
poisonous leech, poisonous leech and normal leech). Non-poisonous leeches are further 
classified into four class (class Iwhite with light golden colour, class II- colour like of 
Senkaluneer, class III- coral like colour and rice sized, class IV- green or lemon colour). 
Poisonous leeches are Black, blackish-red, and rainbow like multicoloured. Normal 
leeches are golden-colour with block.  
Morphology of leech  
 The leeches are segmented worm. Fully matured adults can be up to 20cm in 
length. Its colour is green, brown or greenish brown with darker tone on the dorsal side 
and lighter on ventral side. It has two suckers, one at each end called anterior and 
posterior sucker. The anterior sucker is used for feeding.   
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Maintenance and storage of leech  
 The leeches are stored in well labelled container having multiple pores on the top 
for proper aeration. The temperature should be maintained around 5-27 
0
C, the water of 
the container should be pure and de -chlorinated and should be replaced once in 3 days. 
The place should be darker and ventilated  
Benefits of leech therapy  
 According to Siddha system of medicine Leech sucks impure blood from our 
body, so it is used to detoxify the blood and neutralise the vitiated Thrithodam.  
Important point in leech therapy  
 One session of leech therapy requires about 1-2 hrs and about 1-6 leeches are 
required depending upon the clinical condition. It leaves Y-shaped bite mark and it is 
disappears within 23weeks.Symptoms of excessive blood loss are red skin, itching, pain 
and fever. The leeches should be suck only impure blood, when leeches start to suck pure 
blood produces the symptom of pricking pain and itching at the site of the bite.   
Selection of leeches for leech therapy  
 Non-poisonous are only used. Too small or too long leeches are not to be 
preferred, only medium sized leeches are used.   
Frequency of leech therapy  
 It varies according to the severity of diseases; generally, it should be applied once 
in a week.   
Precaution during leech therapy  
 The patients with bleeding disorders like haemophilia, highly infective patients 
like HIV patients and hepatitis B patients are not advised for leech therapy. The leeches 
used for one person are not used for another person to avoid cross infection. The therapy 
should be done with proper disinfecting condition. Complication of infection were 
occurs only in 2-36% of patients. There are no reports of leech transmitted diseases in 
leech application.  
Complication of leech therapy  
 The most important complication is the risk of leech borne infection caused by 
bacterias aeromonas hydrophilia present in the leech gut, which may cause pneumonia, 
septicaemia or gastroenteritis. Allergic reaction may occur in leech site. Ulcerative 
necrosis may occur due to toxins present in leech saliva. Prolonged bleeding and rarely 
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ulcer formation may occur at the site of bite. Excessive bleeding that may require a blood 
transfusion is another complication in leech therapy.  
Disposal of leech  
 The used leech should be destroyed with 70% of alcohol and disposed like that of 
biomedical waste. 
Mechanism of action  
 In Siddha system of medicine the leech therapy was used as one of the 
bloodletting technique to remove the toxic blood from the body. According to Siddha 
concept, the leech application works on the basis of normalisation of Uyirthathukal by 
removing toxic blood from the body and cure the diseases. Leech therapy was used for 
various diseases especially for Pitham vitiated diseases, because the leech has Thatpa 
Gunam (Cold potency).  
 The apparent benefits of leech therapy are that they help relieve venous 
congestion by removing excessive collective blood physically from congested tissue. 
From modern concept, as proved by various research studies, the efficacy of leech 
therapy is not only in the amount of blood that the leech ingested, but it is also by leech 
saliva which contains more than 100 biological active compounds which cause effect of 
leech therapy. The salivary glands secretion has analgesic, anti-inflammatory, 
bacteriostatic activity. It also have resolving activity, eliminate the microcirculation 
disorders, restore the vascular permeability of tissue and origins, reduce the blood 
pressure, eliminate the hypoxia, increase the immune system activity, detoxifies the 
organism by antioxidant pathway, and improve the bioenergetics status of organism. This 
active compound includes anticoagulant Hirudin, Calin, inhibitor of kallikrein, 
hyaluronidase, histamine like vasodilators, collagenase, analgesic, anti-inflammatory 
substance, destabilase, hirustasin, tryptase inhibitor, Eglin, acetylcholine, 
carboxypeptidase A inhibitors, immune-modulator effect, etc.  
 Hirudin is responsible for anticoagulant of blood and it is used as anticoagulant in 
surgical procedure. Calin is also anticoagulant substance but it is responsible for 
secondary bleeding for approximately 12 hours in leech bite site. Hyaluronidase is 
facilitating the penetration and dilution of pharmacologically active substances into 
tissue, particularly in joint pain and also has antibiotic activity. Destabilase is dissolves 
fibrin and has thrombolytic effect. Hirustasin inhibit strypsin, kallikrein, chymotrypsin 
and neutropholic cathepsin. G.Bdellins has anti-inflammatory effect and inhibits trypsin, 
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plasmin and acrocin. Chloromycetin is potent antibiotic. Eglin is anti-inflammatory and 
inhibits the activity of alpha-chymotrypsin, chymase, subtilisin, elastase and cathepsin. 
Factor X an inhibitor inhibits the activity of coagulation factor X.Aesthetic-like 
substance reduces pain during biting by a leech. Acetylcholine is vasodilator. 
Collagenase reduces collagen and carboxypeptidase A inhibitors increases the inflow of 
blood. Histamine like substances cause dilatation of blood vessels and produce bleeding. 
Some of the substances were also have antiinflammatory effect. On the basis of 
lipotropic activity it can be used for ischemic heart disease. The biological active 
compound present in leech saliva act on target organ through vein during sucking of 
leech and increase the blood circulation in the organ.  
Indication for leech therapy in Siddha system of medicine  
 Traumatic oedema, tumour, abscess, sprain, uncontrolled vomiting, headache, 
abdominal and chest diseases, hepatomegaly, abdominal cramps caused by dysentery, 
whooping cough, eye diseases and joint swelling   
Indication of leech therapy in Ayurveda  
 Abscess, lump, piles, skin diseases, sclerosis, throat diseases, eye diseases, cyst, 
tumour, filariasis, poisoning, pemphigus, headache, dental disorder, etc. 
Indication for leech therapy in Modern medicine 
 In modern medicine, the leech therapy has been used and studied in 
cardiovascular diseases, cancer, diabetes, infection, arthritis, dental concerns, 
haemorrhoids, hearing loss, tinnitus, pain relief, post-plastic surgery, replantation and 
other reconstructive surgeries. Hirudo therapy is a safe, easy to use, beneficial and cost-
effective treatment to save reattached body parts and flaps in reconstructive plastic 
surgery. 
Indication for leech therapy in Unani medicine 
 The commonest indication of leech therapy in Unani medicine as mentioned in 
classic Unani text are varicose vein, blepharitis, painful calf muscles, mania, septic 
wounds, non-healing ulcer, lymphadenitis, inflamed organ, sinusitis, pharyngitis, piles, 
fistula in ano, elephantiasis, at the bite of poisonous animals, skin disorders, warts, 
chloasma, eczema, psoriasis, osteoarthritis, hypertension and vitiligo, etc.  
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Other indications  
 Arthrosis, peri arthritis, rheumatoid arthritis, thrombophlebitis, thrombosis, 
embolism, external ear and chronic ear diseases, eye diseases; including cataracts, 
glaucoma, traumatic injury and inflammation, dental diseases; like gingivitis, paradonitis 
and stomatorrhagia, GI tract; hepatitis, cholecystitis, pancreatitis, stomach ulcer, 
respiratory disorders; asthma, acute rhino pharyngitis, and coryza, gynaecological 
disorders, male and female sterility, endometriosis, and mastitis.  
 Contraindication of leech therapy  
 The leech therapy is contraindicated in Anaemia, pregnancy, allergic patients, in 
extreme cold and hot climate, bleeding disorders like haemophilia, children and old age 
people.  
 Sites which are not suitable for leech application mentioned in Siddha literature 
are testis, penis, breast, eyelid & other fleshy parts, pulsate part (Naadi Parkum Idangal).  
Scientific papers on leech therapy   
 Presently various clinical and experimental studies have been conducted 
internationally to evaluate the efficacy of leech therapy in various diseases condition. 
The leech application has proved very valuable in microsurgeries and in various type of 
arthritis. Leech therapy reduces joint dysfunction, pain and stiffness in people with 
osteoarthritis of knee joint  as reported by new study in the annals of internal medicine . 
A study from Kashmir valley has established the safety and efficacy of leech therapy in 
the management of frostbite. Another study from India proved the anti-inflammatory 
effect of leech therapy in psoriasis patient. Similarly, one more study from India has 
proved the leech therapy gives the significant relief for symptoms of eczema. The leech 
therapy improved incisional skin wound healing in rats. Recently, research is being 
conducted in various aspects to determine the effect of leech therapy in various ailments 
like gout, vitiligo, varicose vein, varicose ulcer, lupus erythematosis, thrombosed piles, 
burger‟s diseases, epidermoid cyst, arthrosis of the first carpo metacarpal Joint and many 
more. 
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MODERN ASPECTS 
SKIN ANATOMY 
INTRODUCTION: 
     The skin covers the entire external surface of the human body and is the principal site 
of interaction with the surrounding world. It serves as a protective barrier that prevents 
internal tissues from exposure to trauma, UV radiation, temperature extremes, toxins and 
pathogenic organisms like bacteria. Other important functions include sensory 
perception, immunologic reaction, thermo regulation and control of invisible fluid loss. 
The integrity has three layers 
1) Epidermis 
2) Dermis 
3) Hypodermis 
Epidermis 
     The epidermis is continually renewing, stratified, squamous epithelium that 
keratinizes and gives rise to derivatives structures called appendages. The majority of the 
cells in the epidermis are the keratinocytes. It has 5 layers. They are from above 
downwards 
1) Stratum corneum 
2) Stratum lucidum 
3) Stratum granulosum 
4) Stratum spinosum 
5) Stratum germanativum 
Keratinocytes 
 The stratum germinativum or the basal layer is immediately superficial to the 
dermoepidermal junction. As keratinocytes divide and differentiate, they move from this 
deeper layer to the more superficial layers. Once they reach the stratum corneum, they 
are fully differentiated keratinocytes devoid of nuclei and are subsequently shed in the 
process of epidermal turnover. 
Melanocytes 
 Melanocytes derived from neural crest cells. Its primarily function is to produce a 
pigment melanin which absorbs radiant energy from the sun and protects the skin from 
the harmful effects of UV radiation. Melanin accumulates in organelles termed 
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melanosomes. Sun exposure makes melanocyte stimulating hormone (MSH), adreno 
cortico tropic hormone (ACTH), estrogens and progesterones stimulate melanin 
production. With aging, a decline is observed in the number of melanocytes populating 
the skin of an individual. Since these cells are of neural crest origin, they have no ability 
to reproduce. 
Langerhans cells 
 Langerhans cells originate from the bone marrow and are found in the basal, 
spinous and granular layers of the epidermis. They serve as antigen- presenting cells. 
They are capable of ingesting foreign antigens, processing them into small peptide 
fragments, binding them with major histocompatibility complexes and subsequently 
presenting them to lymphocytes for activation of the immune system. 
 
Dermis 
 The dermis is formed by connective tissue having fibers and ground substances. 
It varies in thickness about 0.3mm on the eyelid and 3.0mm on the back. The dermis can 
be divided into an upper papillary dermis that consists of loose connective tissue 
containing capillaries, elastic fibers, reticular fibers and some collagen  and the deeper 
reticular dermis recognized by the thicker, aggregated bundles of collagen. Collagen and 
elastic fibers are synthesized by fibroblasts. Collagen contributes about 70% of the dry 
weight of the dermis and is the most common protein in the body. It serves as major 
structural element of skin and has remarkable tensile strength. Ground substances is an 
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amorphous material that consists mainly of water, electrolytes, proteins and 
mucopolysaccharides. These following structures lying in the dermis. 
1) Epidermal appendages 
2) Blood vessels and lymphatics 
3) Nerves muscles 
4) Cells – mast cells, fibroblasts, pericytes, etc., 
Dermo-epidermal junction 
 It is the basement membrane zone that welds the epidermis to underlying dermis. 
This junction is undulated, forming dermal papillae and rete ridges. 
Epidermal appendages 
1) Pilosebaceous unit 
2) Sweat glands 
3) Nail unit 
Pilosebaceous unit 
   It consists of a hair follicle containing hair and sebaceous glands opening into 
follicular canal of hair follicle. Sebaceous gland are lipid secreting holocrine glands. 
They are distributed all over the body except the palm and soles with their maximum 
density in seborrheic area of the body hair structure consists of cuticle, cortex, and 
medulla. These keratinous fibers are of two types in adults. Terminal hairs are thick, 
pigmented and long and are seen on the scalp, eyebrows, axillae, genital areas, etc., 
vellus hairs are small in diameter, short and nonpigmented and therefore difficult to 
discern. 
Sweat glands 
     There are 2 types of sweat glands 
1) Eccrine glands 
2) Apocrine glands 
Eccrine glands 
 These are merocrine glands with tubular structures, which open onto the skin 
directly. Sweat glands are present on the entire surface of the body except the lip, 
external ear canal and labia minora and are most abundant on the palms, soles, forehead 
and axillae. 
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Apocrine glands 
 These tubular glands consist of two main parts the coiled secretary gland and the 
straight excretory duct which opens into the follicular canaljust above the openings of 
sebaceous glands. They are distributed along the mammary line eg. Axillae, areolae, 
periumbilical area, mons pubis and genital and peri anal areas. 
Nail unit 
 It is yet another epidermal appendages. It consists of nail matrix just underneath 
the proximal nail fold which gives rise to nail plate a keratinized structure. The distal 
portion of the nail matrix is visible usually in thumbnail as nail bed and is bounded on 
two sides by lateral nail fold 
Cutaneous Blood supply 
 Cutaneous vessels ultimately arise from underlying named source vessels. The 
cutaneous vessels originate either directly from the source arteries or as terminal 
branches of muscular vessels. Cutaneous vessels ultimately anastomose with other 
cutaneous vessels to form a continuous vascular network within the skin. 
Lymphatics 
 Skin lymphatics parallel to the blood supply and function to conserve plasma 
proteins and scavenge foreign material, antigenic substances and bacteria. These 
unvalved superficial dermal vessels drain into valved deep dermal and subdermal 
plexuses, then coalesce to form larger lymphatic channels which ends in internal jugular 
vein junction bilaterally. 
Skin Innervation  
 Merkel cells of the epidermis Meissner corpuscles detect light touch. Pacini 
corpuscles are specialized to detect pressure. Pain is transmitted through naked nerve 
endings and Krause bulbs detect cold, whereas Ruffini corpuscles detect heat. Cutaneous 
nerves follow the route of blood vessels to the skin. 
Physiology of skin 
1. Protection - self and body  
2. Sense organ 
3. Secretion and excretion 
4. Body temperature regulation 
5. Storage of fat, blood 
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6. Absorption 
7. Gaseous exchange 
Skin phototype 
 The amount of melanin pigment in the skin determines an individual‟s skin  
color. Skin pigment can be inherited genetically or can be acquired through various 
diseases. Hormonal changes during pregnancy can also vary the amount of pigmentation.  
Anatomy of Aging Skin 
 Age associated skin changes include thinning, skin laxity, fragility and wrinkles. 
Sun exposed areas demonstrate additional aging changes including depigmentation, 
premature wrinkling, telangiectasia and actinic elastosis. 
Embryology 
 The whole of skin epidermis and dermis is a unified integrated organ system, but 
it develops from two different primitive embryonic layers - epidermis from the ectoderm 
and dermis from the mesoderm. 
ECZEMA 
DEFINITION: 
 Eczema is a non - contagious chronic skin disease which is characterized by 
erythema, scaling, oedema, oozing and vesiculation. The word eczema seems to have 
originated from the Greek word „ekzein‟ meaning "to boil over" or “to effervesce”. 
Dermatitis comes from the Greek word for skin – and both terms refer to the same skin 
condition. Eczema is an inflammatory skin reaction characterized histologically by 
spongiosis with varying degree of acanthosis, and a superficial perivascular 
lymphohistiocytic infiltrate. The clinical features of eczema may include itching, 
redness,scaling and clustered papulo-vesicles. The condition may be induced by a wide 
range of external and internal factors acting singly or in combination. The term 
dermatitis and eczema are generally regarded as synonyms still some authors use the 
term dermatitis to include all types of cutaneous inflammation. Not all dermatitis is 
eczematous. 
HISTORY: 
The term "atopic dermatitis" was coined in 1933 by Wise and Sulzberger 
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EPIDEMIOLOGY: 
 Eczematous diseases are very common with an estimated prevalence of more than 
10% in the general population. According to health statistics 15-25% of all 
dermatological patients suffer from eczema. Globally eczema affected approximately 
230 million people as of 2010 (3.5% of the population). In India low prevalence in 
northern and eastern part of country (0.42-0.55). ISSAC (International Study Of Asthma 
And Allergies In Childhood) shows prevalence between 2.4% - 6%. Regarding contact 
dermatitis in general population the sufferes are more than 1% and in construction 
workers more than 45%. For the age group 6 to 7 years, the prevalence of current eczema 
ranged from 0.9% in India. 
AETIOLOGY: 
 The causes of eczema are unknown. Effective eczema management requires a 
combination of prevention and treatment. In addition to preventing eczema flare-ups by 
minimizing any known triggers, treatment is also an important part of eczema 
management. Basically, two factors cause dermatitis and eczema. 
 Allergic or sensitive skin. 
 Exposure to an irritant. 
The dermatologist Darier has said that, “There is no eczema but an eczematous 
patient”. The general predisposing causes are Age, Genetic and familial predisposition, 
General debility, Climate, Psychological stress, Local Factors, Food as allergens. 
Age 
Eczema sometimes occurs in infancy, at puberty and at the time of menopause. 
Genetic & familial predisposition 
There is usually a personal or family history of allergy, viz asthma, eczema and 
hay fever. 
General debility 
Lowering of resistance of the individual in general debility predisposes to 
eczema. 
Climate 
Climate extremes like heat and severe cold. 
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Psychological stress 
Local factors 
 Xeroderma or ichthyosis, greasy skin, hyperhidrosis, varicose veins. 
 Direct contact with pet and domestic animals. 
 The frequent use of soaps and cleaning products that tend to affect the 
shiny nature of the skin. 
Food as allergens 
Animal sources 
● Cow‟s milk, Egg white is the allergising factor, any species of fish, meats 
of all kinds can be responsible for allergic reactions. 
Plant sources 
● Wheat flour – allergic reaction due to wheat gluten. 
● Peas, beans and lentils,consumption of edible mushrooms ,vegetables 
such as brinjal, carrot, spinach, cabbage, onion, garlic, sweet potato, 
cauliflower and pumpkin cause allergy in some individuals. 
● Among the fruits, strawberries, bananas, oranges, grapes and apples are 
the principal offenders. Occasionally by pears, cherries, plums, 
gooseberries, Citrus fruits and tomatoes may cause atopic allergy. 
Cosmetics 
Common ingredients in cosmetics such as perfumes, facecreams, 
deodorants, hair dye, shampoos, parabens, benzocaine, lanolin, thimersol, etc. 
Clothing      
Rubber chappals, spectacle, resins, frames, furs, nylon, synthetic dyes. Most   
buttons of    formaldehyde resins, epoxy resins are all common sensitizers. 
Medicaments   
This include Sulphonamides, Penicillin, Streptomycin, Cocaine, Tincture 
benzoin, Neomycin, Furacin, Phenargan cream & sticking plaster etc. Dettol, savlon, 
cetavlon are primary irritants. 
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INDUSTRIAL AND OCCUPATIONAL AGENTS:     
 Agriculturists  - Plants, weeds, fertilizers, oils. 
 Automobile  -  Oil, petrol, solvent, grease, paints, thinner. 
 Building workers  -  Cement, lime, paints, insecticides,kerosene 
oil. 
 Chemical,Pharmaceutical -  Dyes, Chemicals, explosives, solvents, 
       industries    disinfectants, detergents  
 Housewives  -  Soaps, detergents, vegetables, fruits, nickel, 
 polishes, artificial flavours, dyes, flowers. 
 Nurses and Doctors -  Iodine, streptomycin, chlorpromazine, 
tincture. 
 Painters   -  turpentine, paints, detergents 
 Plastic factory workers - Resins, hardeners, solvents, glass, cellulose                             
 Rubber workers  -   T.M.T, M.B.T, dyes, glues, oils 
 Tannery workers  -  Chromate, arsenic, alkalies, acids. 
 Textile workers  -  Formaldehyde, solvents, dyes, bleaches. 
 Scratching, Chemical trauma, Climate, Stress and Strains keep the process 
going with the result that eczema becomes chronic. In practice mixed eczemas are much 
more common than pure entities. History and clinical observation are very important in 
establishing the exact etiological diagnosis. 
IMMUNOLOGY: 
Immunology deals with the body‟s response to antigenic challenge. Sensitization 
develops when a different clone of T-lymphocytes is activated. The sensitized T-
lymphocytes yield two sub populations of lymphocytes.  
1. Memory cells those are responsible for the persistence of contact allergy.  
2. Efferent cells that initiate the allergic response when appropriately 
challenged. 
Allergy & hypersensitivity 
The body behaves in a particular way when it is exposed to a chemical substance 
known as „Allergen‟ for the first time, but changes the nature of its reaction when it is 
exposed for the second and subsequent times. This change is due to proteins known as 
antibodies. The moment, the allergen IgE combination stimulates the mast cells which 
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unload their chemical contents into the surrounding tissues. These chemicals (mediators 
of allergy) cause the manifestations of allergy such as erythema, wheal and flare 
reaction. Flare is due to dilatation of arterioles by local axon reflex and the liberation of 
vasodilator substances like histamine and its byproducts like serotonin, bradykinin, 
acetylcholine from the injured cells like mast cells and basophils etc. The manifestation 
of hypersensitivity may be immediate (or) delayed type. 
Cutaneous Allergy 
In the skin two important but different allergic reactions occur. 
Dermal reaction 
 Dermal reaction is commonly seen in urticaria. Allergic reaction takes place in 
the dermis. Intra dermal tests (scratch) show reactivity. 
 The causative antigen reaches the skin through ingestion, inhalation or injection 
of protein substances and the reacting antibodies circulate in the serum. 
Epidermal reaction 
 It is seen in allergic dermatitis or eczema. 
 The  causative  substance  reaches  the  skin  by  contact. Intra   dermal  allergic  
tests are negative, but patch test shows reactivity 
 Allergen + Epidermal protein – Antigen formation (probably in lymph glands) 
 Allergen + Antibodies – Eczematous reaction (In epidermis) 
 A severe local reaction may result in auto-intoxication & dissemination of 
eczematous reaction to distant  parts. 
Status Eczematicus 
It is believed that in case of severe allergic states, a state may develop when the 
patient becomes hypersensitive to even unrelated substances resulting in status 
eczematicus comparable to status asthmaticus in practice of internal medicine. 
Reaction time 
It is the time taken by a sensitized individual to manifest a clinical reaction 
following contact with a known sensitizer. It is usually 12-24 hours but may vary from 
one hour to 120 hours. 
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Dissemination reaction 
It is a fleeting erythematous macular reaction involving the face and flexures, 
seen in some cases of contact dermatitis. It is caused by the escape of lymphokinins in 
the circulation resulting in vasodilatation at distant site. 
Flare reaction 
 In contact dermatitis, reaction of a previously healed site of a contact dermatitis 
reaction or a positive patch test reaction followed renewed challenge or exposure to the 
same allergen at another site. This is because of persistence of sensitized lymphocytes of 
the site of earlier reaction, which react to minute amounts of antigen that sometimes 
escape into the circulation from the new site and find its way to the old site. Langerhans 
cells are responsible for antigen processing in contact allergy.                                      
Histopathology of eczema 
 The histopathological features of eczema reflect dynamic sequence of changes 
resulting in inflammation of the epidermis and vary the indulging dermal structures. 
These vary with the intensity and stage of eczematous process and are frequently 
modified by secondary events such as trauma and infection. 
 Spongiosis is an intercellular epidermal oedema that leads to stretching and 
eventual rupture of the intercellular attachments with the formation of vesicles. Increased 
epidermal meiotic activity leads to acanthosis, but if spongiosis is intense disintegration 
of the suprapapillary epidermis may cause clefts to form exposing the underlying dermis. 
 In the sub acute stage, spongiosis diminishes and increasing acanthosis is 
associated with formation of a parakeratotic horny layer. This often contains layers of 
dried up serum and pyknotic nuclei of inflammatory cells. Later the ridges become 
elongated and broadened and hyperkeratosis replaces (arakeratosis). The changes are 
then those of lichenification. 
 The infiltrate is predominantly lymphocytic, through polymorphs and eosinophils 
are particularly common in eczematous dry eruption. In the presence of infection, 
polymorphs may invade the epidermis. 
Clinical Features 
Eczema is characterized by superficial inflammatory edema of the epidermis 
associated with vesicle formation. Itching varies from mild to severe paroxysms which 
may even interfere with work and sleep. It can differ in severity, frequency and duration 
45 
 
among individuals. Flare-ups, however, can be unpredictable throughout lifetime. 
Skin areas affected by eczema can exhibit a variety of characteristics including: 
 Blistering 
 Darkening of the area of skin affected by eczema (hyperpigmentation) 
 Dryness 
 Flaking 
 Inflammation (swelling, irritation and warmth) 
 Scaling 
 Small red bumps 
 Thickening of the affected skin due to frequent scratching. Scratching the 
area affected by eczema generally does not relieve the itching and can 
lead to increased inflammation, more intense itching, and harder 
scratching. 
DEVELOPMENT OF SIGNS AND SYMPTOMS IN ECZEMA 
   Erythema 
 
    Papules with oedema 
 
   Vesicles         
          Lichenification 
 
  Weeping, crusting, pustules      
 
     Scaling 
 
  Healthy skin without scars 
TYPES: 
Acute Eczema: 
Acute eczema is accompanied by exudative erythema, edema, and sometimes 
vesicles. It is newly produced eczema ,only several days after its onset. Intercellular 
edema (spongiosis), intense dermal edema, and inflammation occur.  
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Sub acute Eczema   
Sub acute eczema has a severity between that of acute and that of chronic. Such 
eczema is accompanied by erythema and edema, and it is slightly lichenoid. Mild edema 
is produced in the epidermis. Acanthosis and parakeratosis are observed. 
Chronic eczema 
         Chronic eczema is characterized clinically by lichenification. When acute eczema 
continues for more than one week after onset, it is likely to appear lichenified, and the 
diagnosis is chronic eczema. Acanthosis and parakeratosis are noticeable 
histopathologically. However, there is less infiltration of inflammatory cells into the 
epidermis than with acute and subacute eczema. 
CLASSIFICATION 
 Contact dermatitis 
 Atopic eczema 
 Seborrhoeic eczema 
 Nummular eczema 
 Asteatotic eczema 
 Stasis  eczema 
 Autosensitization dermatitis 
 Wiskott-Aldrich syndrome 
1. CONTACT DERMATITIS 
Contact dermatitis is localized to the site of extrinsic stimulation by foreign 
substance or allergic reaction. Eczema reactions such as reddening and blistering occur at 
the contact site.There are specific types of contact dermatitis, such as diaper dermatitis 
and housewive‟s hand eczema. The causative substances include certain plants, chemical 
agents, and nickel, mercury and other metals. 
Clinical features 
Erythema, serous papules, vesicles, erosions and crusts are localized at the 
contact site of the causative agent. The eczematous lesions are relatively sharply 
circumscribed and are intensely itchy. Although only localized areas are affected, erosive 
lesions may become widespread when the causative agent is spread by rubbing and 
scratching. If the inflammation spreads over the entire body, systemic symptoms such as 
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fever may arise. When the causative agent is highly stimulative, it may cause necrosis of 
the skin and ulceration. 
Pathogenesis 
Allergic contact dermatitis basically occurs as a type IV allergic reaction. The 
causative agent invades the body percutaneously and is captured by Langerhans cells. It 
moves to the regional lymph nodes and transmits information about the antigen to 
thymus derived T cells, and they proliferate in the lymph nodes. If the causative agent 
reinvades the body after sensitization, the sensitized T cells become activated to release 
various cytokines, which leads to a prompt inflammatory reaction that causes dermatitis. 
This reaction is not produced by the first contact, but it is produced in previously 
sensitized persons even by contact with a minute amount of the antigen.  
2. ATOPIC DERMATITIS 
Atopic dermatitis is chronic eczema/dermatitis caused by an atopic condition 
(allergic asthma, rhinitis, conjunctivitis). Exudative eczema occurs on the face and ear 
pinna. It is characterized by eruptions of dry pityriatic scales. The patient tests positive 
for white dermographism.  
Atopic dermatitis is classified into three age periods: infantile (age 2 months to 4 
years), childhood (early childhood to puberty), and adolescent/adult.  
A) Infantile atopic dermatitis 
In the early stage of atopic dermatitis in infancy, erythema, scales, and serous 
papules are produced on the head and face and these gradually spread to the trunk. The 
condition becomes exudative: erosions form with crusts and scales attached to the 
surface. It resembles seborrheic dermatitis. Thick crusts on the head and ear notch, and 
lesions around the mouth and lower jaw are also observed. The trunk and extremities 
become dry, and follicular papules aggregate, appearing as goose bumps. Scaly 
erythematous plaques form on these lesions and progress to childhood atopic dermatitis.
  
B) Childhood atopic dermatitis 
In childhood atopic dermatitis the skin becomes dry. Lichenified plaques occur 
on the cubital fossa and popliteal fossa. Cracks are often found in the auricle area (ear 
notch). Multiple follicular papules occur on the dry skin of the trunk. This dermatitis is 
accompanied by intense itching, and it progresses quickly to eczematous crusty lesions. 
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C) Adolescent and adult atopic dermatitis 
The symptoms are similar to those in childhood dermatitis, but the lichenified 
plaques progress and enlarge. Rough, dry, dark brown atopic dermatitis occurs all over 
the upper body. The lesions are more severe and widely distributed than those of 
childhood dermatitis. Thinning of one-third of the lateral eyebrow is present. In serious 
cases, diffuse erythema occurs on the face, and a mottled appearance is seen on the neck 
and upper chest (poikiloderma lesion, dirty neck). Atopic prurigo may occur repeatedly 
on the extremities. 
Pathogenesis 
A defective skin barrier is important for the pathogenesis of atopic dermatitis. 
Filaggrin gene mutations have been shown to be a key predisposing factor for atopic 
dermatitis. Dyshidrosis and decreased content of lipid in the horny cell layer, facial 
pallor, dry skin and multiple small follicular papules are present (atopic skin). The atopic 
skin is vulnerable to extrinsic irritation; intensely itchy eczema is easily produced by 
slight irritation, or even by perspiration or contact with animal fur, wool or chemicals. 
Immune function abnormality:  
Atopic conditions such as allergic asthma, allergic rhinitis, conjunctivitis and 
atopic dermatitis are found in the family and patient‟s history. Patients with atopic 
dermatitis readily produce IgE antibodies. There is a high IgE value and positive 
intracutaneous reactions to various allergens. 
3. SEBORRHEIC DERMATITIS 
 Seborrheic dermatitis occurs on sites of skin where sebum is actively secreted. It 
is characterized by erythematous lesions accompanied by yellowish scales. This is one of 
the most common skin diseases, occurring in infants, adolescents and adults. 
Pityrosporum fungus resident in the skin is a factor in the occurrence. 
Clinical features 
 There is some controversy as to whether seborrheic dermatitis in infants, 
adolescents and adults is the same disease, because there are minor differences in the 
clinical courses. Dermatitis appears as follicular eczema on seborrheic sites or 
intertriginous areas in the head, face, axillary fossa, neck and external genitals. The main 
features of the lesions are oleaginous scales and erythematous plaques that may be 
slightly itchy. 
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In infants, yellowish crusts begin to form on the scalp, eyebrows and forehead. In 
infants, scaly erythematous plaques may also form 2 to 4 weeks after birth. In most cases 
they resolve 8 to 12 months after birth. In adolescents and adults, pityroid scales increase 
and scaly erythematous lesions form on the eyebrows and nasolabial groove. Seborrheic 
dermatitis is chronic and recurrent. 
Pathogenesis 
Triglycerides in sebum are decomposed by microbes resident in the skin to 
produce free acid. The free acid reacts to cause seborrheic dermatitis. It has been 
reported that over proliferation of  Pityrosporum fungi such as Malassezia furfur 
aggravates seborrheic dermatitis. 
4. NUMMULAR ECZEMA (ECZEMA NUMMULARE) 
            Round, relatively large eczematous plaques are produced. Nummular eczema 
may occur at any site on the body, and it tends to progress to autosensitization dermatitis. 
Clinical features 
Nummular eczema is frequently seen in the winter. Multiple round eczematous 
lesions occur, mostly on the extremities (particularly on the extensor surface of the lower 
extremities), trunk, hips and buttocks .At the periphery of the lesions, serous papules 
aggregate, in the center of  which exudative erythema is produced with scales on the 
surface. Most cases are accompanied by intense itching and multiple scars from rubbing 
and scratching. As the lesions progress, they may produce dispersal eruption to progress 
into autosensitization dermatitis. 
Pathogenesis 
Scratched insect bites may develop urticarial lichens that, when rubbed, progress 
to nummular eczema, or nummular eczema may result from asteatotic eczema in the 
elderly, or  it may appear as a symptom of atopic dermatitis. 
5. LICHEN SIMPLEX CHRONICUS 
Synonyms: Lichen Vidal, Circumscribed neurodermatitis 
Lichen simplex chronicus is chronic eczema in which round, intensely itchy 
lichenified plaques form on the nuchal region and extensor aspect of forearms and lower 
legs of middle-aged women. Pigmentation or depigmentation is present in many cases. 
Warty eruptions may proliferate. When skin is repeatedly stimulated by the friction of 
50 
 
clothing or by metal allergens and the site is rubbed and scratched for a long period of 
time, it leads to the occurrence of chronic eczematous lesions.  
6. AUTOSENSITIZATION DERMATITIS 
           Multiple small papules and erythematous lesions accompanied by itching occur 
systemically. They are caused by sudden aggravation of a localized lesion. This 
dermatitis is caused by endogenous allergic reaction. 
Clinical features 
Reddening, swelling and acute aggravation of exudation occur in the lower 
extremities as primary lesions of autosensitization dermatitis (in 50% to 60% of cases). 
Two weeks to several weeks after acute aggravation of reddening, swelling and 
exudation, dispersed eruptions appear. In most cases, the eruptions are erythema, 
papules, serous papules, or pustules of 2 to 5 mm in diameter dispersed symmetrically on 
the extremities, trunk, and face. These are often accompanied by intense itching. 
Systemic symptoms such as fever and fatigue may occur. 
Pathogenesis 
Autosensitization dermatitis arises from endogenous allergic reaction. Decayed 
proteins, bacteria, fungal components, and toxins produced by injured tissues in a 
primary lesion are considered to be the antigens. These may spread through the entire 
body such in blood flow from the primary lesion, or they may spread by rubbing or by an 
accidental dose of the causative substance (orally or intravenously). Autosensitization 
dermatitis is caused by sensitization against the antigens. The primary lesions can be 
nummular eczema, stasis dermatitis, contact der-matitis, atopic dermatitis, tinea pedis, or 
eczematization of a burn. 
7. STASIS DERMATITIS 
Edematous erythema or eczematous plaques form on the lower thighs as a result 
of varicose veins or congestion in the lower extremities. This disease tends to affect 
those who work standing, the elderly, and obese women. It may progress to 
autosensitization dermatitis.  
Clinical features 
Edematous erythema occurs on the lower third of the leg, particularly at the upper 
ankles. The site gradually presents a dark red, scaly, eczematous plaque, pigmentation or 
whitish atrophie blanche. Minor trauma may induce ulceration. Treatments for stasis 
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dermatitis may induce allergic contact dermatitis as a complication, from the application 
of an antiseptic or a topical agent. Aggregated serous papules often progress to 
autosensitization dermatitis. 
Pathogenesis 
Congestion in the cutaneous blood vessels is caused by impairment of venous 
outflow, which leads to bleeding from the capillary vessel loop in the dermal upper layer. 
Hemosiderins deposit in tissues, and the skin takes on a blackish-brown appearance. The 
keratinocytes are injured by further impairment of blood flow. Atrophy and scaling occur 
in the epidermis and there is tendency of ulceration. The skin looses its function as a 
barrier and becomes more reactive to extrinsic irritation, leading to eczematous lesions in 
many cases. 
8. ASTEATOTIC ECZEMA 
Skin dryness (asteatosis, xerosis) occurs when sebum decreases as a result of 
aging or excess washing. When the horny cell layer is destroyed, the skin is vulnerable to 
extrinsic irritation. When asteatosis becomes inflamed and eczematous, the condition is 
called asteatotic eczema. This mostly affects the lower extremities of elderly in dry 
seasons, especially winter. For those who have a habit of excessively washing or rubbing 
the body with a towel, lifestyle guidance to avoid such behavior has therapeutic effects. 
Use of moisturizer prevents skin dryness. 
9. WISKOTT-ALDRICH SYNDROME 
The three major characteristics of this disorder are immunological deficiency (T-
cell dysfunction), thrombocytopenia, and intractable eczema. It is hereditary (X-linked 
recessive). There are decreased levels of immunoglobulins. Bone marrow transplantation 
may be performed. 
Clinical features 
          Wiskott-Aldrich syndrome is characterized by eczema or purpura that occurs in 
newborn babies within 6 months after birth. The eczema that occurs on the head, face, 
buttocks and extremities appears similar to atopic dermatitis and seborrheic dermatitis. 
Purpura is caused by thrombocytopenia. Immune-deficiency-derived infections occur 
repeatedly as the patient grows. Infections are caused by various factors including 
bacteria viruses, fungi and protozoa. Impetigo contagiosa (Staphylococcal infection), 
pseudomonas infection, herpes simplex, varicella (herpes virus infection), and 
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candidiasis are particularly likely to accompany this syndrome, and they tend to become 
aggravated and persistent. Systemic symptoms such as bloody diarrhoea, internal organ 
hemorrhage, infection (e.g. tympanitis, paranasal sinusitis, pneumonia) are seen 
recurrently. 
INVESTIGATIONS OF ECZEMA: 
Patch test 
Patch tests detect type IV (delayed or cell-mediated ) hypersensitivity. It is 
common practice for a battery of around 20 common antigens, including common 
sensitizers such as nickel, rubber and fragrance mix to be applied to the skin of the back 
under aluminium discs for 48 hours. The sites are then examined for a positive reaction 
24 hours later and possibly again a further 24 hours later. The positive test is revealed by 
the development of an eczematous patch with erythema swelling and vesicles at the site 
of application. 
Patch test reaction is graded in the following degrees, 
+ - Only redness 
++ - Marked redness and swelling 
+++ - Marked redness, swelling and papules 
++++ - redness, oedema and vesicles 
Specific IgE 
 Specific IgE levels to antigens can be measured in serum by a specific radio 
allergic sorbent test (RAST). These are occasionally performed to support diagnosis of 
atopic eczema and to determine specific environmental allergens, eg. pet dander, horse 
hair, house dust mite, pollens and foods. 
Prick tests 
Prick tests are a way of detecting cutaneous type I (immediate) hypersensitivity 
to various antigens such as pollen, house dust, mite or dander. 
Bacterial and viral swabs for microscopy and culture 
These are useful tests in suspected secondary infection skin swabs for 
bacteriological assessment will invariably reveal the presence of bacteria. In the case of 
recurrent impetigo in a child with atopic eczema, bacterial swabs should be taken from 
carrier sites (axillae and groin) from both the affected individual and house hold 
members. 
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ASSESSMENT TOOLS : 
1. EASI score 
An EASI score is a tool used to measure the severity and extent (area) of atopic 
eczema (Eczema Area and Severity Index).  
Body regions 
There are four body regions: 
 1. Head and neck                               
 2. Trunk (including genital area)                                           
 3. Upper limbs 
 4. Lower limbs (including buttocks) 
Area score 
  Area score is recorded for each of the four regions of the body. The area score is 
the percentage of skin affected by eczema. 
  Area score  Percentage of skin affected by eczema in each 
region  
         0    no eczema in this region 
         1     1-9% 
         2    10-29% 
                           3     30-49%  
         4    50-69% 
         5    70-89%  
         6    90-100%, the entire region is affected by  
                                                                     eczema  
Severity score 
 The severity score is the sum of the intensity scores for four signs.The four signs 
are: 
1. Redness (erythema, inflammation) 
2. Thickness (induration, papulation, swelling - acute eczema) 
3. Scratching (excoriation) 
4. Lichenification (lined skin, prurigo nodules - chronic eczema) 
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   The average intensity of each sign in each body region is assessed as none (0), 
mild (1), moderate (2) and severe (3). Half scores are allowed. The four intensity scores 
are added up for each of the four body regions to give subtotals A1, A2, A3, A4. 
Calculation for area: Each of the body area scores is multiplied by the area affected 
(C1,C2,C3,C4) 
Total score: The EASI score is C1 + C2 + C3 + C4. 
Outcome results 
 MILD   0 - 7 
 MODERATE  7 - 21 
 SEVERE  21 - 50 
 VERY SEVERE 50 - 72 
2. The SCORAD index 
A = spread.../100 
B = intensity.../18 
C = subjective symptoms.../20 
SCORAD calculation: A/5 + B/2 + C 
1. Extent criteria 
2. Intensity criteria 
o Erythema : stage 1 / stage 2 / stage 3 
o Edema / papulation : stage 1 / stage 2 / stage 3 
o Oozing / crusting : stage 1 / stage 2 / stage 3 
o Excoriation : stage 1 / stage 2 / stage 3 
o Lichenification : stage 1 / stage 2 / stage 3 
3.Subjective symptoms 
            The two most representative items concerning the quality of life of patients are: 
o Pruritus 
o Insomnia 
SCORAD is a clinical tool for evaluating the severity of atopic dermatitis in order 
to provide better management of patient. 
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Diagnosis for all eczemas 
1. Nature of the lesions - size, shape, itching, number of papules, 
pustules, erythema etc., 
2. Distribution - sites of lesion 
3. History of occupation 
4. History of exposure to allergens ie Chemicals, plants, soap , etc., 
5. Personal and family history of such diseases - e.g atopic or allergic 
eczemas 
6. Climate - eg: Dyshidrosis occurs at the change of seasons 
particularly in spring, summer 
7. Patch tests (allergy test) in allergic/ atopic eczemas 
8. Biopsy in rare cases when the lesions do not respond to treatment 
PROGNOSIS OF ECZEMA: 
 Dermatitis and eczema are as rule curable conditions. Eczema are non infective 
except when they are inpetiginized and of the infective variety. They do not leave scars. 
The patient needs reassurance on these points. It must be remembered that epidermis is 
an ectodermal structure and so takes time to heal. Energetic treatment is to be strongly 
discouraged. 
 Acute eczemas heal readily in about 1 - 4 weeks with treatment. Chronic eczemas 
in which anatomical and functional changes set in take time to disappear. Disseminated 
and generalized eczemas are not only slow to heal, but are accompanied by ill health. 
Infantile and atopic eczemas are trouble and uncomfortable. 
 The former lasts till the age of twenty five or even though life. Its course is 
marked by spontaneous remissions and exacerbations. Psychogenic stresses climate 
extremes and poor health aggravate eczema. The cure of these conditions is retarded in 
tropical countries by heat, humidity and the prevalent unhygienic conditions. 
GRADES OF ECZEMA: 
 A useful way to classify eczema is based on the degree of activity and the 
duration the eczema has been active. 
1. Acute 
  Acute in medical language means of rapid onset. Often conditions that come on 
over a short period of time are also quite vigorous in their activity, although strictly 
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speaking acute should not be taken to be another word for severe. Acute eczema 
therefore would be an area that recently flared up and would be red, probably also have 
blisters and possibly some oozing or crusts. 
2. Chronic 
  Chronic properly means long - standing. Once the initial phase of activity has 
died down a bit of skin that has been eczematous for a while is dry, scaly, thickened and 
cracked. 
3. Infected 
  At any stage of eczema it can become infected. This won‟t always be obviously 
different from acute eczema unless there are pus filled blisters. With experience one can 
usually discern the golden crust of infection and pick up the other clues that suggest 
infection. 
 TREATMENT: 
  It consists of  
 Reassuring the patient and his relatives about the disease being curable, 
non infectious and non scarring. Tactful bedside psychotherapy pays 
dividendsin all cases. 
 Elimination of predisposing, exciting and complicating cause. In one 
individual, more than a single cause may be at play. To prevent 
recurrence, advice should be given to the patient regarding exposure to 
causes. Anyone suffering from contact eczema, for instance should be 
advised against any exposure to the possible sources of the causative 
allergens and allegro - immunologically related substances. Patients with 
infective eczemas are requested to treat infection by suitable antibiotic 
regarding the sources of infection. Improving the general state of nutrition 
is also important. 
 Pallitative treatment must be properly carried out to effect a complete 
cure. Their life style should be strictly free from cosmetics.  
PREVENTION: 
People with eczema should not get the smallpox vaccination due to risk of 
developing eczema vaccinatum, a potentially severe and sometimes fatal complication. 
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COMMON TYPES OF ECZEMA 
TYPES SYNONYMS FREQUENCY/AGE 
GROUP 
REMARKS 
Atopic 
dermatitis 
Neurodermatitis, 
Infantile eczema, 
Besner‟s prurigo 
Very common, mostly occur 
in infants and very young. 
Cause unknown, but 
appear to be 
immunologically 
mediated. 
Seborrhoeic 
dermatitis 
Infectious 
eczematoid 
Very common, all age 
groups. 
Probably has microbial 
cause with over growth 
of normal skin flora 
being responsible. 
Discoid eczema Nummular eczema Uncommon - mainly in 
middle aged individuals. 
Cause unknown 
Lichen simplex 
chronicus 
Circumscribed neuro 
dermatitis 
Quite common, mainly in 
young and middle aged 
adults. 
Initial cause appears to 
be a localized 
Eczema 
craguelee 
Ateratotic eczema Uncommon - restricted to 
elderly 
Low humidity and 
vigourous washing 
seem responsible 
Varicose 
eczema 
Stasis dermatitis, 
Gravitational eczema 
Common in the age group 
that has gravitational 
syndrome 
Multiple causes, a 
common variety is 
allergic contact 
dermatitis to 
medicaments used 
Allergic contact 
dermatitis 
    
             - 
Common in all adult age 
groups same as the very old 
Delayed 
hypersensitivity 
response to a specific 
agent 
Primary irritant 
contact 
dermatitis 
Occupational 
dermatitis, house - 
wives eczema 
Very common in adult age 
groups same the very elderly 
Both mechanical and 
chemical trauma 
responsible 
Photosensitivity 
eczema 
           - Not common - mainly in 
adults 
Both photo toxic and 
photo allergic adults 
     -Roxburgh‟s common skin diseases - Ronald Marks 
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MATERIALS AND METHOD 
PRIMARY OBJECTIVE: 
To evaluate the therapeutic efficacy of “Nilavaagai chooranam” (internal) and 
“Thengaai thylam” (external) in the treatment of “ Karappan” (Eczema) with and 
without leech therapy. 
SECONDARY OBJECTIVE:    
To study the Siddha basic principles towards effect of medicine and Leech 
therapy. 
STUDY DESIGN: 
Comparative clinical trial 
STUDY PLACE: 
Ayothidoss Pandithar Hospital,  
National  Institute of  Siddha,  
Tambaram Sanatorium, Chennai-47. 
STUDY PERIOD:  
18   months 
NUMBER OF PATIENTS: 
40 patients (20 patients withtrial drugs and leech therapy, 20 patients with trial 
drugs only) 
TRIAL DRUGS: 
Internal Medicine :  Reference: Aathma Ratchamirdhamenum Vaidhya Saara 
    Sangirakam(Pg No:481 ) 
Dosage  :  1Gram (Thirikadi), twice a day 
Adjuvant  :  Ghee 
Duration  :  48days 
External Medicine :  (Reference:BhogarAruliyaVaithiyaSaram-700 (Pg No:143) 
Duration  :   48 days 
Dosage  :  Q.S 
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INCLUSION CRITERIA: 
• Age: 20 – 65 years 
• Sex: Both Male and Female 
• Clinical features like Itching, Oozing, Erythema, Papules, Vesicles, 
  Scaling and Hyperpigmentation 
• Patients who are willing to undergo Leech application 
• Willing to give specimen of blood for investigation whenever required. 
• Willing to attend OPD or admission in IPD for 48 days. 
• Willing to take photograph before and after treatment 
EXCLUSION CRITERIA: 
• Hypertension and other Cardiac ailments 
• Narcotics 
• Pregnancy and Lactation 
• Evidence of  any skin disease other than eczema 
• Hemophilia 
• Thrombocytopenia 
• Hepatitis B 
• HIV 
• Renal Diseases 
• Severe anaemia 
• Immuno deficiency diseases 
WITHDRAWAL CRITERIA: 
• Intolerance to the drug and development of adverse drug reactions during 
  drug trial. 
• Poor patient compliance and defaulters. 
• Patient unwilling to continue in the course of clinical trial. 
• Any drastic changes occurring in haematological finding during treatment 
  period. 
• Increased in severity of symptoms 
• Patient allergic to leech. 
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STANDARD OPERATING PROCEDURE:  
Source of trial medicines: 
           The required raw drugs for the preparation of Nilavaagai chooranam(Internal) 
and Thengaai thylam (External) were purchased from a well reputed country shop in 
Parrys, Chennai and Gopala aasan shop, Nagercoil. The coconut for oil preparation was 
purchased from Anjugramam, Kanyakumari district. The raw drugs were authenticated 
by concerned department and they were purified as per Siddha literature and the 
medicine was prepared in Gunapadam laboratory of National Institute of Siddha. 
Internal Medicine:Nilavagaai chooranam 
Ingredients: 
 Nilavagaisamoolam(Cassia senna Linn.) -  10 palam (350 grams) 
Milagu(Piper nigrum Linn.) 
Kadukkai(Terminalia chebula Retz.)  
Thandrikkai(Terminalia bellerica Roxb.) 
Seeragam(Cuminum cyminum Linn.)  
Vaaluvai(Celastrus paniculatus Willd.) 
Sirunaagapoo(Mesua ferrea Kosterm.) 
Elam(Elettaria cardamomum Linn.) 
Ilavangapattai(Cinnamom verum Presl.) 
Kadugurogini(Picrorhiza kurroa Pennell.)  -  each ¼ palam (8.75 grams) 
Sivadhai(Operculina turpethum Linn.) 
Thalisapathiri(Taxus baccata Mirb.) 
Jadhikkai(Myristica fragrans Houtt.) 
Kirambu(Syzygium aromaticum Linn.)  
Thippili(Piper longum Linn.) 
Chevviyam(Root of Piper nigrum Linn.) 
Indhuppu(Sodium chloride) 
Koogaineer(Maranta arundinacea Linn.) 
Chukku(Zingiber officinale Roscoe.) 
Senisarkarai(Sugar)           -  Equal amount for Chooranam  
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Purification of trial drugs: 
Nilavaagai(Cassia senna Linn.) 
Whole plant were cut into small pieces and  dried it. Then it was boiled with milk 
and dried. 
   (Ref:Sarakugalin suthee muraigal) 
Milaku(Piper nigrum Linn.)     
Soaked  it in fermented butter milk for 3 hours (1 saamam) and then dried it. 
            (Ref:Sigicha Rathna Deepam) 
Kadukkai(Terminalia chebula Retz.)   
Soaked it under vinegar and evacuate the yellow coloured water after that 
removed the seeds then dried the outer part well. 
(Ref:Sarakugalin suthee muraigal) 
Thandrikkai(Terminalia bellerica Roxb.) 
 Removed the nut and used the remaining part of the drug. 
 (Ref:Sarakugalin suthee muraigal) 
Seerakam(Cuminum cyminum  Linn.)    
Removed the sand and other foreign particle and dried it under sunlight. 
 (Ref: Sigicha Rathna Deepam)
  
Vaaluluvai (Celastrus paniculatus Willd.) 
Removed the dust particles and dried it well. 
 (Ref: Sigicha Rathna Deepam) 
Sirunagappoo(Mesua ferrea Kosterm.)   
Removed the foreign particles and dry it under sunlight. 
 (Ref:Sigicha Rathna Deepam) 
Elam(Elettaria cardamomum Linn.)    
Removed the foreign particles and dried it under sunlight. 
 (Ref:Sigicha Rathna Deepam) 
Lavanka pattai(Cinnamom verum Presl.)  
Dried under sunlight. 
 (Ref: Sigicha Rathna Deepam) 
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Kadugu rohini(Picrorhiza kurroa Pennell.) 
Soaked in Neem leave juice for 3 hrs and dries it in sunlight. 
 (Ref: Sigicha Rathna Deepam) 
Sivathai(Operculina turpethum Linn.) 
Boiled with milk and then dried it well. 
 (Ref:Sarakugalin suthee muraigal) 
Thalisapathiri(Taxus baccata  Mirb.) 
Dried in Sunlight. 
      (Ref:Sigicha Rathna Deepam) 
Jathikkai(Myristica fragrans Houtt.)    
Removed the external covering and cut it to small pieces then dried under 
sunlight. 
 (Ref: Sigicha Rathna Deepam) 
Kirambu(Syzygium aromaticum Linn.)    
Removed the foreign particles and dried it under sunlight. 
 (Ref: Sigicha Rathna Deepam) 
Thippily(Piper longum Linn.)     
 It was fried and then used for trial drug preparation. 
   (Ref: Sarakugalin suthee muraigal) 
Seveeyam(Root of Piper nigrum Linn.)    
Removed the external coverings and dried under sun shine. 
      (Ref: Sigicha Rathna Deepam) 
Indhuppu(Sodium chloride) 
Soaked  in  kaadi   for  a  period  of  3days  then  dried  in  sunlight. 
 (Ref: Sigicha Rathna Deepam) 
Kookai Neer(Maranta arundinacea Linn.)   
Dissolved in pure water and filtered it, the process was repeated for 6 times then 
dried in sunlight. 
 (Ref: Sigicha Rathna Deepam) 
Chukku(Zingiber officinale Roscoe.)  
Soaked  in lime stone water and  peeled out the outer portion. 
 (Ref: Sarakugalin suthee muraigal) 
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Sarkarai(Sugar) (Saccharumofficinarum)    
Grinded well and the fine particle was collected. 
 (Ref: Sigicha Rathna Deepam) 
Method of preparation:        
The raw drugs were dried and powdered separately, then mixed well together and 
then added with equal amount of white sugar and preserved. 
External medicine:Thengaai thylam 
Ingredients: 
Coconut milk (Juice of Cocos nucifera)  -2 padi(2.6 litres) 
Kalluppu (Sodium chloride)    -¼ palam(8.75gms) 
Manjal (Curcuma longaLinn.)   -¼ palam(8.75gms) 
Karunjeeragam (Nigella sativaLinn.)   -¼ palam(8.75gms) 
Method of Preparation  
Above three raw drugs were grounded and mixed with coconut milk and 
subjected to heat until it attained an oil consistency.   
  (Reference Book : Bhogar Aruliya Vaithiya Saram- 700(Pg No:144)
  
DrugStorage: 
The trial drug Nilavaagai chooranam was stored in cleaned and dried glass 
bottles and Thengaai thylam was stored in cleaned and dried narrow mouthed bottles. 
Dispensing: 
 The Powder was given in packet. Oil was given in pet bottles.  
LEECH APPLICATION PROCEDURE: 
SPECIES: 
Hirudoventralis 
SIZE: 
 Moderate size (2 to 3 inch) 
NUMBER OF LEECHES TO BE USED PER SITTING: 
 1-6 leeches depending upon the lesion. 
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SITE OF LEECH APPLICATION: 
 Over the eczematous lesion. 
NUMBER OF LEECH APPLICATION (SITTINGS) 
 4-6 times depending upon the region and severity of disease. 
TIME INTERVAL BETWEEN THE TWO LEECH APPLICATIONS: 
 Seven days. 
DURATION OF LEECH APPLICATION: 
 Upto the leech fall off or maximum period of one hour (morning session). 
STANDARD OPERATING PROCEDURES: 
APPLICATION OF LEECH: 
 The moderate sized, dark brown leeches were used for Leech application. The 
leech application was categorized into  
 1. Pre leech application procedure, 
 2. Leech application procedure, 
 3. Post leech application procedure. 
PRE LEECH APPLICATION PROCEDURE: 
 The leeches to be used were purified with turmeric water and then with pure 
water. The site to be bite were cleaned with pure water. 
LEECH APPLICATION PROCEDURE: 
 The leech was allowed to bite at the site of the lesion. If it not bite, pricking were 
done with sterile needle and allowed the leech to suck. Small gauze piece soaked in 
water was put on the leech for active sucking. 
POST LEECH APPLICATION: 
After the leech felled off spontaneously or induced, the turmeric powder was 
poured on the head portion and allowed to expel the blood. After vomiting, the leech 
were purified with turmeric water and then with pure water. The used leech was 
maintained in a separate labeled jar for that particular person during the study period. 
 The bitten spot were allowed to bleed for 5 minutes. Then dressed and 
compressed with turmeric powder dusted over aloe vera pulp. 
 The patients were observed for one hour and were educated about the bleeding 
condition. 
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 The water in the leech preserved jar was changed once in three days. 
SUBJECT SELECTION: 
 Patients reporting with symptoms of inclusion criteria were subjected to 
screening test and documented using screening proforma 
TESTS AND ASSESSMENTS: 
A. Clinical assessment 
B.   Siddha system of examination 
C. Laboratory investigations 
A. CLINICAL ASSESSMENT: 
 Itching 
 Erythematous lesions with edema 
 Presence of macule / Papule / Vesicle / Pustule 
 Oozing , scaling, lichenification of skin 
 Hyper / hypopigmentation 
 Appearance of new lesions 
 Size of the lesions 
B.  SIDDHA SYSTEM OF EXAMINATION: 
EnVagai Thervugal (Eight Types of Examination) 
1. Naadi (Pulse Perception) 
2. Parisam (Palpatory Perception) 
3. Naa (Tongue) 
4. Niram (Complexion) 
5. Mozhi (Voice) 
6. Vizhi (Eyes) 
7. Malam (Bowel Habits) 
8. Moothiram (Urine ) 
a. Neerkuri 
b. Neikuri 
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C. LABORATORY INVESTIGATIONS 
Haematology 
 Hb(gms%) 
 Total WBC Count (cells/cumm) 
 DC  
  Polymorphs (%) 
  Lymphocytes (%) 
  Eosinophils(%) 
  Monocytes (%) 
  Basophils (%) 
 Total RBC Count (cells/cumm) 
 ESR (mm/hr) 
 Bleeding Time 
Clotting Time 
Blood group & Rh typing 
Clinical biochemistry 
 Blood sugar (Fasting & Postprandial) 
 Blood urea (mg/dl) 
 Serum creatinine (mg/dl) 
Uric acid (mg/dl) 
Lipid profile  
  a) Total cholesterol 
  b) HDL 
  c) LDL 
  d) VLDL 
  e) TGL 
Liver Function Test 
 Total bilirubin 
Direct bilirubin 
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Indirect bilirubin 
 SGOT 
 SGPT 
 Alkaline phosphatase 
 Total protein 
 Serum albumin 
Serum globulin 
Urine 
 Albumin 
Sugar (Fasting & Postprandial) 
 Deposits  
OTHER TESTS 
 HbsAg 
 HIV 
 VDRL 
 HCV 
DATA COLLECTION FORMS: 
Required information were collected from each patient by using the following 
forms 
Form l          :Screening proforma  
Form lI  : Case record form 
Form llI  : Laboratory investigation proforma 
Form lV : Drug compliance form 
Form V : Patient information form 
Form VI : Informed consent form 
Form VII : Pharmacovigilance/Withdrawal form 
Form VIII : Dietary advice form 
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
STUDY NUMBER 
HISTORY TAKING 
LAB INVESTIGATION 
TRIAL DRUG 
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY AND 
TRIAL DRUG 
 
INFORMED CONSENT 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
PHARMACOLOGICAL 
ASSESSMENT 
WITHOUT 
LEECH 
THERAPY 
 
WITH 
LEECH 
THERAPY 
FURTHER MANAGEMENT OF 
ADVERSE DRUG REACTION 
INFORMED TO     
PHARMACOVIGILANCE 
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STUDY ENROLLMENT: 
 Patients reported at the OPD with the clinical symptoms of Karappan were 
examined clinically for enrolling in the study based on the inclusion and 
exclusion criteria.  
 The patients who were enrolled, were  informed (Form-V) about the study, 
trial drug, Leech application, possible outcomes and the objectives of the 
study in the language and terms understandable to them and the informed 
consent were obtained in writing from them in the consent form (Form VI).  
 All these patients were given unique registration card in which the patient‟s 
registration number of the study, address, phone number and Doctor‟s phone 
number etc. were given, so as to report easily whether  any complications 
arise. 
 Complete clinical history, complaints, duration, examination findings and 
laboratory investigations -- were recorded in the prescribed Proforma. 
Screening Form- I were filled up: Form –II and Form –III were used for 
recording the patient‟s history, clinical examination of symptoms, signs and 
laboratory investigations respectively.  
 Patients were advised to take the trial drug regularly and appropriate dietary 
advice was given according to the patient‟s perfect understanding. 
CONDUCT OF THE STUDY: 
 The day before the treatment purgation with AgasthiyarKuzhambu– 130 mg at 
early morning in empty stomach with Sangang kuppi juice were given for balancing the 
deranged Uyirthathu.  
 From the next day onwards, the trial drugs “Nilavaagai chooranam” were given 
internally for 48 days and “Thengaai thylam” were applied externally for 48 days. OPD 
patients were advised to visit the hospital once in 7 days for 48 days. At each clinical 
visit, clinical assessment was done and prognosis was noted. For 20 patients, the drug 
was given for 48 days along with Leech Therapy with 7 days interval.  
             Laboratory investigations were done on the first and the 49
th
 day of the trial. 
After the trial period, the patients were advised to visit the OPD for follow-up for further 
two months to observe any recurrence. Defaulters were not being allowed to continue the 
trial and were withdrawn from the study.  
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DATA ANALYSIS: 
 After enrolling the patient in the study, a separate file were maintained for each 
and every patient and all forms and other information were kept in the file. The screening 
forms were filled separately. The data entry were monitored by the Head of the 
department and faculty members of dept. of Sirappu Maruthuvam. All collected data 
were statistically analysed by Sr. Research Officer (Statistics) for logical errors and 
incompleteness of data to avoid any bias. No modification in the results was permitted 
for unbiased reports. Then final report were generated. 
OUTCOME: 
 The outcome was mainly assessed by reduction in symptoms like itching, oozing 
etc. and also assessed by using EASI SCORE               
Eczema Area and Severity 
Index( EASI)Score 
Before treatment After treatment 
  
CALCULATION OF EASI SCORE 
EASI=0.1{Eh+Ih/Oh/Ph+Exh+Lh}(A)h+0.2{Eu+Iu/Ou/Pu+Exu+Lu}Au+0.3{Et
 +It/Ot/Pt+Ext+Lt}At+0.4{El+Il/Ol/Pl+Exl+Ll}Al 
 Eh -Erythema of head 
 Ih -Induration of head 
 Oh -Oedema of head 
 Ph -Papulation of head 
 Exh -Excoriation of head 
 Lh -Lichenification of head 
 (A)h -Area of head 
Upper extremities-u 
Trunk-t 
Lower extremities-l 
E, I, O, P, Ex, and L are assessed according to a 3-point scale where 0=no 
symptoms, 1=slight, 
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2=moderate, 3=marked. A is assigned a numerical value based on the 
extent of lesions in a given anatomic site: 1=<10%, 2=10-29%, 3=30-
49%, 4=50-69%, 5=70-89% and 6=90-10s0%. 
ADVERSE EFFECT/SERIOUS ADVERSE EFFECT MANAGEMENT:  
 The trial patient not developed any adverse reactions. 
ETHICAL ISSUES: 
1. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab equipments 
were used.      
2. No other external or internal medicines were used other than the trial drug, for 
treating Karappan. There were no infringement on the rights of patient.    
3. The data collected from the patient were kept confidential. The patients were 
informed about the diagnosis, treatment and follow-up.  
4. After the consent of the patient (through consent form) they were enrolled in the 
study.  
5. Informed consent was obtained from the patient explaining to him/her in the 
language understandable to the patient. 
6. Treatment were provided free of cost.  
7. No serious adverse reactions noted. 
8. To avoid cross infection, the leeches used for one person were not allowed to use 
for another person. 
9. After finishing the study, the leeches were discarded. 
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BIO - CHEMICAL ANALYSIS OF NILAVAAGAI CHOORANAM ANALYSED 
AT NATIONAL INSTITUTE OF SIDDHA 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Physical Appearance of sample Dark greenish  
brown colour 
 
2. Solubility: 
a. A little of the sample is shaken well with 
distilled water. 
b. A little of the sample is shaken well with 
con. HCl/ Con. H2So4. 
               
Sparingly Soluble 
in distilled water 
 
Presence of 
Silicate 
3. Action of Heat: 
   A small amount of the sample is taken in a 
dry test tube and heated gently at first and then 
strong. 
                          
No brown fumes 
evolved 
 
Absence of 
Nitrate 
4. Flame Test: 
  A small amount of the sample is made into a 
paste with con. HCl in a watch glass and 
introduced into non-luminous part of the 
Bunsen flame. 
No Bluish green 
flame appeared. 
Absence of 
Copper 
5. Ash Test: 
A filter paper is soaked into a mixture of 
sample and dil. cobalt nitrate solution and 
introduced into the Bunsen flame and ignited 
No Yellow 
coloured flame 
Absence  of 
Sodium 
Preparation of Extract:  5 gm of Nilavaagai Chooranam is weighed accurately and 
placed in a 250ml clean beaker and added with 50ml of distilled water. Then it is boiled 
well for about 10 minutes. Then it is cooled and filtered in a 100ml volumetric flask and 
made up to 100ml with distilled water. 
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S.No EXPERIMENT 
 
OBSERVATION INFERENCE 
I. TEST FOR ACID RADICALS 
1. Test For Sulphate: 
a.2ml of the above prepared extract is taken in 
a test tube to this added 2ml of 4% dil. 
ammonium oxalate solution 
                    
Cloudy 
appearance 
present 
Presence  
of  Sulphate 
2. Test For Chloride: 
2ml of the above prepared extracts is added 
with dil-HNO3 is added until the effervescence 
ceases off. Then 2 ml of Silver nitrate solution 
is added. 
Cloudy  
appearance absent 
Presence 
of Chloride 
3. Test For Phosphate: 
2ml of the extract is treated with 2ml of 
ammonium molybdate solution and 2ml of 
con.HNO3 
                    
Cloudy  yellow 
appearance 
present  
Presence of 
Phosphate  
4.  Test For Carbonate: 
2ml of the extract is treated with 2ml 
magnesium sulphate solution. 
 
Cloudy 
appearance 
present  
Presence 
of  Carbonate 
5 Test For Nitrate: 
1gm of the substance is heated with copper 
turnings and concentrated H2So4 and viewed 
the test tube vertically down. 
No characteristic 
changes 
Absence  
of nitrate 
6 Test For Sulphide: 
1gm of the substance is treated with 2ml of 
con. HCl 
                          
No Rotten egg 
smelling gas 
evolved. 
 
 
Absence of 
sulphide 
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7 Test For Fluoride & Oxalate: 
2ml of extract is added with 2ml of dil. Acetic 
acid and 2ml calcium chloride solution and 
heated 
No cloudy 
appearance 
           
Absence 
of fluoride and 
oxalate 
8. 
 
Test For Nitrite: 
3drops of the extract is placed on a filter 
paper, on that-2 drops of dil.acetic acid and 2 
drops of dil. Benzidine solution is placed. 
                          
No characteristic 
changes 
 
Absence  
of  nitrite 
9. Test For Borate: 
2 Pinches of the substance is made into paste 
by using sulphuric acid and alcohol (95%) and 
introduced into the blue flame. 
                      
Bluish green 
colour flame not 
appeared 
   Absence  
of  borate 
II. TEST FOR BASIC RADICALS 
1. Test For Lead: 
2ml of the extract is added with 2ml of 
potassium iodide solution. 
                         
Yellow precipitate 
was obtained. 
Presence of 
Lead 
2. Test For Copper: 
a. One pinch of substance is made into paste 
with con. HCl in a watch glass and introduced 
into the non-luminuous part of the flame. 
b. 2ml of extract is added with  excess of 
ammonia solution 
 
No Blue colour 
flame 
                          
No Blue colour 
precipitate formed. 
Absence 
of Copper 
3. Test For Aluminium: 
To the 2ml of the extract sodium hydroxide is 
added in drops to excess. 
No characteristic 
changes 
 
Absence 
of Aluminium 
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4. Test For Iron: 
a. To the 2ml of extract add 2ml of ammonium 
thiocyanate solution 
b. To the 2ml of extract 2ml  ammonium 
thiocyanate solution and 2ml  of con. HNO3 is 
added 
                        
Mild red colour 
appeared 
 
Blood red colour 
appeared 
Presence of 
iron 
           
Presence of 
iron 
5. Test For Zinc: 
    To 2m1 of the extract sodium 
hydroxide solution is added in 
drops to excess. 
                     
White precipitate 
was formed 
 
           
Presence of 
Zinc. 
 
6. Test For Calcium:  
2ml of the extract is added with 2ml of 4% 
ammonium oxalate solution  
                    
Cloudy 
appearance and 
white precipitate 
was obtained. 
Presence 
of  Calcium 
7. Test For Magnesium:  
To 2ml of extract sodium hydroxide solution is 
added in drops to excess. 
                     
White precipitate 
is  obtained 
           
Presence of  
Magnesium 
8. Test For Ammonium: 
To 2ml of extract few ml of Nessler's reagent 
and excess of sodium hydroxide solution are 
added. 
Brown colour 
appeared 
Presence  of 
Ammonium 
9. Test For Potassium: 
   A pinch of substance is treated with 2ml of 
sodium nitrite solution and then treated with 
2ml of cobalt nitrate in 30% glacial acetic 
acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
   Absence  
of  Potassium 
10. Test For Sodium: 
    2 pinches of the substance is made into 
paste by using HCl and introduced into the 
blue flame of Bunsen burner. 
                           
No Yellow 
coloured flame 
appeared 
         
Absence 
of  Sodium 
76 
 
11. Test For Mercury:  
   2ml of the extract is treated with 2ml of 
sodium hydroxide solution.  
                          
No yellow 
precipitate was 
obtained. 
      
Absence of 
Mercury 
12. Test For Arsenic:  
   2ml of the extract is treated with 2ml of 
sodium hydroxide solution. 
                          
Brownish red 
precipitate was 
obtained. 
           
Presence 
of Arsenic 
III. MISCELLANEOUS 
1.
  
Test For Starch: 
2ml of extract is treated with weak iodine 
solution  
                             
Blue colour 
developed 
 
Presence  
of  Starch 
2.
  
Test For Reducing Sugar: 
    5ml of Benedict's qualitative solution is 
taken in a test tube and allowed to boil for 
2 minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes. The 
colour changes are noted. 
 
 
No brick red colour 
developed 
 
Absence of 
Reducing 
sugar. 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract is treated with 2ml of 
potassium iodide solution. 
b)  2ml of the extract is treated with 2ml of 
picric acid. 
c)  2ml of the extract is treated with 2ml of 
phosphotungstic acid. 
 
Red colour developed 
 
Yellow colour 
developed               
No white precipitate 
developed                    
 
 
 
  Presence  
of Alkaloids 
4.
  
Test For Tannic Acid:  
2ml of extract is treated with 2ml of ferric 
chloride solution  
                               
Black precipitate was 
obtained 
             
Presence of 
Tannic acid 
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5.
  
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of potassium 
permanganate solution is added.  
                      
Potassium 
permanganate was 
not decolourised 
              
Absence of 
unsaturated 
compound 
6.
  
Test For Amino Acid: 
2 drops of the extract is placed on a filter 
paper and dried well.  
                               
No Violet colour 
developed 
                    
Absence 
of Amino 
acids 
7. Test For Type Of Compound: 
2ml of the extract is treated with 2 ml of 
ferric chloride solution.  
 
Dark blue colour 
 developed 
         
Morphine, 
Phenol 
cresol and 
hydro 
quinone are 
present 
 
 
RESULT: 
 The bio-chemical analysis Nilavaagai chooranam had shown the presence of   
Silicate, Sulphate, Chloride, Phosphate, Carbonate, Lead, Iron, Zinc, Calcium, 
Magnesium, Ammonium, Arsenic, Starch, Alkaloid, Tannic acid, Morphine, Phenol 
cresol and hydroquinone are present. 
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OBSERVATION AND RESULTS 
The observation and results have been tabulated under the following headings. 
 
1. Sex distribution 
2. Age distribution 
3. Kaalam distribution 
4. Socio economic status 
5. Occupational status 
6. Family History 
7. Dietary habits 
8. Paruvakaalam 
9. Thinai  
10. Yakkai Ilakkanam (Physical Constitution) 
11. Gunam  
12. Duration of illness 
13. Clinical features 
14. Site of lesion 
15. Distribution of mukkutram 
16. Udar Kattugal  
17. En Vagai  thervugal 
18.  Neikkuri  
19. Outcome assessment through EASI Score 
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1. SEX DISTRIBUTION 
 
Sl No Sex No. of Cases Percentage 
1 Male 23 57.5% 
2 Female 17 42.5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Observation 
Among the 40 patients included in this study, 57.5% were male and 42.5% were 
female. 
2. AGE DISTRIBUTION 
 
 
Sl. 
No 
Age No. of Cases Percentage 
1 20-30 4 10% 
2 31-40 4 10% 
3 41-50 11 27.5% 
4 51-60 13 32.5% 
    
5 61-70 8 20% 
Male
58%
Female
43%
SEX
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Observation 
 
 Among the 40 patients selected for this study, maximum numbers of patients 
32.5% were in the age group of 51 to 60yrs, 27.5% were in the age group of 41 to 50yrs, 
20% were in the age 61 to 70yrs and 10% were in the age of 21 to 30yrs and 31 to 40yrs. 
 
3. AYUL  KAALAM DISTRIBUTION (According to Age) 
 
In Siddha literature human life has been divided into three periods as follows 
1 Vaatha kaalam 
2 Pitha kaalam 
3 Kaba kaalam 
The duration of each period is said to be 33 years 
Sl 
No 
Kaalam No. of Cases Percentage 
1 Vatha Kaalam (1-33 Years) 4 10% 
2 Pitha  Kaalam (34-66 years) 36 90% 
3 Kaba Kaalam (67-100 years) 0 0% 
 
21-30 yr 31-40 yr 41-50 yr 51-60 yr 61-70 yr
10% 10%
27.50%
32.50%
20%
AGE
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Observation 
 
Out of 40 patients, 36 patients were reported in Pitha kaalam, the remaining 4 in 
Vatha kaalam. 
 
4. SOCIO ECONOMIC STATUS 
 
Sl. No 
ECONOMIC STATUS 
 
No. of Cases Percentage 
1 Low income  19 47.5% 
2 Middle income 15 37.5% 
3 High income 6       15% 
 
 
 
 
 
 
 
 
Vatha Kaalam (1-33 
Years)
Pitha  Kaalam (34-
66 years)
Kaba Kaalam (67-
100 years)
10%
90%
0%
AYUL KAALAM
47%
38%
15%
ECONOMIC STATUS
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Observation 
                Out of 40 patients, 47.5% patients were under low income group, 37.5% 
patients were under middle income group, the remaining 15% patients were under high 
income group. 
 
5. OCCUPATIONAL STATUS 
 
Sl. No Nature of Work No. of Cases Percentage 
1 Driver 2 
5 % 
2 Conductor 1 
2.5% 
3 Traffic police 1 2.5 % 
4 Security 2 5% 
5 Store work 3 7.5 % 
6 Tailor 1 2.5% 
7 Building work 4 10 % 
8 EB officer 1 2.5% 
9 Housewife 14 35 % 
10 Coolie 2 5 % 
11 IT professional 3 7.5% 
12 Shopkeeper 2 5 % 
13 Hair stylist 1 2.5% 
14 Clerk 1 2.5% 
15 District registrar 1 2.5% 
16 Agriculture officer 1 2.5% 
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Observation 
Among 40 patients35% cases were housewife, 10%  were at building work, 7.5% 
of them were store work and IT professional, 5% were driver, security, coolie and 
shopkeeper, 2.5% of them were conductor, traffic police, tailor, EB officer, hair stylist, 
Clerk, District registrar and Agriculture officer. 
6. FAMILY HISTORY 
Sl. No 
 
Criteria 
 
No. of Cases Percentage 
1 
 
Family History (+ve) 
 
2 5% 
2 
 
Family History (-ve) 
 
38 95% 
 
 
 
 
0%
5%
10%
15%
20%
25%
30%
35%
OCCUPATIONAL STATUS
84 
 
 
 
 
 
Observation 
 
 Among 40 patients, 95% of the patients showed no family history, 5% showed 
positive family history. 
7.  DIETARY HABITS 
 
Sl. No Dietary Habits No. of Cases Percentage 
1 Vegetarian 4 10% 
2 Non Vegetarian 36 90% 
 
5%
95%
FAMILY HISTORY
Positive Negative
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Observation 
 
92% cases are non-vegetarian. 
 
8. PARUVA KAALAM 
 
Sl 
No. 
Paruva Kaalam No. of Cases Percentage 
1 Kaar kaalam (Aavani & Purattasi) 0 0% 
2 Koothir Kaalam (Aippasi&Kaarthigai) 0 0% 
3 Munpani Kaalam (Margazhi& Thai) 24 60% 
4 Pinpani Kaalam (Maasi&Panguni) 16 40% 
5 Elavenil Kaalam (Chithirai & Vaikasi) 0 0% 
6 Muthuvenil Kaalam (Aani&Aadi) 0 0% 
 
 
8%
92%
DIETARY HABIT
Vegetarian Non Vegetarian
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Observation 
Among the 40 patients admitted for this study, the highest number of 
patients(60%) reported in Munpani Kaalam, 40% reported in Pinpani Kaalam. 
 
9. THINAI REFERENCE 
 
Sl. No Thinai No. of Cases Percentage 
1 Kurinji (Hill Area) 0 0% 
2 Mullai (Forest Area) 0 0% 
3 Marutham (Fertile Land) 0 0% 
4 Neithal (Coastal Area) 40 100% 
5 Palai (Desert Land) 0 0 
Observation 
Among the 40 patients, 100% of the patients were from Neithal (Coastal Area). 
 
 
 
 
 
 
0%
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60%
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10. YAAKAI ILAKKANAM 
 
Sl. No Yaakai Ilakkanam No. of Cases Percentage 
1 VathaUdal 24 60% 
2 PithaUdal 13 32.5% 
3 KabaUdal 3 7.5% 
4 ThonthaUdal 0 0% 
 
 
 
Observation 
In 40 patients, 60% had VathaUdal, 32.5% had PithaUdal, 7.5% had KabaUdal. 
11. GUNAM (QUALITY AND CHARACTERS) 
 
Sl. No Gunam No. of Cases Percentage 
1 Satthuva Gunam 0 0% 
2 Raso Gunam 40 100% 
3 Thamo Gunam 0 0% 
 
Observation 
In 40 patients 100% had Rasogunam. 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
VathaUdal PithaUdal KabaUdal ThonthaUdal
YAAKAI ILAKKANAM
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12. DURATION OF ILLNESS 
 
Sl. No Duration of Illness No. of Cases Percentage 
1 > 1 Year 8 20% 
2 1-5 Years 26 65 % 
3 6-10 Years 4 10 % 
4 < 10 Years 2 
5% 
 
 
 
 
 
Observation:  
Among the 40 patients the maximum number of patients 65% had the duration of 
illness between 1-5 years , 20% of them had  > 1 Year, 10% were  6-10 yrs, 5% were 
<10 yrs. 
 
 
 
 
 
> 1 Year 1 - 5 Year 6 - 10 Year < 10 Year
20%
65%
10%
5%
DURATION OF ILLNESS
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13. CLINICAL FEATURES 
 
Sl. 
No 
Clinical Features 
No. of Cases Percentage 
BT AT BT AT 
1 Itching 40 15 100% 37.5% 
2 Oozing 29 5 72.5% 12.5% 
3 Erythema 13 6 32.5% 15% 
4 Papules 0 0 o% 0% 
5 Vesicle 0 0 0% 0% 
6 Scaling 39 27 97.5% 67.5% 
7 Hyperpigmentation 40 40 100% 100% 
8 Lichenification 31 24 77.5% 60% 
9 Swelling 16 5 40% 12.5% 
10 Crust formation 20 7 50% 17.5% 
11 Varicosity of veins 14 13 35% 32.5% 
12 Ulceration 17 4 42.5% 10% 
13 Pain 19 10 47.5% 25% 
 
 
 
 
0%
20%
40%
60%
80%
100%
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Observation:   
                  Among 40 patients included in the study, before treatment 100% of cases 
suffered from  itching and hyperpigmentation, 97.5% of them had scaling, 77.5% of 
them had lichenification, 72.5% of them had oozing, 50% of them had crust formation, 
47.5% of them had pain, 42.5%  of them had ulceration, 40% of them had swelling, 35% 
of them had varicosity of veins and 32.5% of them had erythema, after treatment 100% 
of cases had  hyper pigmentation, 67.5% of them had scaling, 60% of them had 
lichenification, 37.5% of them had itching, 32.5% of them had varicosity, 25% of them 
had pain, 17.5%  of them had crust formation, 15% of them had erythema, 12.5% of 
them had oozing and swelling and 10% of them had ulceration .  
14. SITE OF LESION 
Sl. No                Site of Lesion No. of Cases          Percentage 
   1    2 Lower Limb         22           55% 
   2    1 Lower Limb         16           40% 
   3 2 Lower limb with 2 Hand         1            2.5% 
   4 2 Lowerlimb with 1 Hand         1             2.5% 
  
Observation 
         Among 40 patients 55% had the lesion in 2 lower limb, 40% had the lesion in 1 
lower limb and 2.5% had 2 Lower limb with 2 Hand and 2 Lower limb with 1 Hand.  
 
55%
40%
2.50% 2.50%
2 Lowerlimb 1 Lowerlimb 2 Lowerlimb 2hand 2 Lowerlimb 1 hand
SITE OF LESION
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15. DISTRIBUTION OF UYIR THATHUKKAL 
The derangement of Vaatham, Pitham and Kabam in Karappan is as follows 
 
VAATHAM 
 
Sl. No Classification of Vaatham No. of Cases Percentage 
1 Praanan 3 7.5% 
2 Abaanan 3 7.5% 
3 Udhaanan 0 0% 
4 Samaanan 40 100% 
5 Viyaanan 40 100% 
6 Naagan 0 0% 
7 Koorman 0 0% 
8 Kirukaran 0 0% 
9 Devathathan 40 100% 
10 Dananjayan 0 0% 
 
 
Observation  
 Samaanan, Viyaanan and Devathathan was found to be affected in all the 40 
patients, Praanan and Abanan was affected in 7.5% of  patients. 
 
 
7.50% 7.50%
100%
0%
100%
0% 0% 0%
100%
0%
VAATHAM
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PITHAM 
 
Sl. 
No 
Classification of Pitham No. of Cases Percentage 
1 Akkanal (Anarpitham) 0 0% 
2 Vanna Eri (Ranjakam) 3 7.5% 
3 Atralangi (Sathakam) 0 0% 
4 Nokkanal (Alosakam) 0 0% 
5  Ullolli thee (Prasakam) 40 100% 
 
 
 
 
 
Observation 
Prasaka pitham was affected in all the cases. Ranjaka pitham was affected in 
7.5% of patients. 
 
KABAM 
  
 Kabam was not affected in all the cases. 
0%
50%
100%
Analaka 
pitham
Ranjaka 
pitham
Saathaka 
pitham
Aalosaka 
pitham
Prasaka 
pitham
PITHAM
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16. UDAR KATTUKAL 
 
 
Sl. No UdarKattugal No. of Cases Percentage 
1 Saaram 40 100% 
2 Senneer 40 100% 
3 Oon 40 100% 
4 Kozhuppu 40 100% 
5 Enbu 0 0% 
6 Moolai 0 0% 
7 Sukkilam/Suronitham 0 0 % 
Observation:  
Among 40 patients, Saaram, Senneer, Oon and Kozhuppu were affected in all the 
cases.  
 
17. EN VAGAI THERVUKAL 
 
1) Niram 
SL. No  Niram No. of Cases Percentage 
 1       Vaatham         19         47.5% 
 2       Pitham         13         32.5% 
 3       Kabam          8         20% 
 
 
 
 
 
Vatham
47%
Pitham
33%
Kabam
20%
NIRAM
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2) Mozhi (voice) 
 
 
 
 
 
 
 
3) Sparisam 
SL. No Sparisam No. of Cases Percentage 
   1   Veppam        15        37.5% 
   2 Mithaveppam        25        62.5% 
 
 
 
 
 
 
0%
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50%
High Medium Low
MOZHI
38%
63%
SPARISAM
Veppam Mithaveppam
SL. No Mozhi No of Cases Percentage 
   1 High pitched        4          10% 
   2 Medium pitched       20          50% 
   3 Low pitched       16          40% 
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4) Malam 
SL. No Malam No. of Cases Percentage 
   1   Normal        37        92.5% 
   2  Affected        3        7.5% 
 
 
5) Naadi 
 
 
 
 
 
 
 
 
Normal
92%
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8%
MALAM
0%
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NAADI
SL. No Naadi No. of Cases Percentage 
   1 Pithavaatham        2          5% 
   2 Vaathapitham       24          60% 
   3 Pithakabam       14          35% 
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Observation: 
In Envagai thervukal,  
1. Niram - Vaatham was in 47.5%, Pitham was in 32.5% and Kabam was in 
20%.  
2. Mozhi - High pitched was in 10%, Medium pitched was in 50% and Low 
pitched was in 40%  
3. Sparisam - Veppam was in 37.5% and Mithaveppam was in 62.5% 
4. Malam - Only 7.5% was affected. 
5. Naadi - The Naadinadai seen in Karappan patients were Vathapitham in 
60%, Pithakabam in 35%, Pithavatham 5%. 
18. NEIKKURI   
 
Sl. No  Neikkuri No. of Cases Percentage 
1  Vaatha neer  0 0% 
2  Pitha neer 17 42.5% 
3  Kaba neer 23 57.5% 
 
 
Observation: 
 In Neikkuri, Pitha neer was found in 42.5% patients and Kaba neer was found in 57.5% 
patients. 
Vaatha neer 
0%
Pitha neer
43%
Kaba neer 
58%
NEIKKURI
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19. OUTCOME ASSESSMENT THROUGH EASI SCORE 
  
EASI 0 - No Reduction in the score 
EASI 25 - 25% Reduction in the score after treatment 
EASI 50- 50% Reduction in the score after treatment 
EASI 75- 75% Reduction in the score after treatment 
 EASI 100- 100%Reduction in the score treatment 
Observation: 
 30% of them had 25% of reduction in the score after treatment, 27.5% of them 
had 50% of reduction in the score after treatment, 25% of them had 75% of reduction in 
the score after treatment, 10% of them had no reduction in the score, which indicates the 
good improvement after treatment and 7.5% of them had increased in the score after 
treatment which indicates the eczema severity increased after treatment.   
 
0%
5%
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15%
20%
25%
30%
EASI 0 EASI 25 EASI 50 EASI 75 EASI 100
EASI SCORE
Sl. No Results No of Cases Percentage 
1 EASI 0 4 10% 
2 EASI 25 12 30% 
3 EASI 50 11 27.5% 
4 EASI 75  10          25% 
5 
 
EASI 100 0 0% 
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STATISTICAL ANALYSIS 
TREATMENT WITH THE TRIAL DRUG 
All collected data were entered into MS Excel software using different columns 
as variables and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross-tabulations were 
performed. The quantity variables were expressed as Mean ± Standard Deviation and 
qualitative data as percentage. A probability value of <0.0001 was considered to indicate 
as statistical significance. Paired„t‟ test was performed for determining the significance 
between before and after treatment. 
 
The assessment was done using EASI Score in all the 40 patients participated in 
the trial. The mean value of EASI score for all the 40 patients before treatment is 4.21 
and after treatment is 2.39. The p-value is less than 0.0001 which is highly significant. 
The reduction in the Mean was 43%.  
   STATISTICAL ANALYSIS 
 LEECH THERAPY ALONG WITH THE TRIAL DRUG 
 
 
 
The mean value of EASI score for patients with Leech therapy is 4.8 and after 
treatment is 2.52.The p-value is less than 0.0001 which is highly significant. The 
reduction in the Mean was 47.5%. 
EASI score Mean± Std p -value, t - value 
Before treatment 4.21±2.68 p<0.0001, t = 4.30 
After  treatment 2.39± 1.96 
EASI score Mean± Std p –value 
Before treatment 4.8±3.32 p<0.0001 
After  treatment 2.52± 2.13 
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TRIAL DRUG WITHOUT LEECH THERAPY 
 
 
 
 
 
The mean value of EASI score for patients without Leech therapy is 3.62 and 
after treatment is 2.26.The p-value is less than 0.0001 which is highly significant.  The 
reduction in the Mean was 37.5%. Hence this study reveals Leech therapy along with 
trial medicines is to be effective in reducing the symptoms of Karappan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EASI score Mean± Std p –value 
Before treatment 3.62±1.72 p<0.0001 
After  treatment 2.26± 1.80 
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CLINICAL IMPROVEMENT TRIAL DRUG WITH LEECH 
THERAPY 
 
Sl. no 
Op .no/ 
Ip. no. 
     
Age/ 
Sex 
DOI 
             
Date Of 
Admission 
No of 
Days 
Treated 
EASI    Score 
 
GRADE 
BT AT 
1 K42480 42/M 1 yr 27.12.18 48 2.4 0.4 EASI 75 
2 K99583 35/M 3 yrs 7.1.19 48 4.8 0.8 EASI 75 
3 L07620 50/M 6 mon 10.1.19 48 3.6 3.6 EASI  0 
4 L08891 65/M 3 mon 13.1.19 48 4.8 2.4 EASI 50 
5 K98714 50/F 2 yrs 21.1.19 48 4 2.4 EASI50 
6 K50073 52/F 2 ½ yrs 26.1.19 48 4.8 2.4 EASI 50 
7 L11404 62/M 1 yr 26.1.19 48 7.2 4.8 EASI 50 
8 L1707 55/M 2 yrs 29.1.19 48 2.4 4  
9 0108-19 34/M 13 yrs 29.1.19 48 9.6 2.8 EASI 75 
10 L15492 43/M 3 yrs 30.1.19 48 2 1.2 EASI 25 
11 K41314 54/F 2 yrs 10.2.19 48 3.2 2.8 EASI 25 
12 L17650 47/M 6 mon 13.2.19 48 3.2 3.2 EASI 0 
13 0228-19 50/M 5 yrs 15.2.19 48 7.2 1.2 EASI 75 
14 I73962 61/F 1 ½ yrs 18.2.19 48 14.4 3.2 EASI 75 
15 K66805 51/F 5 yrs 4.3.19 48 1.2 0.4 EASI  50 
16 K96927 30/F 7 yrs 6.3.19 48 9.6 3.2 EASI 75 
17 K85275 63/M 5 yrs 7.3.19 48 1.2 1.2 EASI 0 
18 L12532 64/M 3 mon 11.3.19 48 4 9.6  
19 L25367 52/F 6 mon 18.3.19 48 2.4 0.4 EASI 75 
20 J35932 43/F 2 yrs 30.3.19 48 4 0.4 EASI 75 
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CLINICAL IMPROVEMENT TRIAL DRUG WITHOUT LEECH 
THERAPY 
 
Sl. no 
Op .no/ 
Ip. no. 
Age/ 
Sex 
DOI 
Date Of 
Admission 
No of 
Days 
Treated 
EASI    Score  
GRADE 
BT AT 
1 L01684 60/M 3 yrs 2.1.19 48 8.4 8.4 EASI 0 
2 L04532 62/M 1 mon 7.1.19 48 4 5.6  
3 F04578 21/M 4 yrs 5.1.19 48 2.4 1.2 EASI 50 
4 J52734 57/F 2 yrs 7.1.19 48 4.4 2 EASI 50 
5 K98702 28/M 2 yrs 16.1.19 48 5.6 2.4 EASI50 
6 L10589 29/F 1 ½ yrs 16.1.19 48 3.2 2.4 EASI 25 
7 L10821 65/M 2 yrs 23.1.19 48 1.6 0.8 EASI 25 
8 I50989 58/F 5 yrs 23.1.19 48 6.4 2.4 EASI 75 
9 G52624 44/M 5 yrs 24.1.19 48 3.2 2.4 EASI 25 
10 L16627 38/M 4 yrs 29.1.19 48 2.4 1.6 EASI 25 
11 L17301 35/M 8 mon 6.2.19 48 3.6 3.2 EASI 25 
12 K1983 55/F 5 yrs 7.2.19 48 4 2.4 EASI 25 
13 L21313 42/F 7 yrs 10.2.19 48 2.4 1.6 EASI 25 
14 F87188 53/M 1 ½ yrs 14.2.19 48 2.4 1.6 EASI 25 
15 L15503 56/F 4 yrs 16.2.19 48 2.4 1.6 EASI  25 
16 L19280 65/M 30 yrs 16.2.19 48 3.2 1.2 EASI 50 
17 K87129 45/M 6 yrs 18.2.19 48 4.8 1.6 EASI 50 
18 L20279 53/F 3 mon 19.2.19 48 2 0.4 EASI 75 
19 K78532 43/F 3 yrs 20.2.19 48 1.6 1.2 EASI 25 
20 K83327 58/F 10 yrs 5.3.19 48 4.4 1.2 EASI 50 
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WITH LEECH THERAPY 
PATIENT’S BLOOD INVESTIGATION CHART 
 
Sl.no 
Op .no./ 
Ip. no. 
Hb gm% 
TC 
Cells/cu.mm 
RBC 10
6
 
Cells/cu.mm 
ESR/hr 
BT AT BT AT BT AT BT AT 
1 K42480 13.4 11.2 7100 7000 5.3 4.6 2/10 1/8 
2 K99583 13.2 12.3 8000 7700 6.2 6.1 4/10 6/14 
3 L07620 14.9 12 6600 8800 4.8 4 10/22 12/26 
4 L08891 13.7 11.9 9200 8500 4.7 4.2 8/16 10/20 
5 K98714 11.1 11.2 8200 7700 4.1 4.3 60/120 36/72 
6 K50073 11.4 9.4 11400 6800 4.2 3.5 10/22 16/34 
7 L11404 14.2 12.9 5900 5300 4.9 4.5 12/24 14/28 
8 L1707 15.7 14.7 8200 5700 5.1 4.8 4/10 6/14 
9 0108-19 14.1 12 7500 10200 5.3 4.4 12/24 8/16 
10 L15492 15 13.3 10000 12800 4.8 4.6 28/46 14/30 
11 K41314 11.7 11.1 6800 7600 4.2 4.0 54/108 38/76 
12 L17650 13.3 12.4 5500 5300 4.4 3.9 6/14 8/18 
13 0228-19 14.4 13.2 8600 6700 2.8 4.0 44/90 8/16 
14 I73962 13.5 12.7 10300 9300 4.6 4.3 40/80 20/40 
15 K66805 12.8 13.1 5700 5600 4.4 4.6 18/36 10/20 
16 K96927 9.8 9.2 7700 8800 4.5 4.3 50/100 34/70 
17 K85275 14.7 13.4 6900 6400 4.7 4.4 14/30 24/50 
18 L12532 14.6 13.9 9600 10900 4.9 4.5 10/22 6/12 
19 L25367 12.3 11.3 6800 7800 4.5 4.3 10/20 16/32 
20 J35932 10.2 9.4 6900 10400 4.1 4.5 20/42 60/122 
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PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
 
Sl.no 
Op .no./ 
Ip. no. 
Polymorphs Lymphocytes Monocytes Eosinophils 
 BT AT BT AT BT AT BT AT 
1 K42480 72 59 23 33 2 8 3 - 
2 K99583 65 69 30 27 5 - - 4 
3 L07620 69 81 27 15 4 1 - 3 
4 L08891 74 71 23 25 - 4 3 - 
5 K98714 65 63 31 34 4 - - 3 
6 K50073 75 54 20 41 5 5 - - 
7 L11404 61 65 32 30 7 5 - - 
8 L1707 80 66 17 28 - 6 3 - 
9 0108-19 60 73 38 22 - 5 2 - 
10 L15492 58 83 37 15 5 - - 2 
11 K41314 65 71 33 27 - - 2 2 
12 L17650 53 49 43 47 4 2 - 2 
13 0228-19 81 66 16 30 - 4 3 - 
14 I73962 66 58 31 39 - 1 3 2 
15 K66805 64 60 33 35 - 5 3 - 
16 K96927 68 67 27 30 2 - 3 3 
17 K85275 80 60 16 35 4 5 - - 
18 L12532 72 65 23 30 5 5 - - 
19 L25367 71 64 26 32 1 - 2 4 
20 J35932 60 60 36 37 - 1 4 2 
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PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
 
Sl.no 
Op .no./ 
Ip. no. 
Blood 
Sugar(F) 
Blood 
Sugar(PP) 
Blood 
Sugar 
(Random) 
 BT AT BT AT BT AT 
1 K42480 88 80 87 92 - - 
2 K99583 81 66 93 80 - - 
3 L07620 88 72 93 103 - - 
4 L08891 102 80 123 112 - - 
5 K98714 98 94 114 103 - - 
6 K50073 115 94 142 124 - - 
7 L11404 - - - - 97 145 
8 L1707 100 86 117 117 - - 
9 0108-19 70 56 87 99 - - 
10 L15492 - - - - 86 102 
11 K41314 100 103 107 142 - - 
12 L17650 89 85 102 86 - - 
13 0228-19 102 80 163 116 - - 
14 I73962 158 132 267 192 - - 
15 K66805 - - - - 113 86 
16 K96927 77 91 104 121 - - 
17 K85275 - - - - 90 84 
18 L12532 136 135 233 190 - - 
19 L25367 94 82 73 85 - - 
20 J35932 71 75 84 91 - - 
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PATIENT’S RENAL FUNCTION TEST CHART 
 
 
Sl.no 
Op .no./ 
Ip. no. 
Urea 
mg/dl 
 
Creatinine 
mg/dl 
 
Uric Acid 
mg/dl 
 BT AT BT AT BT AT 
1 K42480 17 19 1.0 0.9 6.6 6.9 
2 K99583 14 15 1 0.9 6 5.3 
3 L07620 25 18 1.4 1.2 6.2 6.0 
4 L08891 32 27 0.8 0.9 4.9 4.6 
5 K98714 12 13 0.8 0.9 5.9 5.8 
6 K50073 12 16 0.9 0.8 3.9 4.4 
7 L11404 15 11 1.1 1.1 7 7.7 
8 L1707 12 8 1.2 1.2 5.5 6.2 
9 0108-19 18 36 0.9 0.8 5.9 4 
10 L15492 20 28 1 1.1 4.1 4 
11 K41314 19 25 0.8 0.8 4.9 3.5 
12 L17650 15 15 1.1 1.1 6.2 6.2 
13 0228-19 23 24 1.0 1.0 5.6 5.6 
14 I73962 21 37 0.9 1.0 5.8 7.3 
15 K66805 9 7.8 0.8 0.8 3.2 3.3 
16 K96927 12 22 0.8 0.7 3.4 3.8 
17 K85275 13 12 1 1.1 4.3 5.5 
18 L12532 22 14 1 0.9 4.1 5.9 
19 L25367 26 28 1 1.2 5 5.5 
20 J35932 14 16 0.8 0.9 4.4 4.9 
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PATIENT’S LIVER FUNCTION TEST CHART 
 
 
Sl.no 
Op .no. / 
Ip. no. 
Total 
Bilirubin 
mg/dl 
Direct 
Bilirubin 
mg/dl 
Indirect 
Bilirubin 
mg/dl 
SGOT 
IU 
SGPT 
IU 
Alk.phos 
mg/dl 
 BT AT BT AT BT AT BT AT BT AT BT AT 
1 K42480 0.7 0.6 0.2 0.2 0.5 0.4 19 16 14 14 124 117 
2 K99583 0.4 0.4 0.2 0.2 0.2 0.2 17 13 23 18 89 84 
3 L07620 0.9 0.6 0.3 0.2 0.6 0.4 26 19 33 22 79 76 
4 L08891 0.7 0.6 0.3 0.2 0.4 0.4 12 12 11 20 83 92 
5 K98714 0.6 0.9 0.3 0.4 0.3 0.5 23 17 32 20 113 104 
6 K50073 0.5 0.4 0.2 0.1 0.3 0.3 13 14 14 14 76 63 
7 L11404 0.4 0.4 0.1 0.2 0.3 0.2 21 19 18 18 53 59 
8 L1707 0.7 0.9 0.2 0.3 0.5 0.6 18 17 17 17 77 68 
9 0108-19 1 1.6 0.4 0.6 0.6 1 37 26 44 22 101 65 
10 L15492 0.5 0.8 0.2 0.3 0.3 0.5 33 19 53 33 100 92 
11 K41314 0.6 0.4 0.2 0.1 0.4 0.3 29 24 35 29 88 96 
12 L17650 0.5 0.8 0.2 0.3 0.3 0.5 14 16 21 18 54 57 
13 0228-19 2.0 1.3 0.7 0.4 1.3 0.9 25 15 32 18 80 86 
14 I73962 0.4 0.4 0.1 0.1 0.3 0.3 20 37 26 29 83 77 
15 K66805 0.5 0.3 0.2 0.1 0.3 0.2 18 23 19 29 83 76 
16 K96927 0.4 0.4 0.2 0.2 0.2 0.2 20 17 28 13 108 121 
17 K85275 0.7 0.4 0.3 0.2 0.4 0.2 14 9 12 16 91 84 
18 L12532 0.7 0.5 0.3 0.2 0.4 0.3 22 19 25 3 77 59 
19 L25367 0.4 0.5 0.2 0.2 0.2 0.3 16 12 15 3 92 78 
20 J35932 0.4 0.2 0.2 0.1 0.2 0.1 16 13 11 11 64 91 
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PATIENT’S URINE INVESTIGATION CHART 
 
 
Sl.no 
Op .no. / 
Ip. no. 
Albumin Sugar Deposits 
 BT AT BT AT BT AT 
 1 K42480 Nil Nil Nil Nil 1-3 pus, 1-3 epi 2-3 pus, 2-3 epi 
2 K99583 Nil Nil Nil Nil 2-4 pus, 2-3 epi 3-4 pus, 2-4 epi 
3 L07620 Nil Nil Nil Nil 2-3 pus, 1-2 epi 1-2 pus, 1-2 epi 
4 L08891 Nil Nil Nil Nil 1-2 pus, 2-3 epi 1-2 pus, 1-2 epi 
5 K98714 Nil Nil Nil Nil 2-4pus, 2-4 epi 2-3 pus, 2-4 epi 
6 K50073 Nil Nil Nil Nil 2-3 pus, 1-2 epi 2-3 pus, 2-4 epi 
7 L11404 Nil Nil Nil Nil 1-3 pus, 1-3 epi 1-2 pus, 1-2 epi 
8 L1707 Nil Nil Nil Nil 1-2 pus, 1-2 epi 1-2 pus, 1-2 epi 
9 0108-19 Nil Nil Nil Nil 1-3 pus, 1-3 epi 1-2 pus, 1-2 epi 
10 L15492 Nil Nil Nil Nil 1-2 pus, 1-2 epi 2-4 pus, 1-2 epi 
11 K41314 Nil Nil Nil Nil 2-3 pus, 1-2 epi 2-3 pus, 1-2 epi 
12 L17650 Nil Nil Nil Nil 1-2 pus, 1-2 epi 2-3 pus, 1-2 epi 
13 0228-19 Nil Nil Nil Nil 1-3 pus, 1-3 epi 1-3 pus, 1-3 epi 
14 I73962 Nil Nil Nil Nil 3-4 pus, 1-2 epi 2-3 pus, 2-4 epi 
15 K66805 Nil Nil Nil Nil 3-5 pus, 2-4 epi 4-6 pus, 3-4 epi 
16 K96927 Nil Trace Nil Nil 2-3 pus, 2-4 epi 3-5 pus, 6-8 epi 
17 K85275 Nil Nil Nil Nil 2-4 pus, 2-4 epi 2-3 pus, 1-2 epi 
18 L12532 Nil Nil Nil Nil 4-6 pus, 1-2 epi 2-3 pus, 2-3 epi 
19 L25367 Nil Nil Nil Nil 1-2 pus, 1-2 epi 2-3 pus, 2-4 epi 
20 J35932 Nil + Nil Nil 2-3 pus, 2-3 epi plenty of pus, 1-2 epi 
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WITHOUT LEECH THERAPY 
 
PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
 
Sl.no 
OP .No 
Hb 
gm% 
TC 
Cells/ 
Cu.mm 
RBC 
million 
Cells/ 
cu.mm 
ESR 
(mm/hr) 
 BT AT BT AT BT AT BT AT 
1 L01684 12.4 11.6 10600 11500 3.8 3.6 16/32 20/40 
2 L04532 14.3 14.3 4500 7000 4.5 4.6 10/22 14/30 
3 F04578 15.2 15.1 8900 8100 4.5 4.5 6/12 2/4 
4 J52734 12.4 12.4 9200 12300 4.3 4.5 13/32 10/20 
5 K98702 15 15 6100 7200 5 4.9 12/24 2/4 
6 L10589 10.5 10 11300 10600 5.4 5 30/62 16/34 
7 L10821 13.5 12.7 4900 4200 4.6 4.3 16/32 10/22 
8 I50989 11.4 12 11100 7900 3.9 4.2 20/42 36/72 
9 G52624 17.4 15.6 9000 7000 7.3 6.3 2/4 4/10 
10 L16627 14.9 14.5 7600 6400 5.4 5.2 8/16 6/12 
11 L17301 14.8 14.3 7200 7200 5.3 5 2/6 20/40 
12 K1983 13.1 12.8 12000 12500 4.1 4 50/100 34/68 
13 L21313 13.2 13.3 8800 9200 4.4 4.4 6/12 34/70 
14 F87188 14.7 13.2 5900 7500 5.2 4.5 6/12 20/40 
15 L15503 11.4 10.7 8700 8300 4.7 4.5 54/110 48/96 
16 L19280 13.6 13.4 8300 7200 4.5 4.3 8/16 4/10 
17 K87129 13.1 13.1 7900 7800 4.7 4.6 20/40 6/12 
18 L20279 12.4 11.8 4800 7400 4.4 4.1 20/42 12/24 
19 K78532 11.1 11.2 7900 6200 3.9 4.1 6/12 34/70 
20 K83327 12.7 12.9 8600 11200 4.5 4.5 14/30 26/54 
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PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
Sl.no Op .no 
Polymorphs Lymphocytes Monocytes Eosinophils 
BT AT BT AT BT AT BT AT 
1 L01684 67 71 28 24 5 5 - - 
2 L04532 60 69 35 27 5 4 - - 
3 F04578 66 57 29 38 5 5 - - 
4 J52734 61 67 30 30 1 - 8 3 
5 K98702 60 60 34 36 6 4 - - 
6 L10589 65 67 30 29 5 4 - - 
7 L10821 82 80 12 13 6 7 - - 
8 I50989 85 73 12 24 2 1 3 2 
9 G52624 76 72 22 25 - - 2 3 
10 L16627 75 62 26 31 5 7 - - 
11 L17301 63 71 32 24 5 5 - - 
12 K1983 70 72 25 24 5 4 - - 
13 L21313 75 67 22 32 - - 3 1 
14 F87188 57 70 39 26 4 4 - - 
15 L15503 69 64 28 34 1 - 2 2 
16 L19280 76 74 21 24 - - 3 2 
17 K87129 71 72 22 24 7 4 - - 
18 L20279 53 51 44 47 - - 3 2 
19 K78532 65 60 31 36 4 4 - - 
20 K83327 67 67 28 29 5 4 - - 
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PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
 
 
Sl.no 
Op .no. 
Blood 
Sugar(F) 
Blood 
Sugar(PP) 
Blood 
Sugar 
(Random) 
 BT AT BT AT BT AT 
1 L01684 90 95 131 128 - - 
2 L04532 85 74 116 118 - - 
3 F04578 - - - - 106 93 
4 J52734 74 86 109 98 - - 
5 K98702 157 94 262 142 - - 
6 L10589 82 73 94 89 - - 
7 L10821 130 126 214 199 - - 
8 I50989 102 95 94 124 - - 
9 G52624 91 85 114 108 - - 
10 L16627 89 82 102 71 - - 
11           L17301 95 104 127 156 - - 
12 K1983 98 94 112 126 - - 
13 L21313 110 114 205 208 - - 
14 F87188 - - - - 86 80 
15 L15503 - - - - 98 127 
16 L19280 - - - - 163 93 
17 K87129 - - - - 78 76 
18 L20279 - - - - 91 94 
19 K78532 - - - - 112 205 
20 K83327 100 114 180 182 - - 
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PATIENT’S RENAL FUNCTION TEST CHART 
 
 
 
Sl.no 
 
Op .no 
 
Urea 
mg/dl 
 
Creatinine 
mg/dl 
 
Uric Acid 
mg/dl 
BT AT BT AT BT AT 
1 L01684 12 13 0.9 0.9 4.4 4.8 
2 L04532 17 17 1.0 0.9 5.3 4.7 
3 F04578 42 16 1.0 0.9 7.7 6.8 
4 J52734 23 23 0.8 1.0 5.2 4.7 
5 K98702 12 13 1.0 0.9 7.5 7.1 
6 L10589 19 12 1.0 0.9 4.5 3.3 
7 L10821 19 16 0.8 0.8 4.1 4 
8 I50989 28 25 0.9 0.8 6.2 5.7 
9 G52624 21 26 1 1 4.5 4.7 
10 L16627 15 16 1 1 4.7 5.1 
11 L       L17301 18 17 0.9 0.9 7 7.4 
12 K1983 12 12 1 0.9 4.7 4.4 
13 L21313 16 13 0.9 0.8 6.7 6.5 
14 F87188 24 30 1 1.1 3.2 3.1 
15 L15503 26 28 1.1 1.1 6.9 7.2 
16 L19280 30 24 1.3 1.3 5.2 5.3 
17 K87129 21 23 1 0.9 5.7 5.1 
18 L20279 18 19 0.9 0.9 4.1 3.4 
19 K78532 18 18 0.9 0.9 3.9 3.6 
20 K83327 16 11 0.7 0.7 5.4 5.3 
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PATIENT’S LIVER FUNCTION TEST CHART 
 
 
 
Sl.no 
 
Op .no 
 
 
Total 
Bilirubin 
mg/dl 
 
Direct 
Bilirubin 
mg/dl 
 
 
Indirect 
Bilirubin 
mg/dl 
 
 
SGOT 
IU 
 
SGPT 
IU 
 
Alk.phos 
mg/dl 
 
  BT AT BT AT BT AT BT AT BT AT BT AT 
1 L01684 0.5 0.6 0.2 0.2 0.3 0.4 15 17 15 15 70 79 
2 L04532 1.4 1.2 0.6 0.5 0.9 0.7 17 11 16 7 73 64 
3 F04578 0.4 0.6 0.2 0.2 0.2 0.4 16 18 17 23 70 66 
4 J52734 0.6 0.5 0.1 0.2 0.5 0.3 23 13 21 8 92 122 
5 K98702 0.8 1.2 0.3 0.4 0.5 0.8 37 28 66 52 74 69 
6 L10589 0.3 0.3 0.1 0.2 0.2 0.1 19 18 13 14 82 72 
7 L10821 2 1.6 0.9 0.7 1.1 1 48 45 32 20 121 109 
8 I50989 1.3 0.6 0.5 0.3 0.8 0.3 16 17 10 8 141 151 
9 G52624 0.8 0.7 0.3 0.3 0.5 0.4 15 22 26 24 112 95 
10 L16627 0.7 0.5 0.3 0.2 0.4 0.3 18 18 20 18 100 79 
11           L17301 1 1.4 0.4 0.4 0.6 0.9 22 28 35 68 92 79 
12 K1983 0.5 0.8 0.2 0.3 0.3 0.5 28 30 16 16 84 80 
13 L21313 0.5 1 0.2 0.4 0.3 0.6 15 23 17 25 86 88 
14 F87188 0.5 0.7 0.2 0.3 0.3 0.4 18 18 25 9 54 54 
15 L15503 0.6 0.7 0.2 0.3 0.4 0.4 19 20 17 31 100 82 
16 L19280 0.4 0.3 0.2 0.1 0.2 0.2 17 27 15 23 98 107 
17 K87129 0.9 1.4 0.4 0.6 0.5 0.8 25 21 13 7 95 81 
18 L20279 0.4 0.3 0.2 0.1 0.2 0.2 18 14 20 10 87 79 
19 K78532 0.3 0.3 0.1 0.1 0.2 0.2 22 15 33 13 82 87 
20 K83327 0.7 0.5 0.3 0.2 0.4 0.3 16 10 9 20 99 83 
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PATIENT’S   URINE   INVESTIGATION   CHART 
 
Sl.no Op .no Albumin Sugar Deposits 
  BT AT BT AT BT AT 
1 L01684 Nil Nil Nil Nil 2-4 pus, 2-4 epi 1-2 pus, 1-2 epi 
2 L04532 Nil Nil Nil Nil 2-3 pus, 2-4 epi 1-2 pus, 1-2 epi 
3 F04578 Nil Nil Nil Nil 1-2 pus, 1-2 epi 2-4 pus, 2-3 epi 
4 J52734 Nil Nil Nil Nil 2-3 pus, 2-3 epi 1-2 pus, 1-2 epi 
5 K98702 Nil Nil Nil Nil 1-2pus, 1-2 epi 2-4 pus, 1-2 epi 
6 L10589 Nil Nil Nil Nil 2-3 pus, 1-2 epi 2-3 pus, 2-4 epi 
7 L10821 Nil Nil Nil Nil 1-3 pus, 1-3 epi 1-2 pus, 1-2 epi 
8 I50989 Nil Nil Nil Nil 1-2 pus, 1-2 epi 1-2 pus, 1-2 epi 
9 G52624 Nil Nil Nil Nil 1-3 pus, 1-3 epi 1-2 pus, 1-2 epi 
10 L16627 Nil Nil Nil Nil 1-2 pus, 1-2 epi 2-4 pus, 1-2 epi 
11            L17301 Nil Nil Nil Nil 2-3 pus, 1-2 epi 2-3 pus, 1-2 epi 
12 K1983 Nil Nil Nil Nil 1-2 pus, 1-2 epi 2-3 pus, 1-2 epi 
13 L21313 Nil Nil Nil Nil 1-3 pus, 1-3 epi 1-3 pus, 1-3 epi 
14 F87188 Nil Nil Nil Nil 3-4 pus, 1-2 epi 2-3 pus, 2-4 epi 
15 L15503 Nil Nil Nil Nil 3-5 pus, 2-4 epi 4-6 pus, 3-4 epi 
16 L19280 Nil Trace Nil Nil 2-3 pus, 2-4 epi 3-5 pus, 6-8 epi 
17 K87129 Nil Nil Nil Nil 2-4 pus, 2-4 epi 2-3 pus, 1-2 epi 
18 L20279 Nil Nil Nil Nil 4-6 pus, 1-2 epi 2-3 pus, 2-3 epi 
19 K78532 Nil Nil Nil Nil 1-2 pus, 1-2 epi 2-3 pus, 2-4 epi 
20 K83327 Nil Trace Nil Nil 6-8 pus, 6-8 epi 10-12 pus, 2-4 epi 
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DISCUSSION 
The aim of the trial is to study the therapeutic effect of the drug to reduce the 
symptoms of Karappan such as itching, oozing etc. The clinical features of Karappan can 
be correlated to eczema in modern science. Eczema is a non - contagious chronic skin 
disease which is characterized by erythema, scaling, oedema, oozing and vesiculation.   
The drugs which are mentioned in Siddha literature for the management of 
Karappan were selected and the study is conducted after the proposal was screened by 
the Screening committee of National Institute of Siddha and the trial was also approved 
by the Institutional Ethical Committee (IEC). The trial was registered in Clinical trial 
registry of India. 
The trial drugs were prepared by the Author in the Gunapadam practical 
laboratory, National Institute of Siddha, after getting proper authentication of raw drugs 
from the Medicinal Botany department at National Institute of Siddha. The trial drug was 
prepared by the standard operating procedure as mentioned in the protocol. 
The Biochemical qualitative and quantitative analysis of drugs were performed in 
Biochemistry lab of NIS. The safety of the trial drug usage through biochemical analysis 
were also ensured during the study. It revealed the presence of effective minerals. 
The patients were recruited for the trial based on inclusion and exclusion criteria 
and after getting the consent from the patient. 40 patients were included in this study.  
Out of the 40 cases, 20 patient were treated with trial drug and remaining 20 patient were 
treated with Leech therapy along with trial drug. Separate proforma was maintained for 
every patient. Daily progress chart was also maintained to monitor the clinical signs and 
symptoms of the disease.  
The treatment was aimed at normalizing the deranged thodams and providing 
relief from symptoms. Before treatment the patients were advised to take Agathiyar 
kuzhambu - 130 mg with sanganguppi juice in early morning for purgation.  
The patients were treated with trial drugs Nilavaagai chooranam(internal) twice a 
day with water for 48 days and  Thengaai thylam (external) for 48 days . Patients were 
instructed to take the medicines regularly and advised to follow pathiyam and to avoid 
exposure to allergic substances if any. Out-Patients were asked to visit the hospital once 
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in 7 days. For Out-Patients the internal drug was given for 7 days and external medicine 
was given for 7 days and the clinical assessment was done on 0
th
 day, 8
th
 day, 15
th
 day, 
22
nd
 day, 29
th
 day, 36
th
 day, 43
rd
day and 49
th
day. 
After completion of the study, the patients were advised to visit the Out-Patient 
ward of Department of Sirappu Maruthuvam for another 2 months for follow-up. The 
results observed during the study period were discussed by the author below.   
Among the 40 patients included,  
According to the Gender the disease was found to be higher in males (57.5%) 
compared to females (42.5%). In general, this disease was more common in males, hence 
the study reveals the same. 
In Age group maximum numbers of patients 32.5% were in the age group of 51 
to 60yrs, 27.5% were in the age group of 41 to 50yrs, 20% were in the age 61 to 70yrs 
and 10% were in the age of 21 to 30yrs and 31 to 40yrs. In 51 to 60 yrs the patients were 
hardworkers which is one of the cause for Eczema. In general, this disease was more 
common in this age group, hence the study reveals the same. 
 In my study while seeing socio-economic status  of the patients the disease was 
found to be higher in the low income group 47.5%, moderate in the middle income group 
37.5%, lower in the high income group15%. Increased incident is present in low income 
group, because they were fieldworkers. In general, this disease was more common in this 
low economic group, hence the study reveals the same. 
In Occupational  distribution, Among 40 patients35% cases were housewife, 
10%  were at building work, 7.5% of them were store work and IT professional, 5% were 
driver, security, coolie and shopkeeper, 2.5% of them were conductor, traffic police, 
tailor, EB officer, hair stylist, Clerk, District registrar and Agriculture officer.According 
to occupational distribution, the chemical  handling  person, housewife were mostly 
affected. In general, this disease was more common in people with chemical contact, 
hence the study reveals the same. 
Regarding Family history, 95% of the patients showed no family history, 5% 
showed positive family history. The family history were less importance in disease 
incidence, hence the study reveals the same. 
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In Diet Non vegetarian (92%) is very higher than the vegetarian (8%). According 
to the Siddha literature, Non-vegetarian is one of the causative factor of this 
disease.Hence the study reveals the same. 
In Paruva Kaalam among the 40 patients admitted for this study, the highest 
number of patients(60%) reported in Munpani Kaalam, 40% reported in Pinpani Kaalam. 
According to climate variation highest incidence is involved in Munpani Kaalam. 
According to the Siddha literature, Panikalam in which disease may occur.Hence the 
study reveals the same. 
Regarding Thinai, 100% of the patients were from Neithal(Coastal Area). Vatha 
diseases are predominant in neithal thinai. As per the Siddha text, skin diseases are 
predominant in neithal thinai, which was seen in this study also. 
In Yaakai Ilakkanam, Out of 40 patients, 60% of them were VathaUdal, 32.5% 
were PithaUdal and 7.5% were KabaUdal. 
In Gunam, 100%of cases had Rasogunam. 
In Duration of illness the maximum number of patients 65%had the duration of 
illness between 1-5 years, 20%of them had > 1 Year, 10%were 6-10 yrs, 5%were <10 
yrs. 
 According to the clinical features, Among 40 patients included in the study, 
before treatment 100% of cases suffered from  itching and hyperpigmentation, 97.5% of 
them had scaling, 77.5% of them had lichenification, 72.5% of them had oozing, 50% of 
them had crust formation, 47.5% of them had pain, 42.5%  of them had ulceration, 40% 
of them had swelling, 35% of them had varicosity and 32.5% of them had erythema, 
after treatment 100% of cases had  hyper pigmentation, 67.5% of them had scaling, 60% 
of them had lichenification, 37.5% of them had itching, 32.5% of them had varicosity of 
veins, 25% of them had pain, 17.5%  of them had crust formation, 15% of them had 
erythema, 12.5% of them had oozing and swelling and 10% of them had ulceration . 
 In this study, Among 40 patients, 55% had the lesion in 2 lower limb, 40% had 
the lesion in 1 lower limb and 2.5% had 2 Lower limb with 2 Hand and 2 Lower limb 
with 1 Hand. 
 In Vatham, Samaanan, Viyaanan and Devathathan was found to be affected in 
all the 40 patients, Praanan and Abanan was affected in 7.5% of  patients. 
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In Pitham among 40 cases, Prasaka pitham was affected in all the cases. Ranjaka 
pitham was affected in 7.5% of patients. 
In Kabam, it was not affected in the cases. 
In Udar thaathukkal  among 40 patients, Saaram, Senneer, Oon and Kozhuppu 
were affected in all the cases. 
In Envagai thervukal, 
 1. Niram - Vaatham was in 47.5%, Pitham was in 32.5% and Kabam was     
        in 20%.  
 2. Mozhi - High pitched was in 10%, Medium pitched was in 50% and  
        Low pitched was in 40%  
 3. Sparisam - Veppam was in 37.5% and Mithaveppam was in 62.5% 
 4. Malam - Only 7.5% was affected. 
 5. Naadi - The Naadinadai seen in Karappan patients treated with trial   
        drug were Vathapitham in 60%, Pithakabam in 35%, Pithavatham 5%. 
 In Neikkuri, Pithaneer was found in 42.5% patients and Kabaneer was found in 
57.5% patients. 
STATISTICAL ANALYSIS 
TREATMENT WITH THE TRIAL DRUG 
  The assessment was done using EASI Score in all the 40 patients participated in 
the trial. The mean value of EASI score for all the 40 patients before treatment is 4.21 
and after treatment is 2.39. The p-value is less than 0.0001 which is highly significant. 
The reduction in the Mean was 43%. 
 STATISTICAL ANALYSIS 
 LEECH THERAPY ALONG WITH THE TRIAL DRUG 
The mean value of EASI score for patients with Leech therapy is 4.8 and after 
treatment is 2.52.The p-value is less than 0.0001 which is highly significant. The 
reduction in the Mean was 47.5%. 
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TRIAL DRUG WITHOUT LEECH THERAPY 
The mean value of EASI score for patients without Leech therapy is 3.62 and 
after treatment is 2.26.The p-value is less than 0.0001 which is highly significant.  The 
reduction in the Mean was 37.5%. Hence this study reveals Leech therapy along with 
trial medicines is to be effective in reducing the symptoms of Karappan. 
Outcome Assessment through EASI Score, Out of 40 cases, 30% of them had 
25% of reduction in the score after treatment, 27.5% of them had 50% of reduction in the 
score after treatment, 25% of them had 75% of reduction in the score after treatment, 
10% of them had no reduction in the score, which indicates the good improvement after 
treatment and 7.5% of them had increased in the score after treatment which indicates the 
eczema severity increased after treatment.   
Laboratory investigations of blood and urine were done for all 40 cases. There 
were significant changes in blood haemoglobin and ESR parameters before and after 
treatment. In Leech therapy patients, there is a significant decrease in blood haemoglobin 
after the treatment since it is a bloodletting technique.           
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SUMMARY 
The disease Karappan was taken for the clinical study with Nilavaagai 
chooranam internal medicine and Thengaai thylam for external application after 
scrutinized by the Screening committee of National Institute of Siddha.   
The Clinical study was carried out after obtaining proper permission from IEC 
no. ” NIS/13-IEC/2017-1-09” of National Institute of Siddha and the trial was registered 
in Clinical trial registry of India, CTRI no. CTRI/2018/05/013794. The medicines were 
prepared after obtaining proper authentication.  
40 patients were treated in Ayothidoss Pandithar Hospital of National Institute of 
Siddha. The patients with Karappan were enrolled based on Inclusion and Exclusion 
criteria and detailed study was done. Separate proforma was maintained for each patient 
along with daily progress chart for monitor the prognosis.            
Among the 40 patients 20 patients were advised Leech therapy along with the 
trial medicines and the remaining others received only the trial medicines. The patients 
who received Leech therapy along with their medications responded well since the 
Leech therapy is mainly aimed to reduce the symptoms of Karappan which plays a vital 
role in better prognosis and reduces the relapse of this disease. 
Outcome Assessment through EASI Score, Out of 40 cases, 30% of them had 
25% of reduction in the score after treatment, 27.5% of them had 50% of reduction  in 
the score after treatment, 25% of them had 75% of reduction in the score after treatment, 
10% of them had no reduction in the score,  which indicates the good improvement after 
treatment and 7.5% of them had increased in the score after treatment which indicates the 
eczema severity increased after treatment. The results shows the good improvement of 
patients after treatment and thus proves the efficacy of the medicine and Leech therapy. 
The patient doesn‟t complain of any adverse effects or difficulties during the 
course of treatment. Thus the drug is found to be safe and effective in the management of 
Karappan with and without Leech therapy.  
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CONCLUSION 
             The clinical trial proves the efficacy of the trial drugs by reducing the clinical 
signs and symptoms like Itching, Oozing and hyperpigmentation, etc and provides better 
cure. Out of 40 cases, 30% of them had 25% of reduction in the score after treatment, 
27.5% of them had 50% of reduction in the score after treatment, 25% of them had 75% 
of reduction in the score after treatment, 10% of them had no reduction in the score, 
which indicates the good improvement after treatment and 7.5% of them had increased in 
the score after treatment which indicates the eczema severity increased after treatment. 
Thus these results revealed good relief from the disease  after treatment. 
 The trial medicines were prepared from easily available ingredients and the 
palatability of medicine is better and the dosage is also convenient. 
Leech therapy along with trial drug shows good results in patients. When these 
affected individuals get a better management with this trial drug and Leech therapy, it 
would be a great benefit for the society. 
In the present study there was no adverse effect were reported in clinical trial. 
The Clinical trial conducted in selected patients was satisfactory and encouraging. 
Further studies may be taken up to establish the efficacy of the drug and Leech therapy. 
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DRUG REVIEW 
1) epythif: 
 jhtutpay; ngah; :  Cassia senna 
 Family   : Caesalpiniaceae 
 gad;gLk; cWg;G :  ,iy 
 Rit   :  ifg;G (ntFl;ly;) 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 ePh;kyk;Nghf;fp 
 kykpsf;fp 
Fzk;: 
 “epyhthiu apd;Fze;jhd; ePNfs; kapNy! 
 gy%y thAntg;G ghitr;- rpyfpue;jp 
 nghy;yhj Fd;kk; nghUKkyf; fl;LKjy; 
 vy;yh kfw;Wnkd vz;" 
 ,jdhy; %ythA> ntg;G> fpue;jp> Fd;kk;> ehl;gl;l kyr;rpf;fy; ,itfs; 
ePq;Fk;. 
Chemical constituents: 
 Sennosides A & B, Glucoside, Kampferin, Anthraquinone, essential oil, 
Chrysophanic acid, Iso - rhamnetin, Calcium oxalate 12% in leaves. Oxy - methyl - 
anthraquinones, flavanols, Rhein, Emodin, Aloe - emodin, Sennidin - 8.8 - diglucoside, 
Dianthrone diglucoside. 
Uses: 
          Laxative and purgative, used in constipation, loss of appetite, hepatomegaly, 
splenomegaly, indigestion, malaria, skin diseases, jaundice and anaemia. 
 Externally powdered leaves mixed with vinegar and made intoa plaster are 
applied locally in certain skin diseases.  
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2) kpsF: 
 jhtutpay; ngah; :  Piper nigrum 
 Family   :  Piperaceae 
 gad;gLk; cWg;G :  tpij> nfhb 
 Rit   :  ifg;G> fhh;g;G 
 jd;ik  : ntg;gk; 
 gphpT   : fhh;g;G 
nra;if: 
 fhwYz;lhf;fp 
 mfl;Lthafw;wp 
 Kiwntg;gfw;wp 
 jbg;Gz;lhf;fp 
 ntg;gKz;lhf;fp 
 tPf;fq;fiur;rp 
 thjklf;fp 
 er;rhp 
Fzk;: 
 “ rPjRuk; ghz;L rpNyj;kq; fpuhzpFd;kk; 
 thjk; mUrpgpj;jk; kh%yk;- XJrd;dp 
 ahrkg]; khuk; mld;Nkfk; fhrkpit 
 ehrq; fwpkpsfpdhy; “ 
 “ NfhZfpd;w gf;ftyp Fa;aTNuh fk;thj 
 Nrhzpjq;f Oj;jpw;Fs; Njhd;WNeha;- fhzhpa 
 fhJNeha; khjh;Fd;kq; fhkhiy ke;jnkd;wPh; 
 VJNeha; fhapUf;fpy; <q;F." 
 ,jdhy;> Fsph;Ruk;> ghz;L> Nfhio> fopr;ry;> Fd;kk;> thA> Ritapd;ik> 
ntwp> %yk;> rd;dpahrk;> mg];khuk;> gpuNkfk;> ,Uky;> gf;fthjk;> Fa;aNuhfk;> 
Nrhzpjthjk;> nrtptyp> ,uj;jFd;kk;> nrhpahik> fhkhiy ,it NghFk;. 
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Chemical constituents: 
 Sabinene (15 - 25%), Limonene (5 - 20%), Caryophyllene (10 - 15%), β - pinene 
(10 - 12%), α - pinene (8 - 12%), acid amides. Pungent substances - Chavicine, Piperine, 
Pipirine, Piperidine.  
Uses:  
 The berries well known for their stomachic, anodyne and antibacterial properties 
are prescribed for treating dyspepsia, vomiting, diarrhoea and colic resulting from cold. 
They can also be used as an insecticide against clothes moths. 
 It is acrid, pungent, hot, and carminative also used as antiperiodic. Externally it is 
rubefacient and stimulant to the skin and resolvent. On the mucous membrane of the 
urethra it acts like cubes; Piperine is a mild antipyretic and antiperiodic. 
Antiasthmatic activity: 
  Most of the herbal practioners and old people believed that addition of powdered 
peppercorn to green tea reduced asthma. Kim et al. reported that oral administration of 
piperine in different proportion to mice suppressed and reduced the infiltration of 
eosinophil, hyper responsiveness and inflammation due the suppression of the production 
of histamine, interleukin- 5, immunoglobulin E and interleukin-4.  
Anti-inﬂammatory activity: 
   The in vitro anti-inﬂammatory activities were evaluated on interleukin 1β 
stimulated fibroblast like synoviocytes obtained from rheumatoid arthritis, while anti-
arthritic including analgesic activities was evaluated on carrageen an induced acute paw 
model of pain and arthritis in rats. Te prostaglandin E2, cyclooxygenase 2, interleukin 6 
and matrix metalloproteinase levels were evaluated by ELISA and RTPCR methods of 
analysis. Piperine treated groups were found to reduce the synthesis of prostaglandin 
E2in a dose dependant comportment at the concentrations of 10-100 μg/mL. It 
significantly inhibited the synthesis of prostaglandin E2 even at 10 μg/mL.Te expression 
of interleukin 6 and matrix metallo-proteinase 13 were also inhibited. 
Immuno-modulatory activity: 
   In vitro immunomodulatory activity of piperine was evaluated to enhance the 
efficacy of rifampicin in a murine model of Mycobacterium tuberculosis infection. 
Mouse splenocytes were used to evaluate in-vitro immunomodulation of piperine for 
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cytokine production, macrophage activation and lymphocyte proliferation. Piperine 
treated mouse splenocytes demonstrated an increase in the secretion of T-1 cytokines 
(IFN-γ and IL-2), increased macrophage activation and proliferation of T and B cell. 
Protective efficacy of piperine and rifampicin (1 mg/kg) combination against 
Mycobacterium tuberculosis was reported due to immunomodulatory activity. 
3) fLf;fha;: 
 jhtutpay; ngah; :  Terminalia chebula 
 Family   :  Combretaceae 
 gad;gLk; cWg;G : gpQ;R> gok; 
 Rit   : Kf;fpa Rit Jth;g;G> mj;Jld; rpwpJ ,dpg;G>  
     Gspg;G> fhh;g;G> ifg;G 
 jd;ik  : ntg;gk; 
 gphpT   :  ,dpg;G 
nra;if: 
 grpj;jPj;Jhz;b 
 cly; cukhf;fp 
Fzk;: 
 “ jhil fOj;jf;fp jhY Fwpaptplg; 
 gPil rpypgjKw; NgjpKlk;- Milnal;lhj; 
 Jhykpb Gz;thj Nrhzpfh khiyapuz; 
 lhykpb Nghk;thpf;fh ahy;.” 
 ,J grpj;jPiaj; Jhz;br; nrhpg;gpf;f nra;J> clw;fl;LfSf;F td;ik 
je;J> KJik tunthl;lhkw; nra;Ak;. md;wpAk; tho;ehs; ngUf;ifAk;> 
mwpitAk;> Mw;wiyAk; jUk;. Mjyhy; ,/njhU fhafw;gg; nghUshff; 
nfhs;sg;gLfpwJ. FlypYs;s ,aw;ifr; rf;jpiaj; Jhz;b kyj;ij 
ntspg;gLj;Jjy;> fpoj;jd;ikiaj; jLj;jy; Mfpadthk;. ,/jd;wpAk; fd;dk;> 
fOj;J> eh> Mz;Fwp ,t;tplq;fspd; Neha;fs;> fhybg;Gw;WNeha;> mjpJhyk;> 
,bg;Gz;> thj Nrhzpjthjk;> fhkhiy> jhtu> rq;fktplq;fs; ,it Nghk;. 
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Chemical constituents: 
 Tannin, 20 - 40% Gallic acid, 30% Chebulinic acid, Palmitic acid, Stearic acid, 
Oleic acid, Linoleic acid, Arachidic acid, Behenic acid. Purgative principle - 
Anthraquinone, Sennoside. 
Uses: 
 The fruits are astringent, sweet, acrid, bitter, sour, thermogenic, anodyne, anti-
inflammatory, vulnerary, alterant, stomachic, laxative, purgative, carminative, digestive, 
anthelmintic, cardiotonic, aphrodisiac, antiseptic, diuretic, febrifuge, depurative and 
tonic. They are useful in vitiated condition of tridosa, wounds ulcers, inflammations, 
gastropathy, anorexia, helminthiasis, flatulence, haemorrhoids, jaundice, hepatopathy, 
spleenopathy, pharyngodynia, hiccough, cough, uropathy, versical and renal calculi, 
cephalalgia, epilepsy, opthalmopathy, skin diseases, leprosy, intermittent fever, cardiac 
disorders, stomatitis, neuropathy and general debility. 
 Myrobalans are a safe and effective purgative, astringent and alterative.Unripe 
fruits are more purgative and the ripe are astringent. Ripe fruit is considered as purgative 
removing bile and phlegm and to adjust bile. 
Immuno-modulatory activity: 
   Aqueous extract of T. chebula produced an increase in humoral antibody titre 
and delayed type hypersensitivity in mice. T. chebula found effective against the 
progression of advanced glycation end products-induced endothelia cell dysfunction. 
Crude extract of T. chebula stimulated cell mediated immune response in experimental 
amoebic liver abscess in golden hamsters. The formulation showed highest cure rate of 
73% at 800 mg/kg body weight in hepatic amoebiasis. In immune-modulation studies, 
humoral immunity was improved where Tcell counts remained unaffected in the animals, 
but cell-mediated immune response was stimulated.  
Anti-inflammatory activity: 
   Aqueous extract of dried fruit of T. chebula showed anti-inflammatory activity 
by inhibiting inducible nitric oxide synthesis. Chebulagic acid extracted from tender fruit 
of T. Chebula significantly suppressed the onset and progression of collageninduced 
arthritis in mice. T. chebula in a polyherbal formulation (Aller-7) exhibited anti-
inflammatory effect against arthritis in rats. 
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Immunomodulatory activity: 
   Ethanolic extracts- Study confirms the immunomodulatory activity of ripe T. 
Chebula fruits as evidenced By increase in the concentration of antioxidant enzymes, 
GSH, T and B cells, the proliferation of which play important roles in immunity. This 
phenomenon also enhances the concentration of melatonin in Pineal gland as well as the 
levels of cytokines. Gallic acid and chebulagic acid were isolated from the extract of a 
herbal medicine, kasha (myrobalans: the fruit of Terminalia chebula) as active principles 
that blocked the cytotoxic t lymphocyte (ctl)-mediated cytotoxicity. 
Anti-allergic activity: 
   T. chebula, ingredient of a polyherbal formulation (Aller-7), showed potent in 
vitro antiallergic activity. Hydro-ethanol extract of T. chebula exhibit anti-histamine and 
anti-spasmodic in guinea pig ileum. Oral administration of an aqueous extract of fruit 
significantly suppressed histamine release from rat peritoneal mast cells 117 and also 
significantly increased production of tumour necrosis factor (TNF) by anti-dinitrophenyl 
IgE. 
4) jhd;wpf;fha;: 
 jhtutpay; ngah; :  Terminalia bellerica 
 Family   :  Combretaceae 
 gad;gLk; cWg;G :  ,iy> gok;> tpij 
 Rit   :  Jth;g;G 
 jd;ik  :  ntg;gk; 
 gphpT   : ,dpg;G 
nra;if: 
 Jth;g;gp 
 Nfhioafw;wp 
 kykpsf;fp 
 cukhf;fp 
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Fzk;: 
 “ rpye;jptplk; fhkpag;Gz; rPohd Nkfq; 
 fye;JtUk; thjgpj;jq; fhNyh- lyh;e;Jlypy; 
 Cd;wpf;fha; ntg;g Kjpugpj; Jq;fuf;Fe; 
 jhd;wpf;fha; ifapnyLj; jhy;. 
 Mzpg;nghd; Nkdpf; foFk; xspAkpFk; 
 Nfhzpf;nfhs; thjgpj;jf;nfhs;ifNghk;- jhdpf;fha; 
 nfhz;lth;f;F NkfkWk; $wh mdw;wzpAk; 
 fz;lth;f;F thjk;Nghk; fhz;."  
 ,jdhy;> rpye;jpeQ;R> Mz;Fwpg;Gz;> nts;is> FUjpaoy;Neha;> tsp jP 
Fw;wq;fshy; tUk; Neha;fs; Nghk;. NkYk; ,J> clw;F moifAk; xspiaAk; 
nfhLj;J Kf;Fw;wq;fisAk; jd;dpiyg;gLj;Jk;. 
Chemical constituents: 
 Gallo tannic acid, resins, Triterpines, sterols, Phenolics. 17% tannin, β - 
sitosterol, Gallic acid, Ellagic acid, Ethyl galate, Galloyl glucose, Chebulagic acid, 
Bellericanin - cardiac glycoside. 
Uses: 
 The bark is mildly diuretic and useful in anaemia and leucoderma. The fruits are 
astringent, acrid, sweet, thermogenic, anti-inflammatory, anodyne, styptic, narcotic, 
digestive, anthelmintic, aperient, expectorant, ophthalmic, antipyretic, antiemetic and 
rejuvenating. They are useful in vitiated conditions of kapha and vata, cough, bronchitis, 
pharyngitis, insomnia, dropsy, dyspepsia, flatulence, dipsia, vomiting, haemorrhages, 
ophthalmopathy, strangury, splenomegaly, cephalalgia, skin diseases, leprosy, fevers, 
ulcers and general debility. The mature and dry fruit is constipating and is useful in 
diarrhoea and dysentery. The oil obtained from the seeds are useful in dyspepsia, skin 
diseases, leucoderma and greyness of hair. 
 Astringent, tonic, expectorant and laxative. 
Immune response in vitro: 
   In vitro Phagocytic activity and lymphocyte proliferation assay were carried out 
in methanolic extract of on the mouse immune system (Aurasorn Saraphanchoti witthaya 
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et al., 2008). In both assay, stimulation of macrophage phagocytosis and maximal 
activation of phytohemagglutinin were observed. Finally, the authors concluded that the 
methanolic extract of T. belerica affected the mouse immune system, specifically both 
the cellular and humoral immune response in vitro. 
5) rPufk;: 
 jhtutpay; ngah; :  Cuminum cyminum  
 Family   :  Apiaceae 
 gad;gLk; cWg;G :  tpij 
 Rit   :  fhh;g;G> ,dpg;G 
 jd;ik  :  jl;gk; 
 gphpT   :  ,dpg;G 
nra;if: 
 mfl;Lthafw;wp 
 ntg;gKz;lhf;fp 
 grpj;jPj;Jhz;b 
 Jth;g;gp 
Fzk;: 
 “ gpj;jnkD ke;jphpiag; gpd;dg; gLj;jpatd; 
 rj;JUit Ae;Jwe;J rhjpj;J- kj;jndDk; 
 uhridA kPntd;W ez;igg; gyg;gLj;jp 
 NghrdF lhhpnrAk; Nghh;” 
 ,jdhy;> moy; Nghk;. tapw;Wtyp> tha;Neha;> <uy;Neha;> fhrk;> fy;yilg;G> 
FUjpf;fopr;ry;> ,iug;G> Fuw;fk;ky;> %f;FePh; gha;jy;> ntwp> tspNeha;fs; 
tpyFk;. ,/J clYf;F tYitj; je;J> fz;Zf;Ff; Fsph;r;rpiaAk; 
cz;Lgz;Zk;. 
Chemical constituents: 
 Cuminol (or) Cuminaldehyde, Cymol (or) Cymene, Thymene, Carvone, Thymol, 
resin, mucilage, malates. 
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Uses: 
 Seeds are carminative, aromatic, stomachic, stimulant and astringent. Seeds are 
cooling in effect. 
 Immunomodulatory: 
   The oral treatment of cumin stimulated the T cells (CD4 and CD8) T1 
cytokines‟ expression in normal and cyclosporine-An induced immune suppressed 
animal. Cumin also depleted T lymphocytes, decreased the elevated corticosterone levels 
and size of adrenal glands and increased the weight of thymus and spleen in stress 
induced immune suppressed mice.  
Immunological effect: 
   The health modulating effects and immunomodulatory properties of Cuminum 
cyminum were evaluated using flowcytometry and ELISA in normal and immune-
suppressed animals. Cuminum cyminum stimulated the T cells and Th1 cytokines 
expression in normal animals. Swiss albino mice subjected to Cyclosporine-A induced 
immunesuppression were dosed orally with Cuminum cyminum (25, 50, 100 and 200 
mg/kg) on consecutive days. The results showed that administration significantly 
increased T cells (CD4 and CD8) count and Th1 predominant immune response in a dose 
dependent manner, suggesting immunomodulatory activity through modulation of T 
lymphocytes expression. In restraint stress induced immunesuppressed animals, 
Cuminum cyminum countered the depleted T lymphocytes, decreased the elevated 
corticosterone levels and size of adrenal glands and increased the weight of thymus and 
spleen. 
6) thYSit: 
 jhtutpay; ngah; :  Celastrus paniculatus 
 Family   :  Celastraceae 
 gad;gLk; cWg;G :  ,iy> tpij> nea; 
 Rit   :  ifg;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
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nra;if: 
 fhkk;ngUf;fp 
 ntg;gKz;lhf;fp 
 clw;Nww;wp 
 tpah;itg;ngUf;fp 
 ehbAukhf;fp 
Fzk;: 
 “ tapw;Wf; fLg;Gtyp khwhf; fpuhzp 
 gapj;jpaq; fhrky ge;jQ;- rapf;fnthzhr; 
 #jpfh thjKk; Nghe; njhy;th YSittpijf; 
 fhjpet rpj;jh; nkhop ahk;" 
 ,J tapw;Wf; fLg;G> fLg;Gld; $ba FUjpf; fopr;ry;> ,Uky;> mdy;> 
Crpapy; Fj;JtJNghy cz;lhFk; iffhy; ePj;jy; Nghk;. tapw;iw typf;Fk;. 
Chemical constituents: 
 Active principle - Celastrine, Paniculatin, tannin. Sesquiterpene alkaloids, 
Celapagine, Celapanigine, Celapanine, hydrolysis gave Polyalcohol A, C & D. 
Uses:  
 The bark is abortifacient, depurative and a brain tonic. The leaves are 
emmengogue and the leaf sap is a good antidote for opium poisoning. The seeds are 
acrid, bitter, thermogenic, emollient, stimulant, intellect promoting, digestive, laxative, 
emetic, expectorant, appetiser, aphrodisiac, cardiotonic, anti-inflammatory, diuretic, 
emmenagogue, diaphoretic, febrifuge and tonic, and are  useful in vitiated conditions of 
vatam and kapham, abdominal disorders, leprosy, pruritis,skin diseases, paralysis, 
cephalalgia, arthralgia, asthma, leucoderma, cardiac debility, inflammation, strangury, 
nephropathy, amenorrhoea, dysmenorrhoea and fever and for stimulating the intellect 
and sharpening the memory. The seed oil is bitter, thermogenic    and intellect promoting 
and is useful in abdominal disorders, beri-beri and sores. 
 Oil is rubefacient; seeds are alterative, stimulant and nervine; seeds and oil 
stimulate intellect and sharpen memory.  
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Analgesic and Anti-inflammatory: 
   A methanolic extract of the flowers of C. paniculatus exhibits analgesic and 
antiinflammatory activities in the hot water tail immersion test in mice and carrageenan 
induced pedal edema in rats.  
7) rpWehfg;G+: 
 jhtutpay; ngah; :  Mesua ferrea 
 Family   :  Clusiaceae 
 gad;gLk; cWg;G :  ,iy> nkhf;F> G+> tpij> Nth;> gl;il 
 Rit   :  rpWifg;G> Jth;g;G 
 jd;ik  :  jl;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 Jth;g;gp 
 mfl;Lthafw;wp 
 kz%l;b 
 fhwYz;lhfp 
 ePh;kyk;Nghf;fp 
 tpah;itg;ngUf;fp 
Fzk;: 
 “ rpWehfg; G+tpdJ nra;ifjidr; nrhy;Nthk; 
 FwpahFk; Nkfj;ijf; nfhy;Yk;- newptpl;Lj; 
 jPjha;r; nry;thAitAe; jPh;f;FkpU kw;Nghf;Fk; 
 Nfhjha;! ,ijawpe;J nfhs;." 
 ,J nts;is> ,Uky;> fopr;ry; Nghf;Fk;. NkYk;> ePuilg;G> FUjpg; 
Nghf;F> Gz;> nfhg;Gsk;> fhnyhpr;ry; Mfpait Nghf;Fk;. 
Chemical constituents: 
 Oleo - resin, tannin, Palmitic acid, Stearic acid, Oleic acid and Linoleic acid, 
Palmitostearo - olein, Dipalmito - olein, Distearo - olein, Stearo diolein, Palmito - 
diolein, Linoleodiolein, Triolein. 
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Uses: 
 The flowers are astringent, bitter, acrid, mildly heating, anodyne, sudorific, 
digestive, carminative, constipating, anthelmintic, diuretic, alexipharmic, expectorant, 
stomachic, haemostatic, aphrodisiac, febrifuge and cardiotonic. They are useful in 
vitiated conditions of pitham and vatam, asthma, cough,hiccough, halitosis, leprosy, 
scabies,dermatopathy, pruritis, pharyngodynia, vomiting, dysentery, haemorrhoids, 
ulcers, burning sensation of the feet, dipsia, impotency, leucorrhoea, haemoptysis, 
strangury, cephalagia, fever and cardiac debility. The seed oil is used in vitiated 
conditions of vata and skin diseases. 
 Dried blossoms, root and bark are bitter, aromatic and sudorific, bark is mildly 
astringent, unripe fruits are aromatic, acrid and purgative. Oleo resin exuding from the 
bark, root etc. is aromatic and demulcent. Pericarp of the fruit is astringent. „Blossoms 
are astringent and stomachic‟. Dried flowers are astringent and stomachic; also stimulant 
and carminative. 
 Immunomodulatory activity: 
   M. ferrae ﬂower buds in a poly herbal formulation; ACII was studied for 
immune modulation effect on radiation induced immune suppression. It is observed high 
increase in circulating antibody especially in animals treated with ACC II further there is 
no change in the weight of body. WBC count increased. Whereas no change in 
hemoglobin was seen in normal or drug treated animals. There is also no change in 
lymphocyte, neutrophil ratio. Bone marrow get improved along with this improvement is 
seen in α-esterase cells too, thymus weight increases. Although ACII effect is seen in 
normal and cyclophosphamide treated animals. By using various specific and nonspecific 
immune response in animals for seeing Immuno modulatory activity of M.ferrae seed oil 
was studied by isolating mesuol from M.ferrae seed. It is observed that in humoral 
response model. Mesuol cause increase in dose dependent in antibody (9th and 6th day) 
as well as induced. Immuno suppression which is seen in sheep RBC (7th and 14th day) 
of experiment. Where as in cellular immune response model, an increase in Paw volume 
was observed on 23rd day in rat treated with SRBC (Sheep RBC). Further mesuol help in 
restoring hematological property in cyclophosphamide induced myelosuppression model. 
So after discussing all this report indicate clearly the modulatory activity of mesuol. 
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Anti-inﬂammatory activity: 
   Using albino rats Mesuaxanthone A and Mesuaxanthone B (MXA and MXB) 
from M. Ferrae were observed by carrageenan induced hind Paw oedema and granuloma 
pouch tests. MXA shows 37% MAB showed 49% reduction when compound with 
normal group. But it is known than xanthones show signifcant anti-inﬂammatory 
property in normal and adrenalectomised rats. So xanthones used here for its important 
inﬂammatory activity. 
8) Vyk;: 
 jhtutpay; ngah; :  Elettaria cardamomum 
 Family   : Zingiberaceae 
 gad;gLk; cWg;G :  gok; 
 Rit   :  fhh;g;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 ntg;gKz;lhf;fp 
 mfl;Lthafw;wp 
 grpj;jPj;Jhz;b 
Fzk;: 
 “ njhz;il tha;fTs; jhYF jq;fspy; 
  Njhd;Wk; Nehajp rhuk;gd; Nkfj;jhy; 
 cz;il Nghy;vOq; fl;b fphpr;ruk; 
  coiy the;jp rpye;jp tp\Q;Ruk; 
 gz;il ntf;if tpjhfNeha; fhrKk; 
  ghOQ; Nrhkg; gpzptpe;J el;lKk; 
 mz;il aPistd; gpj;jk; ,itf;nfy;yhk; 
  My khq;fko; Vy kUe;jNj…" 
 ,J> njhz;il> jhs;> tha;> fPo;tha; ,itfspy; cz;lhFk; Neha;fisAk;> 
,Uky;> fopr;ry;> ePh;r;RUf;F> neQ;rpd; Nfhiof;fl;L> rpye;jp eQ;R ,tw;iwAk; 
Nghf;Fk;. moiy Mw;Wk;. ntz;zPiug; (tpe;J) ngUf;Fk;. 
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Chemical constituents: 
 Terpinyl acetate, Cineole, free terpineol, Limonene, starch, potassium salts, 
nitrogenous mucilage, yellow colouring matter ligneous fibre and ash containing 
manganese. 
Uses: 
 The seeds are aromatic, acrid, sweet, cooling, stimulant, carminative, digestive, 
stomachic, diuretic, cardiotonic, abortifacient, alexeteric, expectorant and tonic and are 
useful in asthma, bronchitis, haemorrhoids, strangury renal and vesical calculi, halitosis, 
cardiac disorders, anorexia, dyspepsia, gastropathy, hyperdipsia, burning sensation, 
debility and vitiated conditions of vatam.  
 Powerful aromatic, stimulant, carminative, stomachic and diuretic. These 
properties are due to the essential oil contained in the seeds. 
9) ,ytq;fg;gl;il: 
 jhtutpay; ngah; :  Cinnamomum verum 
 Family   :  Lauraceae 
 gad;gLk; cWg;G :  gl;il 
 Rit   :  fhuKk; ,dpg;GKilaJ 
 jd;ik  :  jl;gk; 
 gphpT   :  ,dpg;G 
nra;if: 
 ntg;gKz;lhf;fp 
 mfl;Lthafw;wp 
 fhkk;ngUf;fp 
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Fzk;: 
 “ jhJel;lk; Ngjp rUttp\k; MfpaNeha; 
 G+jfpu fQ;rpye;jpg; G+r;rptplQ;- rhjptplk; 
 Ml;Lkpiug; NghbUky; MfpaNeha;f; $l;lkw 
 Xl;lkpy tq;fj; Jhp. 
 rd;dytq; fg;gl;il jhd;Fsph;r;rp Az;lhf;Fk; 
 ,d;Dkpuj; jf;fLg;ig aPh;f;Fq;fhz;- Kd;dKWk; 
 ce;jpf; fLg;gfw;Wk; cz;%yg; Gz;Nghf;Fk; 
 fe;jkpF G+q;FoNy! fhz;" 
 ,J ghk;Gf;fb> rpye;epg;G+r;rpf;fb Kjypaitfspd; eQ;irg; Nghf;Fk;. ,/J 
,iug;G> ,Uky;> tapw;Wf;fLg;G> cs;%yg;Gz; ,itfisg; Nghf;Fk;. clw;Ff; 
Fsph;r;rpia cz;Lgz;Zk;. 
Chemical constituents: 
 Eugenol, Cinnamaldehyde, Cinnamon oil, Trans - cinnamaldehyde, essential oil, 
Terpene. Root - Eugenol, Saffrol, Benzaldehyde and Terpene. 
Uses: 
 The bark is acrid, bitter, sweet, aromatic, astringent, aphrodisiac, deodorant, 
stimulant, alexeteric, expectorant, febriguge, diuretic and carminative.It is useful in 
bronchitis, asthma, cephalalgia, odontalgia, cardiac diseases, diarrhoea, uropathy, nausea 
and vomiting, flatulence, fever, halitosis and restoring normal skin colour on the face. 
Cinnamon oil is stomachic, carminative, emenagogue and styptic and is useful in 
anorexia, inflammations, stimachalgia vitiated conditions of vatam , odontalgia, vomiting 
and tubercular ulcers. 
 Astringent, stimulant and carminative.  
Anti-inflammatory activity:  
 In vitro various essential oils, including cinnamon bark oil, used in the treatment 
of rheumatism and inflammation as well as some of their main constituents and phenolic 
compounds known for their irritant and pungent properties were screened for activity as 
inhibitors of prostaglandin biosynthesis. A combination of a prostaglandinsynthesizing 
cyclo-oxygenase system from sheep seminal vesicles and an HPLC separation technique 
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for the metabolites of arachidonic acid was used as test system. Cinnamon bark oil 
showed inhibitory cyclo-oxygenase activity. The active compound is probably eugenol 
(Wagner et al., 1986).  
Anti-inflammatory activity: 
  In vivo Dry ethanolic extract of Cinnamomum zeylanicum administered orally to 
rats at 400 mg/kg body weight showed an anti-inflammatory effect against chronic 
inflammation induced by cotton pellet granuloma indicating an anti-proliferative effect 
(Atta & Alkofahi, 1998).  
Eugenol (Cinnamomum verum)  
Anti-inflammatory: 
   The study concluded beneficial effect of eugenol administrated at 5 and 10 
mg/kg per B.W. against lipopolysaccharide (LPS) induced acute lung injured (ALI) 
mice, for this purpose 0.5 mg/kg LPS was intratracheally infused. Examination of lung 
tissues and bronchoalveolar lavage fluid (BALF) suggested anti-inflammatory effect due 
to reduced production of pro-inflammatory cytokines. 
 Additionally, in vitro studies revealed that clove oil polyphenol inhibits nuclear 
factor-kB (NFkB) activation in lipopolysaccharides initiated macrophages induced by 
inactivated cyclooxygenase activity (COX-2) and tumor necrosis factor (TNFa). 
Cyclooxygenase activity is prompted by LPS, cytokines and growth factors. During 
pulmonary inflammation in mouse, elevated TNF-a and neutrophils were significantly 
reduced by eugenol at a dose of 160 mg /kg per body weight. It also protected against 
chemically induced dysfunction of macrophages and balanced the pro-inflammatory 
mediators. 
Immunomodulatory activity: 
   Mahapatra et al. investigated the in vitro protective effect of eugenol (1–20 
μg/mL) against nicotine-induced (10 mM nicotine) cellular damage in mice peritoneal 
macrophages by analysing the radical generation, lipid, protein, DNA damage and 
endogenous anti-oxidant status. The results indicated that eugenol could be used as 
modulator of nicotineinduced cellular damage and immunomodulatory drug against 
nicotine toxicity. 
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10) fLFNuhfpzp: 
 ngah;   :  Picrorhiza kurroa 
 Family   :  Scrophulariaceae 
 gad;gLk; cWg;G :  Nth; 
 Rit   :  ifg;G> fhh;g;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 Kiwntg;gfw;wp 
 ngUq;fopr;rYz;lhf;fp 
 grpj;jPj;Jhz;b 
 Flw;GOtfw;wp 
Fzk;: 
 “ khe;jQ; Ruikak; thAfug; ghdhkQ; 
 Nrh;e;jkyf; fl;L jphpNjhlk;- Nghe;jnghl;Lg; 
 Gz;tapW NehapitNghk; nghw;nfhbNa- NgjpAz;lhk; 
 jpz;fLF Nuhfzpf;Fj; Njh;." 
 khe;jk;> Ruk;> Iag; ngUf;F> fug;ghd;> rPjf; fopr;ry;> tapw;Wtyp> Gz;fs;> 
tsp Neha;fs; vd;Dk; ,itfs; Nghk;. 
Chemical constituents: 
 Phenylethanoid, Phenolic glycosides, Picrorhizin, glucose, wax, Cathartic acid, 
Kutkin, Kurrin, D - mannitol, Vanillic acid, Kutkiol, Kutkisterol. 
Uses: 
 The rhizomes are bitter, acrid, cooling, laxative, carminative, digestive, 
stomachic, anthelmintic, anti-inflammatory, depurative, cardiotonic, galactopurifier, 
expectorant, antipyretic and antiperiodic and purgative in large doses. They are useful in 
vitiated conditions of kapham and pittam, burning sensation, constipation, gastropathy, 
flatulence, colic, anorexia, verminosis, inflammations, leucoderma, leprosy, skin 
diseases, cardiac disorders, hypotension, cough, asthma, bronchitis, hiccough, fever, 
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bilious fever, intermittent fever, diabetes, jaundice, haemorrhoids, impurity of breast 
milk and general debility. 
 In small doses, it is a bitter stomachic and laxative, and in large doses, a cathartic. 
It is reputed as an antiperiodic and cholagogue.  
Anti-asthmatic activity: 
   P.kurroa has been studied extensively for its anti-asthmatic activity. The crude 
extract of P.kurroa roots reduced the frequency and severity of asthmatic attacks and the 
need for regular bronchodilators. The activity has been attributed to compounds such as 
androsin and apocynin, which have been shown to inhibit allergen and PAF- induced 
bronchoconstriction. Dorsch W et al (1991) reported the major anti asthmatic principle of 
Picrorhiza kurroa, was used as a lead compound for detailed structure- activity 
relationship. More than 25 synthesized or commercially available acetophenones with 
modified substitution patterns were screened in the Plethysmographic guinea pig model 
using PAF and/or ovalbumin as challenging agents for the generation of bronchial 
constriction. Whereas the aglycones in most cases were more effective than the 
corresponding glycosides, substitution patterns in position 3 and 4 of the phenyl ring and 
the keto function attached to the phenyl ring were found to be essential for marked anti 
asthmatic effect. 3,5-Dimethoxy-4-hydroxyacetophenone showed the highest activity of 
all tested compounds. Initial in vitro studies on the mode of action could not sufficiently 
explain the mechanism of antiasthmatic activity. Mahajani S.S. et al (1977) reported 4 
weeks pre-treatment with disodium cromoglycate (DSCG) and the powdered roots of the 
herb Picrorhiza kurroa, rendered guinea pigs less sensitive to histamine when compared 
with appropriate controls. The bronchodilator effects of isoprenaline and adrenaline were 
found to be markedly enhanced. The severity and duration of the allergic bronchospasm 
was significantly less in animals pretreated with the two drugs. Furthermore, the total 
histamine content of the lung tissue in animals pretreated with DSCG and Picrorhiza 
kurroa was significantly less than that in the untreated controls. The pretreatment was 
also found to exhibit inhibitory effect on the immunological release of histamine and 
SRS-A from chopped lungs. 
Immunomodulatory activity: 
   The effect of an ethanolic extract of each drug was studied on delayed type 
hypersensitivity, humoral responses to sheep red blood cells, skin allograft rejection, and 
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phagocytic activity of the reticuloendothelial system in mice. Picrorhiza kurroa was 
found to be a potent immunostimulant of both cell mediated and humoral activity. Amit 
Gupta et al (2006) evaluated the effects of biopolymeric fraction RLJ-NE-205 from 
Picrorhiza kurroa on the in vivo immune function of the mouse. Balb/c mice were treated 
with the biopolymeric fraction RLJ-NE205(12.5, 25 and 50 mg/kg body weight) for 14 
days with sheep red blood cells (SRBC) as an antigen Haemagglutination antibody (HA) 
titre, plaque forming cell (PFC) assay, delayed type hypersensitivity (DTH) reaction, 
phagocytic index, proliferation of lymphocytes, analysis of cytokines in serum and 
CD4/CD8 population in spleen (determined by flow cytometry) were studied. At the 
dose of 50mg/kg significant increases in the proliferation of lymphocytes and cytokine 
levels in serum were observed.  
Anti-inflammatory activity: 
   Apocynin is a constituent of root extracts of Picrorhiza and has been reported to 
possess antiinflammatory properties in laboratory animals. Apocynin concentration 
dependently inhibited the formation of thromboxane A2, whereas the release of 
prostaglandins E2 and F2α was stimulated. Apocynin inhibited arachidonicacid induced 
aggregation of bovine platelets, possibly through inhibition of thromboxane formation. 
The rhizome of Picrorhiza scrophulariiflora is used to treat inflammatory diseases as a 
traditional medication. The ethanol extract of Picrorhiza scrophulariiflora in rabbits 
improves accelerated atherosclerosis through inhibition of redox-sensitive inflammation. 
Anti- allergic and Anti- anaphylactic activity:  
  C.C.Baruah et al (1998) studied a standardized iridoid glycoside fraction from 
the root and rhizome of Picrorhiza kurroa at a dose of 25mg/kg inhibited passive 
cutaneous anaphylaxis in mice, rats and protected mast cells from degranulation in a 
concentration dependant manner. Its effect was also studied in sensitised guinea pig 
ileum preparation in vitro (Schultz-Dale study) and in normal guinea pig in vivo 
(Konzett- Rossler, in preparation). There was inhibition of the SchultzDale response in 
sensitised guinea pig ileum, but the bronchospasm induced by histamine could not be 
antagonised or prevented by Picroliv, indicating the absence of a direct post- synaptic 
histamine receptor blocking activity. 
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Immunostimulatory activity: 
   Sharma ML, Rao CS and Duda PL studied extract of Picrorhiza kurroa leaves 
(PKLE) was found to stimulate the cell mediated and humoral components of the 
immune system as well as phagocytosis in experimental animals. PKLE elicited a dose- 
related increase in SRBC, induced 4hr (early) and24hr (delayed) hypersensitivity 
reactions in mice and rats, andhorse serum induced Arthus reaction in guinea pigs. It also 
enhanced the humoral immune responses in mice and rats and phagocytic function of the 
cells of the reticuloendothelial system in mice. PKLE exhibited no mitogenic activity but 
augmented the responsiveness of murine splenocytes to T cells mitogens 
phytohaemagglutinin and concanavalin A and B cell mitogen lipopolysaccharide. 
11) rptij: 
 jhtutpay; ngah; :  Operculina turpethum 
 Family   :  Convolvulaceae 
 gad;gLk; cWg;G :  Nth; 
 Rit   :  ifg;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 ePh;kyk;Nghf;fp 
Fzk;: 
 “ cs;s kyKk; cjthh;j;j Kk;tapw;iwf; 
 nfhs;Sgpj;j thjKk;Nghq; $Wq;fhy;- gps;isfl;Fr; 
 nrg;G fpurKk;Nghe; NjNd! Ayfj;Js; 
 jg;gpy; rptijf;Fj; jhd;." 
 ,jdhy; cs;%yk;> tapw;Ws;Sz;lhFk; NfLfs;> jPtsp (gpj;jthj) 
Neha;fSk; rpWgps;isfSf;Fz;lhFk; rpy Neha;fSk; Nghk;. 
Chemical constituents: 
 Glucoside - Turpethin. Glycosidic resin, α - turpethein, β - turpethein. 
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Uses: 
 The roots are bitter, acrid, sweet, thermogenic, purgative, 
carminative,anthelmintic, expectorant, antipyretic, hepatic, stimulant, hydragogue. They 
are useful in colic, constipation, dropsy, vitiated conditions of vatam, paralysis, myalgia, 
arthralgia, pectoralgia, bronchitis, obesity, helminthiasis, gastropathy, ascitis, 
inflammations, intermittent fever, leucoderma, pruritis, ulcers, erysipelas, haemorrhoids, 
tumors, jaundice, consumpation and opthalmia. 
 Ipomoea turpethum Root root bark of „white turpeth‟ which are in common use 
are cathartic and laxative; the dark variety „black turpeth‟ is drastic in action like 
hellebore black and therefore it is not in use.  
Anti-inflammatory activity: 
   An experimental study was carried out (Rajashekar M et al; 2006) to evaluate 
the effect of oral administration of root powder of O. turpethum and its polyherbal 
formulation Avipattikarchurna on rat paw edema in albino rats. Results indicated that 
pretreatment with the root powder of O. turpethum and Avipattikara churna (100 mg/kg 
body weight) reduced the formalin induced edema volume to the extent of 36.45% and 
27.11% respectively. Antiinflammatory potential of different extracts (ethanolic, aqueous 
and ethereal) of O. turpethum has been reported in carrageenan-induced paw oedema, 
cotton pellet-induced granuloma and formalin induced arthritis animal model of rats. The 
aqueous extract was reported more potent fraction in all three animal models.In another 
study, pre-treatment of roots of Operculina turpethum and its polyherbal formulation 
Avipattikar Churna (100 mg/kg body weight) showed anti-inflammatory activity in rat 
paw oedema induced by formalin in experimental animal model. 
CLINICAL TRIALS  
 In an open, uncontrolled clinical study (Shailej Gupta; 2009), powder of O. 
turpethum roots administered as a single dose of 30 gm with fermented rice water 
(Kanji) for Virechana procedure produced strong purgation in 30 patients of Amavata i.e. 
Rheumatoid Arthritis. This purificatory procedure produced statistically significant 
improvement in the subjective parameters like joint pain, stiffness, swelling, tenderness, 
and in global assessment for overall improvement. Also there was a statistically 
significant reduction in the ESR values in the study patients. Many patients may not 
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tolerate one time dose of 30 Gms Trivrit powder. So it should not be recommended for 
each and every patient of rheumatoid arthritis. 
12) jhsprg;gj;jphp: 
 jhtutpay; ngah; :  Taxus baccata 
 Family   :  Pinaceae 
 gad;gLk; cWg;G :  ,iy 
 Rit   :  fhh;g;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 grpj;jPj;Jhz;b 
 mfl;Lthafw;wp 
 Nfhioafw;wp 
 cukhf;fp 
Fzk;: 
 “ ehrp fsg;gpzpfs; ehl;gl;l- fhrQ;R 
 thrk; mUrp tdkq;fhy;- tPrptU 
 Nkfke;jk; mj;jpRuk; tpl;NlFe; jhspr;rj;jhy; 
 MFQ; Rfg;gpur tk;." 
 ,ijf; fopr;ry;> Ruk;> ehl;gl;l ,Uky;> ,iug;G> the;jp> tha;T> mrPuzk;> 
mj;jpRuk; ,itfSf;F toq;fyhk;. ,jdhy;> Rfg;gpurtKz;lhFk;. 
Chemical constituents: 
 Crystalline alkaloid - Taxine, essential oil. 
Uses: 
 Leaves are carminative, stomachic, tonic, astringent, antispasmodic and 
expectorant. 
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13) [hjpf;fha;: 
 jhtutpay; ngah; :  Myristica fragrans 
 Family   :  Myristicaceae 
 gad;gLk; cWg;G :  fha; 
 Rit   :  Jth;g;G> fhh;g;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 ntg;gKz;lhf;fp 
 mfl;Lthafw;wp 
 %h;r;irAz;lhf;fp 
 kz%l;b 
 fhkk;ngUf;fp 
 cukhf;fp 
Fzk;: 
 “ jhJ el;lk; Ngjp rUthrp aQ;rpu Neha; 
 XJRth rq;fhrk; cl;fpuzp- NtNjh 
 byf;fha; tUk;gpzpNghk; Vw;wkay; gpj;jq; 
 Fyf;fh aUe;Jth;f;Ff; $W." 
 ,jdhy; tpe;J FiwT> ngUq;fopr;ry;> thAtpdhYz;lhFk; Neha;> 
jiytyp> ,iug;G (Rthrk;)> ,Uky; (fhrk;)> ehl;gl;l fopr;ry;> ntg;gj;ij 
Kd;dpl;L tUk; gpzpfs; ,itfs; NghFk;. Mdhy;> kaf;fj;ijj; jUk;. NkYk; 
,J> tapw;Wtyp> tapw;Wg;nghUky;> mf;fpdp ke;jk; ,itfisAk; Nghf;Fk;. 
Chemical constituents: 
 Myristicin, Myristic acid, Essential oil - Sabine, Pinene, Camphene, p - Cymene, 
Phellandrene, Terpinene, Limonene, Myrcene, Terpene derivates - Linalool, Geraniol, 
Terpinol,  Phenylpropanoids - Myristicin, Elemicin, Safrole. 
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Uses: 
 Nutmeg is aromatic, stimulant and carminative;in large doses, narcotic. Concrete 
oil is used as a rubefacient; volatile oil is stimulant, aperient and carminative. Mace is 
carminative and aphrodisiac. Wood is astringent. The content of an ethereal oil 6-10% in 
combination with myristicine gives the nutmeg a tonicising action on the stomach; its 
effect on the mucous membrane of the urinary passages is irritative, which may account 
for its use as an aphrodisiac and abortifacient (Dr.Kobert). In large doses, nutmeg oil has 
anarcotic action and produces nausea, somnolence and headaches (Dr.Marfori – 
Bachem). Drs.Paracelsus, Lonicerus and Matthiolus, used nutmegs with a constipating 
action; also as a diuretic against gastric catarrh and cardiac fibrillation.  
Anti-inflammatory activity: 
   The anti-inflammatory activity of Myristica fragrans was evaluated in 
carrageenan-induced edema in rats and acetic acid induced vascular permeability in 
mice. It was observed that the antiinflammatory effect was approximately the same as 
that of Indomethacin. The results propose that myristicin present in mace is responsible 
for antiinflammatory action.The antiinflammatory property of myristicin might be due to 
inhibition of chemokines, cytokines, nitrous oxide and growth factors in double stranded 
RNA (dsRNA) stimulated macrophages via the calcium pathway.The methanol extract 
from seeds of Myristica fragrans used for the treatment of inflammatory diseases also 
had inhibitory effects on nitric oxide (NO) production. 
14) fpuhk;G: 
 jhtutpay; ngah; :  Syzygium aromaticum 
 Family   :  Myrtaceae 
 gad;gLk; cWg;G :  G+ 
 Rit   :  fhuKk; tpWtpWg;GKs;sJ 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 ,rptfw;wp  
 mfl;Lthafw;wp  
 grpj;jPj;Jhz;b 
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Fzk;: 
 “ gpj;j kaf;fk; NgjpnahL the;jpAk;Nghk; 
 Rj;jtpuj; jf;fLg;Ge; Njhd;WNkh- nkj;j 
 ,ytq;fq; nfhz;ltUf; Nfw; RfkhFk; 
 kykq;Nf fl;Lnkd tho;j;J. 
 Rf;fpyel; lq;fh;z #h;atpaq;f yhQ;rde;jhl; 
 rpf;fy;tplhr; rh;th rpag;gpzpA- kf;fpf;Fl; 
 lq;fg; G+NthL jhpglUe; Njhd;wpypy; 
 tq;fg;G+ NthLiuj;J th." 
 ,J kaf;fk;> Ngjp> the;jp> FUjpf;fopr;ry;> ehl;gl;l fopr;ry;> 
vUtha;f;fLg;G> nrtpNeha;> rpte;jkr;rk;> fWj;jkr;rk;> fz;zpy; G+> gilfs; 
Mfpatw;iw ePf;Fk;. 
Chemical constituents: 
 Protein, Carbohydrates, Tannin, Oleanolic acid, Eugenol acetate, Caryophyllene, 
Eugenol. 
Uses: 
 The cloves are acrid, bitter, aromatic, refrigerant, ophthalmic, digestive, 
carminative, stomachic, stimulant, antispasmodic, antibacterial, rubefacient,aphrodisiac, 
appetiser, expectorant, emollient, anthelmintic, sialogogue, rejuvenating, galactopurifier, 
diuretic, febrifuge and tonic. They are useful in halitosis, odontalgia, opthalmopathy, 
flatulence, colic, gastropathy, anorexia, cough, asthma, vitiated comditions of kapham 
and pitham, burning sensation, skin diseases, helminthiasis, agalactia, impurity of breast 
milk, strangury, fever, cephalalgia, neuralgia, lumbago, nostalgia, dental caries, 
hyperacidity, vomiting, dipsia, hepatopathy, general debility and tuberculosis. The oil is 
useful in catarrh, cough, bronchitis, vitiated conditions of vata, gastrohelcosis, flatulence, 
colic, skin diseases, dyspepsia, vomiting, odontalgia, dental caries and cephalalgia. 
Externally the oil is used as a rubefacient and counterirritant. 
 Bark, leaves and seeds are astringent. Berry as a whole is astringent. Juice of the 
fruit is stomachic, astringent, diuretic and anti diabetic.  
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Antiallergic effects: 
   Kim et al (1998) investigated the effect of a hot water extract (DER app. 14:1) 
of clove on the immediate hypersensitivity in rats. The extract inhibited the compound 
48/80-induced systemic anaphylaxis in rats with an IC50 of 31.25 mg/kg when 
administered intraperitoneally. The extract also inhibited the local immunoglobulin E-
mediated passive cutaneous anaphylactic reaction (IC50 = 17.78 mg/kg, i.v., IC50 = 
19.81 mg/kg, p.o.). The extract also inhibited dose-dependently the induced histamine 
release from rat peritoneal mast cells. Clove essential oil increased the total white blood 
cell count and enhanced the delayed-type hypersensitivity response in mice. Moreover, it 
restored cellular and humoral immune responses in cyclophosphamide-
immunosuppressed mice in a dose-dependent manner. The immunostimulatory activity 
found in mice treated with clove essential oil is due to improvement in humoral and cell 
mediated immune response mechanisms (Carrasco et al 2009).  
 
15) jpg;gpyp: 
 jhtutpay; ngah; :  Piper longum 
 Family   :  Piperaceae 
 gad;gLk; cWg;G :  fha;> mhprp 
 Rit   :  fhh;g;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  ,dpg;G 
nra;if: 
 ntg;gKz;lhf;fp 
 mfl;Lthafw;wp 
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Fzk;: 
 “,Uky; Fd;kk; ,iug;G fag;gpzp 
  <is ghz;L re;ahrk; mNuhrfk; 
 nghUky; Cij rpug;gpzp %h;r;irNeha; 
  G+hpf; FQ;ry Njhlk; gPypfKk; 
 tUk yg;ngUf; NfhL kNfhjuk; 
  thjk; MjpKj; NjhlQ; Ruq;Fsph; 
 ngUkhiyg;Ghp Nkfg; gplfKk; 
  NgUe; jpg;gpypg; Nguq;Fiuf;fNt." 
 ,jdhy; ,Uky;> Fd;kk;> ,iug;G> Iag;gpzp> <is> ghz;L> kaf;fk;> 
Ritapd;ik> nghUky;> jiytyp> %h;r;ir> ePNuw;wk;> njhz;ilNeha;> %f;F- fhJ- 
fz; Neha;fs;> GONeha;fs;> fz; ,Lf;F Mfpait ePq;Fk;. ePw;wtpe;J ,WFk;. 
Chemical constituents: 
 Piperine, Piperlonguminine, Piplartine, resin, volatile oil, starch, gum, fatty oil, 
inorganic matter and alkaloid. 
Uses: 
 Roots and fruiting spikes are used in treating diarrhoea, indigestion, jaundice, 
urticarial, abdominal disorders, hoarseness of voice, asthma, hiccough, cough, piles, 
malarial fever, flatulence, vomiting, thirst, oedema, earache, wheezing, chest congestion, 
throat infections, worms, sinusitis. This considered as rejuvenating plant. 
 Infusion is stimulant, carminative and alterative, tonic more powerful than black 
pepper; also aphrodisiac, diuretic, vermifuge and emmenagogue. Externally rubefacient. 
Root is stimulant.  
Piperine (Piper nigrum, Piper longum)  
Antiasthmatic activity: 
   Kim et al., 2009 induced asthma in Balb/c mice by ovalbumin sensitization. 
Piperine (4.5 and 2.25 mg/kg) was orally administered 5 times a week for 8 weeks and it 
was found that piperine- treated groups had suppressed eosinophil infiltration, allergic 
airway inflammation and airway hyper responsiveness and these occurred by suppression 
of the production of interleukin-4, interleukin-5, immunoglobulin E and histamine. 
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16) nrt;tpak;: 
 jhtutpay; ngah; :  Root of Piper nigrum 
 Family   :  Piperaceae 
 gad;gLk; cWg;G :  Nth; 
 Rit   :  ifg;G> fhh;g;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 fhwYz;lhf;fp 
 mfl;Lthafw;wp 
 Kiwntg;gfw;wp 
 jbg;Gz;lhf;fp 
 ntg;gKz;lhf;fp 
 tPf;fq;fiur;rp 
 thjklf;fp 
 er;rhp 
Fzk;: 
 “ #iy mUfprd;dp njhy;ypUky; <isgpj;jk; 
 Nkiyf; Fuw;fk;ky; ntq;fsNeha;- %yRuk; 
 ft;tpaq;fj; NjW fdjh tutplKQ; 
 nrt;tpaq; nfhs;stpLe; Njh;." 
 ,jdhy; #iy> Ritapd;ik> Kg;gpzp> ehl;gl;l Ruk;> ePbj;j ,Uky;> 
<is> ntwp> Fuw;fk;ky;> njhz;ilNeha;> Ruk;> vYk;igg; gw;wp VWfpd;w eQ;R 
Mfpaitfs; Nghk;. 
Chemical constituents: 
 Sabinene (15 - 25%), Limonene (5 - 20%), Caryophyllene (10 - 15%), β - pinene 
(10 - 12%), α - pinene (8 - 12%), acid amides. Pungent substances - Chavicine, Piperine, 
Pipirine, Piperidine. 
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17) ,e;Jg;G: 
 Chemical name: Sodii chloridum impura or Sodium chloride impura 
 Other name: Rock salt 
nra;if: 
 kyfhhp  
 mfl;Lthafw;wp 
 rpWePh; ngUf;fp  
 grpj;jPj;Jhz;b  
Fzk;: 
 “ ml;lFd;k ke;jk; mrph;f;fuQ;#h; rPjgpj;je; 
 Jl;litak; ehbg;Gz; Nlhlq;fs;- nfl;lkyf; 
 fl;Ltpl tpe;ijaf; fhkpaNeha; td;fug;ghd; 
 tpl;Ltpl tpe;Jg;ig tps;." 
 “ nrd;dpf;fz;zh gw;Whh; nrtpfTs;fz; lk;gfNeha; 
 re;epah rq;fhre; jgfkpiug;- Gd;dpuj;j 
 %yQ; rpye;jpesp %bfeQ; #ij ty;yp 
 #yQ; rpijAkpe;jhw; nrhy;." 
 ,e;Jg;gpdhy; vz;tpj Fd;kk;> myrk;> fggpj;jk;> fghjpf;fk;> euk;Gf;fpue;ep> 
jphpNjh\k;> kyge;jk;> tp\k;> Rf;fpyk;> fg cgjk;gk;> fLtd; Mfpa Neha;fs;;;;: 
jiy> tpop> eh> je;j%yk;> jhJ> fd;dk;> fz;lk;> Nahdp ,t;tplj;J Neha;fs; 
re;epahark;> Nej;jpufhrk;> jhfk;> Rthrk;> ,uj;j %yk; Kjypa gpzpfs;> rpye;jp> 
Njs;> vyp ,tw;wpd; tp\q;fs;. thjf; fLg;G> #iy Kjypad ePq;Fk;. 
Chemical constituents: 
 Small proportion of iodine. 
Uses: 
 In small doses it is highly carminative, stomachic and digestive. It promotes the 
appetite and assists digestion and assimilation. In large doses it is cathartic; in still larger 
doses it is emetic. Rock salt possesses stronger purgative properties than cream of tartar, 
but like this it is not a satisfactory cathartic given alone.It is given in dyspepsia and other 
abdominal disorders. 
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18) $ifePW: 
 jhtutpay; ngah; :  Maranta arundinaceae 
 Family   :  Marantaceae 
 gad;gLk; cWg;G :  fpoq;F- ,jpypUe;J kh vLf;fpwhh;fs; 
 Rit   :  ,dpg;G 
 jd;ik  :  jl;gk; 
 gphpT   :  ,dpg;G 
nra;if: 
 Fsph;r;rpAz;lhf;fp 
 cs;soyhw;wp 
  clYukhf;fp 
Fzk;: 
 “NkdpapLk; tha;f;F kpUJthk; Mf;fpAz;zj; 
 jhdpUky; ntg;gjpf jhfkpit- VdpUf;Fk; 
 mk;Ng wpsq;fpoq;fp jpahth;f;F khkzg;G+q; 
 nfhk;Ng! $ iff;fpoq;iff; $W." 
 
 ,jdhy; ,Uky;> Ruk;> ePh;Ntl;if ePq;Fk;. clw;F Cl;le; jUk;. 
Chemical constituents: 
 Starch, moisture, crude protein, fat, Dextrin, sugars, crude fibre and ash. 
Uses: 
 Starch obtained from rhizome is astringent, sweet, refrigerant, tonic, aphrodisiac, 
emollient, expectorant, febrifuge and rubefacient. It is useful in dysentery, diarrhoea, 
dyspepsia, bronchitis, cough and also as a nourishing food for infants, invalids and 
convalescents. 
 It is nutrient and demulcent. 
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19) Rf;F: 
 jhtutpay; ngah; :  Zingiber officinale 
 Family   : Zingiberaceae 
 gad;gLk; cWg;G :  fpoq;F (cyh;e;jJ) 
 Rit   :  fhh;g;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 ntg;gKz;lhf;fp 
 grpj;jPj;Jhz;b 
 mfl;Lthafw;wp  
Fzk;: 
 “#iyke;jk; neQ;nrhpg;G NjhlNkg; gk;koiy 
 %yk; ,iug;gpUky; %f;FePh;- thyfg 
 Njhlkjp rhue; njhlh;thj Fd;kePh;j; 
 Njhlk;M kk;Nghf;FQ; Rf;F." 
 
 “thjg; gpzptap Whjw; nrtptha; 
  typjiy typify typapU tpopePh; 
 rPjj; njhLthp Ngjpg; gyNuh 
  rpfkyp Kfkf Kfkpb fgkhh; 
 rPjr; Ruk;tphp Ngjr; RuNeha; 
  njwpgLnkdnkhop Fth;Gtp jdpNy 
 <Jf; FjTkp jPJf; Fjth 
  njDk;tpjp apiyet RWFz KdNt." 
 Rf;fpdhy; nrhpahik> khh;nghpr;ry;> GspNag;gk;> ntg;gk;> fPo;tha;Neha;> 
,iug;G> ,Uky;> fopr;ry;> ePNuw;wk;> Fd;kk;> tapw;Wg;gprk;> fhJf; Fj;jy;> 
KfNeha;> jiyNeha;> Fiytyp> ghz;L> tapw;Wf;Fj;jy;> IaRuk; Nghk;. 
 
152 
 
Chemical constituents: 
 Volatile oil, Gingerol, Camphene, Phellandrene, Zingiberine, Cineol, Borneol, 
Oleo - resin - Gingerin, resins, starch, k - oxalate. 
Uses: 
 The raw ginger is acrid, thermogenic, carminative, laxative and digestive. It is 
useful in anorexia, vitiated conditions of vatam and kapham, dyspepsia, pharyngopathy 
and inflammations. The dry ginger is acrid, thermogenic, emollient, appetizer, laxative, 
stomachic, stimulant, rubefacient, anodyne, aphrodisiac, expectorant, anthelmintic and 
carminative. It is useful in dropsy, otalgia, cephalalgia, asthma, cough, colic, diarrhoea, 
flatulence, anorexia, vitiated conditions of vata and kapha, dyspepsia, 
cardiopathy,pharyngopathy, cholera, nausea, vomiting, elephantiasis and inflammations. 
 Aromatic, carminative, stimulant to the gastrointestinal tract and stomachic also 
sialogogue and digestive.Externally, a local stimulant and rubefacient.  
Antiinflammatory activity: 
   Recent study documented the ability of a hexane fraction of dried ginger 
methanolic extract to suppress proinflammatory gene expression in LPSactivated BV2 
microglial cells, thus displaying antineuroinflammatory activity. Gingerol and 
structurally related pungent principles of ginger including shogaol exert inhibitory 
effects on biosynthesis of prostaglandins and leukotrienes through suppression of 
prostaglandin synthase or 5lipoxygenase. Several reports have addressed the anti-
inflammatory effects of whole ginger extract on the production of NO/iNOS, 
PGE2/COX-2, TNF-a, IL-1b, and macrophage chemoattractant protein-1 (MCP- 1) in 
murine macrophages, such as RAW264.7 cells and J774.1 cells, as well as human 
monocytes, U937 cells. The proposed mechanism behind 6shogaol inhibition of NO 
evolution in stimulated macrophages involves down regulation of inflammatory iNOS 
and COX-2 gene expression by inhibition of the activation of NF-jB, because NF-jB 
plays a critical role in the coordination of the expressions of proinflammatory enzymes. 
For the human being, the consumption of fresh ginger demonstrated promising results for 
the decrease of arthritis-induced. These results show that ginger could be used as anti-
inflammatory agent and thus as anti-pain. 
 
153 
 
Immunomodulatory activity: 
   The beneficial effects of ginger in treating coughs, colds and flu is probably 
linked to immuneboosting properties of the plant.Few studies have examined the 
potential immunomodulatory activity of ginger. Non-specific immunity was increased in 
rainbow trout eating a diet containing 1% of a dried aqueous ginger extract for three 
weeks.Mice fed a 50% ethanolic ginger extract (25 mg/kg) for seven days had higher 
haemagglutination antibody titre and plaque-forming cell counts, consistent with 
improved humoralimmunity. One in vitro study found that ginger suppressed lymphocyte 
proliferation; this was mediated by decreases in IL-2 and IL- 10 production. 
20) rPdpr;rf;fiu: 
 jhtutpay; ngah; :  Saccharum officinarum 
 Family   : Gramineae 
 gad;gLk; cWg;G :  fUg;gQ;rhW> rh;f;fiu> Nth; 
 Rit   :  ,dpg;G 
 jd;ik  :  rPjk; 
 gphpT   :  ,dpg;G 
nra;if: 
 mOfyfw;wp 
 cs;soyhw;wp  
Fzk;: 
 “ rPdpr; rh;f;fiuf;Fj; jPuhj td;RuKq; 
 $dpf;Fk; thjj;jpd; $l;LwTk;- Vdpw;Fk; 
 the;jp nahLfpUkp khwhj tpf;fYNk 
 Nghe;jpiria tpl;Lg; Guz;L." 
 ,J thjRuk;> thjNeha;> the;jp> Ez;GO> tpf;fy; ,itfisg; Nghf;Fk;. 
Chemical constituents: 
 Mucilage, resin, fat, albumen, Guanine in small quantity, Ca - oxalate. 
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Uses: 
 It increases the solubility of lime in water. It acts as food and nutrient to adipose 
tissue hence sugar or sugar forming food is necessary to health, absence of it leads to 
rapid emaciation. Sugar is antiseptic, demulcent. It produces heat and energy. Root of 
sugarcane  is demulcent, stimulant and diuretic. 
 The leaf ash is use to treat sore eyes, the stem juice is use to treat sore throat. 
21) Njq;fha;g;ghy;: 
 jhtutpay; ngah; :  Milk of Cocos nucifera 
 Family   :  Palmae 
 gad;gLk; cWg;G :  ,iy> FUj;J> G+> ghis> fha;> Nth;fs;> XL 
     (rpul;il) 
 Rit   :  ,dpg;G 
 jd;ik  :  jl;gk; 
 gphpT   :  ,dpg;G 
nra;if: 
 Fsph;r;rpAz;lhf;fp 
 kykpsf;fp 
 clYukhf;fp 
 rpWePh;g;ngUf;fp 
Fzk;: 
 “thjkhk; gpj;jKWk; td;fug;g Dk;glUe; 
 jhJkpftp Uj;jpahe; jho;FoNy- Nghjey;y 
 md;d kpwq;F kjpAUrpAz;lhFe; 
 njd;dq;fha;g; ghyhw; nwsp." 
 Rit kpFe;j> ,g;ghiyr; Nrhw;wpy; fye;Jz;zpd; tpUg;gKz;lhk;> cly; 
td;ik ngWk;. MapDk; tspjP Fw;wq;fisAk; fug;ghd; NehiaAk; cz;lhf;Fk;. 
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Chemical constituents: 
 Sugar - Mannitol, gum, albumen, tartaric acid and mineral water. Saccharose, 
Myonostol, Scyllo - inositol, Sorbitol, Diphenylurea, aliphatic 
alcohols,ketones,Leucoanthocyanins, 2 - propyleneglycol, Glycerol, Sucrose, Glucosan, 
Ferricopnin, Cocositol, Mono and sesquiterpenes, Campesterol, Cycloartenol, Squalene, 
Stigmasterol. 
Uses: 
 Coconut milk is refrigerant, nutrient, aperients, diuretic and anthelmintic. Oil 
from the shell is rubefacient and antiseptic and used externally. Root of the coconut is 
diuretic. Atarry oil is prepared from the shell of the nut which is used only externally in 
the treatment of ringworm. Milk or water of the green fruit is a cooling refrigerant drink, 
useful in urinary disorders. Root of the coconut is used in uterine diseases. 
 Juice from the midrib at the lower base of the leaf  issued in treating maternal 
postpartum illness. Coconut milk is used to treat fish poisoning. The oil is used as an 
emetic and as a purgative. The juice from a green coconut is given to women who have 
difficult pregnancies. Juice from the fruit is taken to treat kidney problems. The coconut 
is said to have vermicide properties. Diarrhoea and dysentery are treated with parts of 
this plant. 
 22) kQ;rs;: 
 jhtutpay; ngah; :  Curcuma longa 
 Family   : Scitaminaceae 
 gad;gLk; cWg;G :  fpoq;F 
 Rit   :  fhh;g;G> ifg;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 kz%l;b 
 mfl;Lthafw;wp 
 ntg;gKz;lhf;fp 
 <uy;Njw;wp  
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Fzk;: 
 “nghd;dpwkhk; Nkdp Gyhdhw;w Kk;NghFk; 
 kd;D GUl trpakhk;- gpd;dpnaOk; 
 the;jpgpj;j Njhlikak; thjk;Nghe; jPgdkhq; 
 $h;e;jkQ;r spd;fpoq;Ff;F." 
 “jiytypeP Nuw;wQ; risahj Nkfk; 
 ciyTjU gPdrj;jp DhNl- typRug;G 
 tpQ;R fbtplKk; tPWtpu zq;fSk;Nghk; 
 kQ;rs; fpoq;Ff;F khy;." 
 clypw; G+rpf;Fspf;f clYf;Fg; nghd;dpwk; jUk;. Gyhy; ehw;wj;ij 
ePq;Fk;. Mz;fs; kdj;ijf; ftur;nra;Ak; grpiaAKz;lhf;Fk;. ,jdhy; the;jp> 
tsp> jP> Iaf;Fw;wk;> jiytyp> ePNuw;wk;> nts;is> %f;FePh;gha;jy;> Itiftyp> 
tPf;fk;> tz;Lf;fb> ngUk;Gz; ,itNghk;. 
Chemical constituents: 
 Alkaloid - Curcumin, Turmeric oil (or) Turmerol, Caproic acid, Valeric acid, d - 
sabinene, d - a - phellandrene, Cineol, d - borneol, Sesquiterpine, Zingiberene, 
Turmerone, dehydroturmerone, y & a - alanto lactone, Curcumene. 
Uses: 
 Juice of the fresh rhizome is applied to recent wounds, bruises and  leech bites. 
Internally it is used as an anthelmintic. Root is usefully administered in intermittent 
fevers. It is also given internally with cow‟s urine in prurigo and eczema. Mixed with 
gingelly oil it is applied to the body to prevent skin eruptions. The fumes are also used to 
relieve hysterical fits. Milk boiled with turmeric rhizome added to it and then sweetened 
withnsugar is a popular remedy for cold. Internally turmeric is given in infections of the 
liver and in jaundice. 
 The rhizome is well known for its anti - gastric - ulcer, anti - inflammatory and 
cholagogic properties. It is used in the treatment of gastric and duodenal ulcer, hepatitis, 
jaundice, menstrual disorders, post partum or menstrual haematometra, contusions, 
rheumatism, pain in the extremities, boils and impetigo. 
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23) fUQ;rPufk;: 
 jhtutpay; ngah; :  Nigella sativa 
 Family   :  Ranunculaceae 
 gad;gLk; cWg;G :  tpij 
 Rit   :  ifg;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhh;g;G 
nra;if: 
 mfl;Lthafw;wp 
 rpWePh;g;ngUf;fp 
 UJTz;lhf;fp 
 ghw;ngUf;fp 
 GOf;nfhy;yp 
 grpj;jPj;Jhz;b 
 Jhf;Fzpg;GOf;nfhy;yp 
 twl;rpafw;wp  
Fzk;: 
 “ fUQ;rP ufj;jhd; fug;gndhL Gz;Zk; 
 tUQ;rpuha;g; gPerK khw;Wk;- mUe;jpdhy; 
 fha;r;ry; jiytypAq; fz;typAk; NghKyfpy; 
 tha;r;r kUe;njdNt it." 
 kz;ilf; fug;ghd;> Gz;> cl;#L jiyNeha;> fz;Nzha; ,itfSk; 
rpuq;F> tapw;Wg; nghUky;> Fd;kk;> khh;Gtyp> ,Uky;> the;jp> Xf;fhsk;> tPf;fk;> 
fhkhiy MfpaitfSk; ePq;Fk;.  
Chemical constituents: 
 Volatile oil, albumin, sugar, mucilage, organic acids - Metarbin, toxic glucoside - 
Melanthin, Helleborin, Arabic acid, Carvone, Carvene, Cymene, Myristic acid, Palmitic 
acid, Stearic acid, Oleic acid, Linoleic acid, Trilinolein acid, Oleodilinolein acid, 
Dioleolinolein acid, Palmito - oleo - linolein acid, Stearo - oleolinolein acid. 
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Uses: 
 Seeds given with butter milk to cure obstinate hiccup, corrective of purgatives 
and are also useful indigestion, loss of appetite, fever, diarrhea, dropsy puerperal 
diseases etc. With sweet oil the decotion forms a useful application in the skin diseases. 
Brayed in water its application removes swellings from hands and feet. Seeds fried, 
bruised tied in muslin bag and smelt relieve cold and catarrh of the nose by constant 
inhalation. 
 The seeds are acrid, bitter, thermogenic aromatic, carminative, diuretic, 
emmenagogue, anodyne, antibacterial, anti - inflammatory, deodorant, appetizing, 
digestive, anthelmintic, constipating, sudorific, febrifuge, stimulant, galactagogue and 
expectorant. 
24) fy;Yg;G: 
 Chemical name: Sodii chloridum or Sodium chloride 
 Other name: Common salt, Table salt 
nra;if: 
 mOfyfw;wp 
 Kiwntg;gfw;wp 
 GOf;nfhy;yp 
 tPf;fKUf;fp  
Fzk;: 
 “ IakWQ; #iy aNuhrpgpj;jQ; rj;jpnahL 
 nta;agpzp al;lFd;kk; tpl;NlFk;- nga;tisNa 
 thjkjp jhfk; kyf;fl;Lk; NghKyfpw; 
 NfhjWfy; Yg;igf; nfhL." 
 fy;Yg;gpdhy; fgk;> Fj;jy;> mUrp> gpj;jk;> the;jp> c\;zthA> 
vz;tpjFd;kk;> thjNeha;>  ehtwl;rp> kyge;jk; ,it VFk;. 
Uses: 
 Antiseptic, antiperiodic, anthelmintic and deobstruent. It keeps the globulin of the 
blood in solution. It increases the secretion of the gastric juice . Internally in small doses 
it increases the secretion of the salivary and gastric glands, sharpens appetite and 
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promotes digestion. It excites thirst and thus assists absorption of liquid food. In a diluted 
form it enters the blood and dissolves albumins and globulins. It is also a rubefacient. It 
acts as an emetic in large doses and in still larger doses it is a powerful purgative.  
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Internal Medicine - Nilavaagai chooranam 
       Ingredients                                                        Powder form  
Nilavaagai 
                               
Milagu 
                                 
Kadukkai 
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Thandrikkai 
                                  
                 
 
Seeragam 
                                   
 
 
Vaaluvai 
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Sirunaagapoo 
                             
 
Elam 
                             
 
Illavangapattai 
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Kadugurogini 
 
                               
Sivadhai 
                                      
Thalisapathiri 
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Jadhikkai 
                                
Kirambu 
                                                                                       
 
Thippili 
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Cheviyam 
                              
 
Indhuppu 
                                        
  
Koogaineer 
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Chukku 
                                             
Purification methods 
Nilavaagai - Pittaviyal Technique 
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 Sivathai - Pittaviyal Technique 
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Kadugurogini 
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Chooranam Preparation - Vasthirakayam 
                      
External Medicine - Thengaai thylam 
        Thengaai pal                             Manjal  
             
     Karunjeeragam                                               Kalluppu  
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Oil preparation 
                    
 
                      
 
              
 
 
175 
 
     
 
   
 
   
176 
 
         
Nilavaagai chooranam (Prepared Medicine) 
            
   Thengaai thylam (Prepared Medicine) 
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Leech Procedure 
 
                     
 
 
            
 
 
 
 
178 
 
 
 
 
             
 
   
                  
 
 
 
179 
 
                    
 
                            
  
                 
 
 
180 
 
Patients with Leech therapy 
Patient 1 
Before treatment 
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During treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
 
After treatment 
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After treatment 
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Patient 2 
Before treatment 
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During Treatment 
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Patients without Leech therapy 
Patient 1 
Before treatment 
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After treatment 
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Before treatment 
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After treatment 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST -  GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A COMPARATIVE CLINICAL TRIAL TO EVALUATE THE  THERAPEUTIC 
EFFICACY  OF SIDDHA HERBAL  FORMULATION “NILAVAAGAI 
CHOORANAM” (INTERNAL) AND “THENGAAI THYLAM” (EXTERNAL) IN 
THE MANAGEMENT OF “KARAPPAN” (ECZEMA) WITH AND WITHOUT 
LEECH THERAPY. 
[PRINCIPAL INVESTIGATOR: Dr.V. Asha jeba keerthana] 
    REG NO: 
FORM l - SCREENING & SELECTION PROFORMA 
 SL.NO                                                             OP NO:   
 NAME:                                                 AGE/GENDER:                CONTACT NO: 
INCLUSION CRITERIA 
Age :20-65Yrs                                                                                               Yes/ No Papules Yes/ No    
Itching Yes/ No Scaling Yes/ No    
Oozing   Yes/ No    Vescicles Yes/ No    
Erythema    Yes/ No    Hyperpigmentation   Yes/No    
Willing to give 
blood for 
investigation  
Yes/ No    Lichenification Yes/ No    
Willing to undergo 
leech therapy 
Yes/ No    Willing to attend OPD or 
admission in IPD for 48 days  
Yes/No    
If the symptom more than 5, may be included for the  clinical trial. 
EXCLUSION CRITERIA :H/O 
Hypertension Yes/No    Evidence of  any skin disease other than eczema Yes/ No    
Hemophilia 
 
Yes/No    Pregnancy and Lactation Yes/No    
H IV Yes/No    Cardiac ailments Yes/No    
Narcotics Yes/No Thrombocytopenia Yes/No 
Hepatitis B Yes/No Renal diseases Yes/No 
ADMITTED TO TRIAL  :YES          NO                         If yes, serial No: 
  OPD                                            IPD 
Date:        
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                                                      Signature of the HOD  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST -  GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A COMPARATIVE CLINICAL TRIAL TO EVALUATE THE  THERAPEUTIC  
EFFICACY  OF  SIDDHA  HERBAL FORMULATION “NILAVAAGAI 
CHOORANAM” (INTERNAL) AND “THENGAAI THYLAM” (EXTERNAL) IN 
THE MANAGEMENT OF “KARAPPAN” (ECZEMA) WITH AND WITHOUT 
LEECH THERAPY. 
[PRINCIPAL INVESTIGATOR: Dr.V.Asha jeba keerthana ] 
FORM II – CASE RECORD FORM 
STUDY  NO                                                                           OP / IP NO:    
 NAME:                                                                                   AGE/GENDER:  
ADDRESS :                                                                             CONTACT NO  : 
RELIGION  :  H / M / C / O          
OCCUPATION:                                                                       INCOME: 
MARRITAL STATUS:    MARRIED                                   UNMARRIED         
DATE OF INITIAL ASSESSMENT:                                       
COMPLAINTS & DURATION:                                                                                                                                                                                        
PERSONAL HISTORY: 
         PERSONAL HABITS YES NO IF YES SPECIFY 
DURATION 
AMOUNT/Qty 
             Smoking     
           Tobacco Chewing     
            Alcohol     
          Narcotic  Drug Addiction     
 
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
 FAMILY HISTORY: 
 Whether this problem runs in family?         1. Yes                               2.No         
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     If yes, mention the relationship of  affected person(s) 
                                               1._________________ 
                                               2._________________ 
DIETARY HABIT:     
1.Vegetarian                                              2.Non-vegetarian 
 MENSTURAL HISTORY AND OBSTETRIC HISTORY: 
 
GENERAL EXAMINATION: 
• Body weight [Kg]  :                      
• Height [cms]   :                        
• Body Temperature [0F]  :   
• Blood Pressure (mm/Hg)  :      
• Pulse Rate /min.  : 
• Heart Rate / min.  : 
• Respiratory Rate /min.  :     
• Pallor  :   
• Jaundice  :   
• Clubbing  : 
• Cyanosis  : 
• Pedal Oedema  : 
• Lymphadenopathy         :  
• Jugular vein  pulsation :   
 
 VITAL ORGANS EXAMINATION: 
 Heart          
Lungs  
Brain 
Liver   
Kidney    
Spleen 
Stomach 
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 SYSTEMIC EXAMINATION: 
Cardio-vascular system 
Respiratory system         
Gastro intestinal system   
Central nervous system 
Uro-genital system     
Endocrine system       
  
SIDDHA SYSTEM OF EXAMINATION  
1. THEGI (TYPE OF BODY CONSTITUTION): 
1. Vaathaudal                               3. Kabaudal 
2. Pithaudal                         4. Thonthaudal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji                           4. Neithal 
2. Mullai                              5. Paalai 
3. Marutham 
3. KAALAM: 
1. Kaarkaalam                           4. Pinpanikaalam 
2. Koothirkaalam                5. Ilavenilkaalam 
3. Munpanikaalam              6. Muthuvenilkaalam 
4. GUNAM: 
1. Sathuvam        2. Rasogunam  3. Thamogunam 
5.PORIPULANGAL(SENSORY ORGANS): 
 
0
th
 
day 
8
th
 
day 
15
th
 
day 
22
nd 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
Mei (skin)         
Vaai(mouth)         
Kan (eye)         
Mooku(nose)         
Sevi (ear)         
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6. KANMENDRIYAM(MOTOR ORGANS): 
 
0
th
 
day 
8
th
 
day 
15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
Kai(upperlimb)         
Kaal(lowerlimb)         
Vaai(speech)         
Eruvai 
(excretory organ) 
        
Karuvai 
(reproductive 
organs) 
        
7. KOSANGAL (SHEATH):          
 
0
th
 
day 
8
th
 
day 
15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
AnnamayaKosam         
Pranamayakosam         
Manomayakosam         
Vignanamayakosam         
Aananthamayakosam         
8. UYIR THATHUKKAL (THREE HUMOURS): 
A) VALI 
 0
th
 
day 
8
th 
day 
15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th 
   day 
43
rd
   
day 
49
th   
 day 
Praanan         
Abaanan         
Viyaanan         
Udhaanan         
Samaanan         
Naagan         
Koorman         
Kirukaran         
Devathathan         
Dhananjeyan         
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B) AZHAL 
 
0
th
 
day 
8
th 
day 
15
th
 
day 
22
nd 
 
day 
29
th
 
day 
36
th
 
day 
43
rd
  
day 
49
th
  
day 
Analaka pitham         
Prasaka pitham         
Ranjaka  pitham         
Aalosaka 
pitham  
        
Saathaka 
pitham 
        
C) IYAM:             
 0
th
 
day 
8
th
 
day 
15
th
 
day 
22
nd
 
day 
29
th
  
day 
36
th
  
day 
43
rd
  day 
49
th 
 
day 
Avalambagam         
Kilethagam         
Pothagam         
Tharpagam         
Santhigam         
 
9. SEVEN UDAL DHATHUS: (7 SOMATIC COMPONENTS)  
 0
th    
 
day 
8
th
    
day 
15
th
  
day 
22
nd
 
day 
29
th
  
day 
36
th 
 
day 
43
rd
 
day 
49
th
  
day 
Saaram         
Senneer         
Oon         
Kozhuppu         
Enbu         
Moolai         
Sukkilam / 
Suronitham 
        
 
ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION]  
I. NAADI: [PULSE PERCEPTION] 
 
0
th
 
day 
8
th  
day 
15
th 
day 
22
nd 
day 
29
th
  
day 
36
th
  
day 
43
rd
  
day 
49
th
  
day 
        
II. SPARISAM: 
0
th
  
day 
8
th
   
day 
15
th
  
day 
22
nd  
day 
29
th
  
day 
36
th 
  
day 
43
rd
  
day 
49
th
  
day 
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III. NAA:[TONGUE] 
0
th
  
day 
8
th
  
day 
15
th 
 day 
22
nd 
 
day 
29
th
  
day 
36
th  
day 
43
rd
  
day 
49
th 
 day 
        
IV.NIRAM: [COMPLEXION]   
     1.Vaatham                                              3. Kabam 
     2. Pitham 
V.MOZHI: [VOICE] 
     1. High Pitched                                      2. Low Pitched 
     3. Medium Pitched 
VI.VIZHI: [EYES]  
0
th
  
day 
8
th
  
day 
15
th
  
day 
22
th
  
day 
29
th
  
day 
36
th
  
day 
43
rd
  
day 
49
th
  
day 
        
VII. MALAM: [BOWEL HABITS / STOOLS] 
     Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
VIII. MOOTHIRAM [URINE EXAMINATION]   
Neerkkuri Before treatment After treatment 
Niram 
 
  
Edai   
Manam   
Nurai   
Enjal   
 
NEIKURI Before treatment After  treatment 
Aravu (Serpentine fashion)   
Aazhi (Annular/Ringed fashion)   
Muthu (Pearl beaded fashion)      
Kalappu (Mixed fashion)   
Other fashion   
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CLINICAL EXAMINATION:                  
CLINICAL EXAMINATION OF SKIN 
1.Site:     ----------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------- 
2. Colour:  Normal  Reddish  Black  Greyish 
3. Shape:  Irregular  Coin shape Dispersed  
4. Itching:  No  Mild  Moderate Severe 
5.Oozing:  No  Mild  Moderate Severe 
6. Erythema:  No  Mild  Moderate Severe 
7. Bleeding:  No  Mild  Moderate Severe 
8. Crusting:  No  Mild  Moderate Severe        
9. Lichenification: No  Mild  Moderate Severe   
 10. Scaling:  No  Mild  Moderate Severe     
     YES                      NO 
 14. Ulcération: 
 15. Macule:   
 16. Papule: 
 17. Pustule:  
       18. Blister: 
 19.Vesicle :   
 20. Pigmentation:                   Normal                          Hypo                       Hyper  
LEECH THERAPY ASSESSMENT FORM 
STUDY NO:                                           OP/IP NO: 
Day  Date              Site No. of Lesions appeared 
Day 1    
Day 8    
Day 15    
Day 22    
Day 29    
Day 36    
Day 43    
Day 49    
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CLINICAL ASSESSMENT DURING AND AFTER TRIAL 
 
 OP/ IP NO:                               STUDY NO:                         NAME:  
 AGE/GENDER:                     DATE OF RECRUITMENT: 
 0 After 8 
days 
After 
15 days 
After 
22 days 
After 
29 days 
After 
36 days 
After 
43 days 
After 
49 days 
Itching         
 Oozing          
Erythema          
Papules         
Vesicle         
Scaling         
Pigmentation         
Lichenification         
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                    Signature of the HOD 
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                                         NATIONAL INSTITUTE OF SIDDHA 
  AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST-GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A COMPARATIVE CLINICAL TRIAL TO EVALUATE THE  THERAPEUTIC 
EFFICACY OF SIDDHA HERBAL FORMULATION “NILAVAAGAI 
CHOORANAM” (INTERNAL) AND “THENGAAI THYLAM” (EXTERNAL) IN 
THE MANAGEMENT OF “KARAPPAN”(ECZEMA) WITH AND WITHOUT 
LEECH THERAPY. 
 
[PRINCIPAL INVESTIGATOR: Dr.V.Asha jeba keerthana ] 
 
        FORM III – LABORATORY INVESTIGATIONS FORM 
STUDY NO:                       OP / IP NO:                                     AGE/GENDER:    
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE TMT  
( DATE) 
AFTER TMT 
(DATE) 
Hb( gm/dl) 
M:12-15 
F:11.5-14 
  
T.WBC (cells/cu.mm) 
4000-
11000 
  
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
T.RBC(million cells/cu.mm)   M:4.0-5.5 
  F:3.5-4.5 
  
  ESR(mm/hour) ½ hr. M:1-13 
F:1-20 
  
1hr 
Bleeding Time 1-3 minutes   
Clotting Time 3-8 minutes   
Blood group & Rh typing    
 
 
 
Blood Investigations 
Normal 
Values 
Before TMT 
(DATE) 
After TMT 
(DATE) 
Blood glucose 
(mg/dl) 
Fasting    70-110   
PP    80-140   
Random    80-120   
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RFT (mg/dl) 
Blood urea    16-50   
Serum creatinine    0.6-1.2   
Serum uric acid 
M:3-9  
F:2.5-7.5 
  
LFT (mg/dl) 
Total bilirubin    0.2-1.2   
Direct bilirubin    0.1-1.2   
Indirect bilirubin    0.2-0.7   
SGOT  (IU/L)    0-40   
SGPT (IU/L)    0-35   
Alkaline phosphatase 
(IU/L) 
   80-290   
Lipid profile 
Total cholesterol 
(mg/dl) 
150-225   
HDL (mg/dl) 30-63   
LDL (mg/dl) <130   
VLDL (mg/dl) <40   
TGL (mg/dl) <160   
Urine 
investigations 
Before TMT( Date) After TMT ( Date) 
Albumin   
Fasting sugar   
PP sugar   
Deposits   
OTHER TESTS: 
 HbsAg      HIV 
 VDRL      HCV 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                     Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST-GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A COMPARATIVE CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA HERBAL FORMULATION “NILAVAAGAI 
CHOORANAM” (INTERNAL) AND “THENGAAI THYLAM”(EXTERNAL) IN THE 
MANAGEMENT OF “KARAPPAN” (ECZEMA) WITH AND WITHOUT LEECH 
THERAPY . 
   
[PRINCIPAL INVESTIGATOR: Dr.V.Asha jeba keerthana ] 
 
FORM IV - DRUG COMPLIANCE FORM 
STUDY NO                              OP / IP NO:          NAME:                                             
AGE/GENDER: 
  
 OPD PATIENTS 
On 1
st       
 day-Date:  Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 8
th
     day-Date:   Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 15
th   
 day-Date:              Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 22
nd
   day-Date:  Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 29
th
   day-Date:   Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 36
th
   day-Date:              Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 43
rd    
 day-Date:  Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 49
th
    day-Date:   Drugs issued:  (Gms) Drugs returned:    (Gms) 
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IPD PATIENTS 
 
 
Date Morning Evening Day Date Morning Evening 
Day 1    Day25    
Day2    Day26    
Day3    Day27    
Day4    Day28    
Day5    Day29    
Day6    Day30    
Day7    Day31    
Day 8    Day32    
Day9    Day33    
Day10    Day34    
Day11    Day35    
Day12    Day36    
Day13    Day37    
Day14    Day38    
Day15    Day39    
Day16    Day40    
Day17    Day41    
Day18    Day42    
Day19    Day43    
Day20    Day44    
Day21    Day45    
Day22    Day46    
Day23    Day47    
Day24    Day48    
 
Date:          
 
Station: 
 
Signature of the Investigator 
 
Signature of the Lecturer                                                                       Signature of the HOD         
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST-GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
A COMPARATIVE CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA HERBAL FORMULATION “NILAVAAGAI CHOORANAM” 
(INTERNAL) AND “THENGAAI THYLAM” (EXTERNAL) IN THE MANAGEMENT OF 
“KARAPPAN” (ECZEMA) WITH AND WITHOUT LEECH THERAPY. 
FORM V – PATIENT INFORMATION SHEET 
Name of Principal Investigator: Dr.V.Asha jeba keerthana 
Name of the institute: National Institute of Siddha, Tambaram Sanatorium, Chennai-47. 
I, Dr.V.Asha jeba keerthana, studying M.D(Siddha) at National Institute of  
Siddha, Tambaram Sanatorium is doing a trial on Karappan(Eczema). Eczema is a most 
common persistent skin disease, occurring throughout the world. In this regard, I am in a 
need to ask you few questions. I will maintain confidentiality of your comments and data  
obtained . There will be no risk of disclosing your identity and no physical, 
psychological or professional risk is involved by taking part in this study. Taking part in 
this study is voluntary. No compensation will be paid to you for taking part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. If you agree to be a 
participant in this study, you will be included in the study primarily by signing the 
consent form and then you will be given the internal medicine NILAVAAGAI 
CHOORANAM -1g BD with GHEE for 48 days, THENGAAI THYLAM (External 
medicine) and Leech therapy(for selected person). 
 The information I am collecting in this study will remain confidential. I will ask 
you few questions through a questionnaire. It will take approximately 20 min of time. 
Your name won‟t be mentioned in the lab investigation form instead a code will be used. 
If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.V.Asha jeba keerthana, PG Scholar cum principal 
investigator of this study, National Institute of Siddha, Chennai-47. You can also contact 
the Member-secretary of Ethics committee, National Institute of Siddha, Chennai 
600047.  
Tel No: 044-22380789 for rights and participation in the study. 
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahj;jpjh]; gz;bjH kUj;Jtkid - nrd;id 47 
fug;ghd; Neha;f;fhd rpj;j kUe;Jfspd; (epythifr; #uzk; kw;Wk; 
Njq;fha;j; ijyk;) ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt 
Ma;tpw;fhd jfty; gbtk;. 
Kjd;ik Muha;r;rpahsH ngaH: kUj;JtH: tp. M\h n[g fPHj;jdh 
epWtdj;jpd; ngaH: Njrpa rpj;j kUj;Jt epWtdk; nrd;id 47 
  rpj;j kUj;Jt epWtdj;jpy; gl;l Nkw;gbg;Ggapd;WtUk; ehd; 
kUj;JtH tp. M\h n[g fPHj;jdh fug;ghd; vd;Dk; Nehapy; kUj;Jt 
Muha;r;rpapy; <Lgl;Ls;Nsd;. fug;ghd; vd;Dk; Neha; cz;lhtjw;fhd 
mbg;gil fhuzk; fpUkpfs; md;W. RizAs;s rpy nghUl;fs;> 
fk;gsp Nghd;wit Njhypy; cuha;tjhYk;> me;jfuz 
NtWghLfshYk;> rpy tif czTg; nghUl;fshYk; cz;lhtjhf 
$wg;gLfpwJ. ,J gut $ba Neha; md;W. ,e;j Muha;r;rp 
rk;ge;jkhf rpy Nfs;tpfis Nfl;fTk;> Njitahd Ma;tf 
ghpNrhjidf;F jq;fis cl;gLj;jTk; cs;Nsd;. ,J rk;ge;jkhd 
jq;fsJ midj;Jtptuq;fSk; ufrpakhf itf;fg;gLk; vd cWjp 
mspf;fpNwd;. ,jpy; gazg;gb Kjypa ve;j cjtpj; njhifAk; 
toq;fg;gl khl;lhJ. ,e;j Muha;r;rpapd; NghJ clYf;F NtW ghjpg;G 
Vw;gLk; gl;rj;jpy; Njrpa rpj;j kUj;Jtkidapy; jf;f rpfpr;ir 
mspf;fg;gLk;. ,e;j Muha;r;rpf;F jhq;fs; tpUg;gj;jpd; Nghpy; cl;gLk; 
gl;rj;jpy; cs;kUe;jhf epythifr; #uzj;ij nte;ePH (1fpuhk;) 2 
Ntis> nte;ePhpy; czTf;Fg; gpd; 48 ehl;fs; cl;nfhs;s Ntz;Lk;. 
ntsp kUe;jhf Njq;fha; ijyk; ntspNa jlt Ntz;Lk;. ntsp 
NehahsHfs; 7 ehl;fSf;F xUKiw kUj;Jtkidf;FtuNtz;Lk;. 
tpUg;gk; njhptpf;Fk; gl;rj;jpy; Nehahspf;F ml;il tply; rpfpr;irAk; 
mspf;fg;gLk;. 
ml;il tpLjy; rpfpr;ir vd;gJ ml;ilia NehAs;s ,lj;jpy; 
tplr;nra;J ,uj;jj;ij cwpQ;r nra;tjd; %yk; Nehapd; jd;ikia 
Fiwf;Fk; KiwahFk;. ,jdhy; ve;j tpj gf;f tpisTfSk; 
Vw;glhJ. tpiutpy; Nehapd; jd;ik FiwAk;. 
,e;j rpfpr;ir Kiw rpj;j kUj;Jtj;jpy; neLq;fhykhf 
gpd;gw;wg;gl;L tUfpwJ. ml;ilahy; cwpQ;rg;gLk; ,uj;jj;jpd; msT 
kpf kpf Fiwe;j msNt MFk;. vdNt ve;j ghjpg;Gk; Vw;glhJ. 
xt;nthU gad;gLj;jg;gl;l ml;il kw;nwhU Nehahspf;F 
gad;gLj;jg;glkhl;lhJ. 
,e;j Muha;r;rpapy; Nehapduhf NrHe;j gpwF cq;fSf;FtpUg;gk; 
,y;iynadpy; vg;NghJ Ntz;LkhdhYk; tpyfp nfhs;syhk;. ,e;j 
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Muha;r;rp rk;ge;jkhf kw;wtpguq;fSf;Fk; Nehapd; jd;id gw;wpAk; 
Kjd;ik Muha;r;rpahsuhd kUj;JtH tp. M\h n[g fPHj;jdh (gl;l 
Nkw;gbg;ghsH rpwg;GkUj;Jt Jiw) mZfTk;. ifg;Ngrp vz; 
9442830149. NkYk; ,e;j Muha;r;rpf;F IEC rhd;W ngwg;gl;Ls;sJ. 
,e;j kUe;J rpwg;ghf fug;ghd; Neha;f;fhf mq;fPfhpf;fg;gl;l rpj;j 
kUj;JtE}ypy; $wg;gl;Ls;sJ. Vw;fdNt cgNahfj;jpy; cs;s ,J 
Nghd;wkUe;J ,Jtiu Nehahspfsplk; ve;j tpj gf;f 
tpisTfisAk; Vw;gLj;jtpy;iy. NkYk; czT Kiwapy; 
kUj;Jtuhy; $wg;gLk; gj;jpak; fhf;FkhW mwpTWj;jg;gLfpwJ. 
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      NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL,CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A COMPARATIVE CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA HERBAL FORMULATION “NILAVAAGAI 
CHOORANAM” (INTERNAL) AND “THENGAAI THYLAM” (EXTERNAL) IN 
THE MANAGEMENT OF “KARAPPAN” (ECZEMA) WITH AND WITHOUT 
LEECH THERAPY. 
 
FORM VI- INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have 
the right to withdraw from the study at any time without affecting my further medical 
care”. 
"I have received a copy of the information sheet/consent form". 
 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that 
the individual has given consent freely.”                                                   
Date: 
 
Signature of a witness                                                          Left thumb Impression  
                                                                                              of the Participant     
(Selected by the participant bearing no connection with the survey team)   
 
Signature of the Investigator 
 
 Signature of the Lecturer                          Signature of the HOD 
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahj;jpjh]; gz;bjH kUj;Jtkid - nrd;id 47 
fug;ghd; Neha;f;fhd rpj;j kUe;Jfspd; (epythifr; #uzk; kw;Wk; 
Njq;fha;j; ijyk;) ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt 
Ma;tpw;fhd 
xg;Gjy; gbtk; - Ma;thsuhy; rhd;wspf;fg;gl;lJ 
ehd; ,e;j Ma;T Fwpj;j midj;J tpguq;fisAk; Nehahspf;F GhpAk; 
tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
Njjp:        ifnahg;gk;: 
,lk;:        ngah;: 
    Nehahspapd; xg;Gjy; 
 vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;> kUe;jpd; jd;ik 
kw;Wk; kUj;Jt topKiw gw;wpAk;> njhlh;e;J vdJ cly; ,af;fj;ij 
fz;fhzpf;fTk;> mjid ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l 
ghpNrhjidfs; gw;wp jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; 
$wg;gl;lJ. 
 ehd; ,e;j kUj;Jt Ma;tpd; NghJ> vg;nghOJ Ntz;LkhdhYk; ,e;j 
Ma;tpypUe;J vd;id tpLtpj;J nfhs;Sk; chpikia njhpe;jpUf;fpNwd;. ehd; 
vd;Dila Rje;jpukhf Njh;T nra;Ak; chpikiaf; nfhz;L fug;ghd; 
Neha;f;fhd epythifr; #uzk; (cs;kUe;J) kw;Wk; Njq;fha;j; ijyk; 
(ntspkUe;J) kUe;jpd; ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;F 
vd;id cl;gLj;j xg;Gjy; mspf;fpNwd;. 
Njjp:        ifnahg;gk;: 
,lk;:        ngah;: 
cwTKiw:       rhl;rpf;fhuh; ifnahg;gk;: 
ngah;: 
tphpTiuahsh; ifnahg;gk;:    Jiwj;jiyth; 
ifnahg;gk; 
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A COMPARATIVE CLINICAL TRIAL TO EVALUATE THE  THERAPEUTIC 
EFFICACY OF SIDDHA HERBAL FORMULATION “NILAVAAGAI 
CHOORANAM” (INTERNAL) AND “THENGAAI THYLAM” (EXTERNAL) IN 
THE MANAGEMENT OF “KARAPPAN”(ECZEMA) WITH AND WITHOUT 
LEECH THERAPY. 
 
[PRINCIPAL INVESTIGATOR: Dr.V.Asha jeba keerthana ] 
 
FORM VII- PHARMACOVIGILANCE/WITHDRAWAL 
FORM 
1. Patient / consumer identification (please complete or tick boxes below as 
appropriate) 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR SIDDHA DRUGS 
 
 
Please note:  i.All consumers / patients and reporters information will remain 
confidential. 
         ii. It is requested to report all suspected reactions to the concerned, 
even if it does not have complete data, as soon as possible. 
Peripheral Center code:     State: 
Name  Father name Patient / Record 
No. Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / 
Age: 
Sex:     M / F 
Weight : 
Degam: 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha 
Drugs 
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2. Description of the suspected Adverse Reactions (please complete boxes below) 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 Geographical area: 
3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha      
Any other 
system of 
medicines 
     
4. Brief details of the Siddha Medicine which seems to be toxic: 
Details Drug – 1 Drug – 2 Drug – 3 
a) Name of the medicine    
b) Manufacturing unit 
and batch No. and date 
   
c) Expiry date    
d) Purchased and 
obtained from 
   
e) Composition of the 
formulation / Part of the 
drug used 
   
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or 
used as self medication.  
d) Any other relevant information. 
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5. Treatment provided for adverse reaction: 
 
 
 
6. The result  of the adverse reaction / side effect / untoward effects (please complete 
the boxes below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   
No. 
Reaction abated after drug stopped or dose reduced: 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? 
If yes, give name and address of 
hospital 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition  
Any Others  
9. H/O previous allergies / Drug reactions:  
10. Other illness (please describe): 
11. Identification of the reporter: 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / 
Attendant / Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
Address: 
Telephone / E – mail if any : 
 
Signature of the reporter:     Date: 
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Please send the completed form to:  
    The Director 
    National Institute of Siddha, 
(Pharmacovigilance Regional Centre For Siddha 
Medicine), 
    Tambaram Sanatorium, Chennai-600 047. 
 (O) 044-22381314 Fax : 044 – 22381314 
Website : www.nischennai.org 
Email: nischennaisiddha@yahoo.co.in 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence 
of ADR   
 
 
 
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                  Signature of the HOD  
  
 
 
 
 
 
Who Can Report? 
 Any Health care professionals like Siddha Doctors /  
Nurses / Siddha Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence 
and protected to the fullest extent.  
 Submission of report will be taken up for remedial 
measures only not for legal claim  
Name & address of the 
RRC-ASU/ PPC-ASU 
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FORM VIII - DIETARY ADVICE FORM 
 
Nrh;f;f $ba czTfs;: 
 KUq;ifg;gpQ;R (Drumstick),  
 mtiug;gpQ;R 
 fhul; (Carrot), 
 gPl;&l; (Beetroot), 
 fhprhiy 
 nghd;dhq;fz;zp 
 kzj;jf;fhsp 
 rpWfPiu 
 griyf;fPiu (Palak), 
 fwpNtg;gpiy (curry leaves) 
 nfhj;jky;yp (coriander)  
 khJis (Pomegranate) 
 Mg;gps; (Apple) 
 NghPr;ir (Dates) 
 mj;jp (Fig) 
 jpuhl;ir (Grapes) 
 rg;Nghl;lh (Sappotta) 
 cyh; jpuhl;ir (Dry grapes) 
 Ntfitj;j fha;fwpfs; (vegetables) 
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jtph;f;f Ntz;baitfs;: 
 fk;G> Nrhsk;> 
 Nfo;tuF> jpid (Millets) 
 rhik> 
 thiof;fha; (Ripe banana)  
 G+rzpf;fha; (Pumpkin) 
 Nfhopf;fwp (Chicken) 
 kPd; (Fish) 
 ez;L (Crab) 
 fUthL (Dry fish) 
 Kl;il (Egg) 
 nfha;ah (Guava)  
 Gsp (Tamarind) 
 CWfha; (Pickles) 
 Gifapiy (Tobacco) 
 kJ mUe;Jjy; (Alcohol) 
 ngz;Nghfk;. 
FspaYf;F: 
 Nrhg;G> rPaf;fha; jtph;f;fTk;. 
 ghrpg;gaW khT> fliy khT Nja;j;J Fspf;fTk;. 
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